<<<<<<< HEAD
study;condition_arm1;condition_arm2;multi_arm1;multi_arm2;outcome_type;instrument;rating;instrument_symptom;primary_instrument;cov_time_point;study_time_point;time_weeks;time_days;primary_timepoint;post_crossover;n_arm1;mean_arm1;sd_arm1;n_arm2;mean_arm2;sd_arm2;n_change_arm1;mean_change_arm1;sd_change_arm1;n_change_arm2;mean_change_arm2;sd_change_arm2;event_arm1;totaln_arm1;event_arm2;totaln_arm2;baseline_m_arm1;baseline_sd_arm1;baseline_n_arm1;baseline_m_arm2;baseline_sd_arm2;baseline_n_arm2;d1;d2;d3;d4;d5;rob;year;drug_arm1;drug_arm2;dose_arm1;dose_arm2;name_arm1;name_arm2;n_dosing_sessions;mean_age;percent_women;diagnosis;target_group;design;blinding;doi;registration_number;full_ref;.id;.g;.g_se;.log_rr;.log_rr_se;.event_arm1;.event_arm2;.totaln_arm1;.totaln_arm2
Back 2024;psil;ncn;NA;NA;msd;madrs;clinician;depression;1;Pre-first dose 1;Day -8;-1,14;-8,000;0;NA;15;27,670;5,27000000000000;15;28,400;7,39000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;Low;Low;Low;Low;Low;Low;2024;psilocybin;niacin;25 mg;100 mg;psilocybin arm;niacin arm;1;38,0000000000000;50,0000000000000;dep;NA;parallel;double-blind;10.1001/jamanetworkopen.2024.49026;NCT05163496;Back, A. L., Freeman-Young, T. K., Morgan, L., Sethi, T., Baker, K. K., Myers, S., McGregor, B. A., Harvey, K., Tai, M., Kollefrath, A., Thomas, B. J., Sorta, D., Kaelen, M., Kelmendi, B., & Gooley, T. A. (2024). Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial. JAMA Network Open, 7(12), e2449026. https://doi.org/10.1001/jamanetworkopen.2024.49026;Back2024_msd_madrs_Day-8_-1.14_clinician_psil_ncn_NA_NA;-0,11066608890309594;0,365443493603394;NA;NA;NA;NA;NA;NA
Back 2024;psil;ncn;NA;NA;msd;madrs;clinician;depression;1;Post-first dose 4;Day 28;4,00;28,000;1;NA;15;6,330;6,72000000000000;15;19,070;10,34000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;Low;Low;Low;Low;Low;Low;2024;psilocybin;niacin;25 mg;100 mg;psilocybin arm;niacin arm;1;38,0000000000000;50,0000000000000;dep;NA;parallel;double-blind;10.1001/jamanetworkopen.2024.49026;NCT05163496;Back, A. L., Freeman-Young, T. K., Morgan, L., Sethi, T., Baker, K. K., Myers, S., McGregor, B. A., Harvey, K., Tai, M., Kollefrath, A., Thomas, B. J., Sorta, D., Kaelen, M., Kelmendi, B., & Gooley, T. A. (2024). Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial. JAMA Network Open, 7(12), e2449026. https://doi.org/10.1001/jamanetworkopen.2024.49026;Back2024_msd_madrs_Day28_4.00_clinician_psil_ncn_NA_NA;-1,42153552640955994;0,410986356401838;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;change;qids-sr;self-report;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;30;-8,000;5,47722557505166;29;-6,000;5,38516480713450;NA;NA;NA;NA;14,500;3,90000000000000;30;16,400;4,10000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;dep;NA;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_change_qids-sr_Week6_3.00_self-report_psil_esc_NA_NA;-0,36330936175831902;0,262611586674514;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;change;bdi-1a;self-report;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;30;-18,400;12,29581251542210;29;-10,800;9,61636572702590;NA;NA;NA;NA;29,100;6,80000000000000;30;28,700;7,00000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;dep;NA;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_change_bdi-1a_Week6_3.00_self-report_psil_esc_NA_NA;-0,67801807970489791;0,267986899585578;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;change;ham-d-17;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;30;-10,500;5,47722557505166;29;-5,100;5,38516480713450;NA;NA;NA;NA;19,200;2,30000000000000;30;18,400;3,40000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;dep;NA;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_change_ham-d-17_Week6_3.00_clinician_psil_esc_NA_NA;-0,98093527674746128;0,276026275889254;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;change;madrs;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;30;-14,400;9,31128347758782;29;-7,200;9,15478017212866;NA;NA;NA;NA;27,900;4,00000000000000;30;26,900;5,30000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;dep;NA;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_change_madrs_Week6_3.00_clinician_psil_esc_NA_NA;-0,76936100137055774;0,270125147933961;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;msd;qids-sr;self-report;depression;1;Post-second dose 1;Week 6;3,00;21,000;1;NA;30;6,900;5,90000000000000;29;10,100;5,80000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14,500;3,90000000000000;30;16,400;4,10000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;dep;NA;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_msd_qids-sr_Week6_3.00_self-report_psil_esc_NA_NA;-0,53967873292569379;0,265237432013847;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;msd;bdi-1a;self-report;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;30;10,700;11,00000000000000;29;17,900;11,10000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;29,100;6,80000000000000;30;28,700;7,00000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;dep;NA;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_msd_bdi-1a_Week6_3.00_self-report_psil_esc_NA_NA;-0,64301693596713383;0,267235040715549;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;msd;ham-d-17;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;30;8,300;5,50000000000000;29;13,600;5,20000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;19,200;2,30000000000000;30;18,400;3,40000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;dep;NA;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_msd_ham-d-17_Week6_3.00_clinician_psil_esc_NA_NA;-0,97669793075590361;0,275895471772229;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;msd;madrs;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;30;13,000;10,00000000000000;29;19,800;8,50000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;27,900;4,00000000000000;30;26,900;5,30000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;dep;NA;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_msd_madrs_Week6_3.00_clinician_psil_esc_NA_NA;-0,72202724206718649;0,268985534799480;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;response;qids-sr;self-report;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21;30;14;29;14,500;3,90000000000000;30;16,400;4,10000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;dep;NA;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_response_qids-sr_Week6_3.00_self-report_psil_esc_NA_NA;-0,49850120170936724;0,300373270489182;0,3715635564324830;0,226343824951325;21;14;30;29
Carhart-Harris 2021;psil;esc;NA;NA;remission;qids-sr;self-report;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;30;8;29;14,500;3,90000000000000;30;16,400;4,10000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;dep;NA;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_remission_qids-sr_Week6_3.00_self-report_psil_esc_NA_NA;-0,67099216954833840;0,306156690535671;0,7198702507006988;0,340598645707439;17;8;30;29
Carhart-Harris 2021;psil;esc;NA;NA;response;bdi-1a;self-report;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;23;30;12;29;29,100;6,80000000000000;30;28,700;7,00000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;dep;NA;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_response_bdi-1a_Week6_3.00_self-report_psil_esc_NA_NA;-0,83667810429445455;0,315989993146670;0,6166860144654681;0,242889897379194;23;12;30;29
Carhart-Harris 2021;psil;esc;NA;NA;remission;bdi-1a;self-report;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;30;5;29;29,100;6,80000000000000;30;28,700;7,00000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;dep;NA;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_remission_bdi-1a_Week6_3.00_self-report_psil_esc_NA_NA;-0,99934093835083038;0,338703230909486;1,1898738799464341;0,437043976571857;17;5;30;29
Carhart-Harris 2021;psil;esc;NA;NA;response;ham-d-17;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22;30;7;29;19,200;2,30000000000000;30;18,400;3,40000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;dep;NA;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_response_ham-d-17_Week6_3.00_clinician_psil_esc_NA_NA;-1,17335476888894030;0,330230008279525;1,1112307526273211;0,347124756186685;22;7;30;29
Carhart-Harris 2021;psil;esc;NA;NA;response;madrs;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;30;6;29;27,900;4,00000000000000;30;26,900;5,30000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;dep;NA;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_response_madrs_Week6_3.00_clinician_psil_esc_NA_NA;-1,10815056090644326;0,330863916168362;1,1700712526502546;0,385811579287926;20;6;30;29
Carhart-Harris 2021;psil;esc;NA;NA;remission;ham-d-17;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15;30;3;29;19,200;2,30000000000000;30;18,400;3,40000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;dep;NA;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_remission_ham-d-17_Week6_3.00_clinician_psil_esc_NA_NA;-1,17485144826604637;0,391842523093344;1,5755363607584190;0,576353978077689;15;3;30;29
Carhart-Harris 2021;psil;esc;NA;NA;remission;madrs;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;30;2;29;27,900;4,00000000000000;30;26,900;5,30000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;dep;NA;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_remission_madrs_Week6_3.00_clinician_psil_esc_NA_NA;-0,95500795088472690;0,459878100635296;1,4701758451005926;0,737085489720893;9;2;30;29
Davis 2021;psil;wl;NA;NA;msd;bdi;self-report;depression;0;Post-second dose 1;Week 5;1,00;7,000;0;0;13;8,200;8,90000000000000;11;35,200;9,10000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;7,00000000000000;13;34,500;10,00000000000000;11;Low;Some concerns;Some concerns;Low;Low;Some concerns;2021;psilocybin;waitlist;"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;immediate treatment group;delayed treatment group;2;39,8666666666667;66,7777777777778;dep;NA;crossover;open-label;"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";NCT03181529;Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285;Davis2021_msd_bdi_Week5_1.00_self-report_psil_wl_NA_NA;-2,89930264844220353;0,596396246972318;NA;NA;NA;NA;NA;NA
Davis 2021;psil;wl;NA;NA;msd;bdi;self-report;depression;0;Post-second dose 2;Week 8;4,00;28,000;1;0;13;8,200;7,00000000000000;11;35,900;8,40000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;7,00000000000000;13;34,500;10,00000000000000;11;Low;Some concerns;Some concerns;Low;Low;Some concerns;2021;psilocybin;waitlist;"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;immediate treatment group;delayed treatment group;2;39,8666666666667;66,7777777777778;dep;NA;crossover;open-label;"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";NCT03181529;Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285;Davis2021_msd_bdi_Week8_4.00_self-report_psil_wl_NA_NA;-3,48779651560760939;0,663090832701423;NA;NA;NA;NA;NA;NA
Davis 2021;psil;wl;NA;NA;msd;qids-sr;self-report;depression;0;Post-second dose 1;Week 5;1,00;7,000;0;0;13;5,200;4,60000000000000;11;31,900;5,60000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,200;3,60000000000000;13;17,400;3,60000000000000;11;Low;Some concerns;Some concerns;Low;Low;Some concerns;2021;psilocybin;waitlist;"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;immediate treatment group;delayed treatment group;2;39,8666666666667;66,7777777777778;dep;NA;crossover;open-label;"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";NCT03181529;Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285;Davis2021_msd_qids-sr_Week5_1.00_self-report_psil_wl_NA_NA;-5,07565447275226678;0,862303533688809;NA;NA;NA;NA;NA;NA
Davis 2021;psil;wl;NA;NA;msd;qids-sr;self-report;depression;0;Post-second dose 2;Week 8;4,00;28,000;1;0;13;5,500;3,60000000000000;11;17,700;3,70000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,200;3,60000000000000;13;17,400;3,60000000000000;11;Low;Some concerns;Some concerns;Low;Low;Some concerns;2021;psilocybin;waitlist;"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;immediate treatment group;delayed treatment group;2;39,8666666666667;66,7777777777778;dep;NA;crossover;open-label;"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";NCT03181529;Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285;Davis2021_msd_qids-sr_Week8_4.00_self-report_psil_wl_NA_NA;-3,23093088729085398;0,633341175482840;NA;NA;NA;NA;NA;NA
Davis 2021;psil;wl;NA;NA;msd;grid-ham-d;clinician;depression;1;Post-second dose 1;Week 5;1,00;7,000;0;0;13;8,000;7,10000000000000;11;23,800;5,40000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,900;3,60000000000000;13;22,500;4,40000000000000;11;Low;Some concerns;Some concerns;Low;Low;Some concerns;2021;psilocybin;waitlist;"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;immediate treatment group;delayed treatment group;2;39,8666666666667;66,7777777777778;dep;NA;crossover;open-label;"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";NCT03181529;Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285;Davis2021_msd_grid-ham-d_Week5_1.00_clinician_psil_wl_NA_NA;-2,38972798584679724;0,543559686244671;NA;NA;NA;NA;NA;NA
Davis 2021;psil;wl;NA;NA;msd;grid-ham-d;clinician;depression;1;Post-second dose 2;Week 8;4,00;28,000;1;0;13;8,500;5,70000000000000;11;23,500;6,00000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,900;3,60000000000000;13;22,500;4,40000000000000;11;Low;Some concerns;Some concerns;Low;Low;Some concerns;2021;psilocybin;waitlist;"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;immediate treatment group;delayed treatment group;2;39,8666666666667;66,7777777777778;dep;NA;crossover;open-label;"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";NCT03181529;Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285;Davis2021_msd_grid-ham-d_Week8_4.00_clinician_psil_wl_NA_NA;-2,48065716535764702;0,552588609503246;NA;NA;NA;NA;NA;NA
Davis 2021;psil;wl;NA;NA;msd;phq-9;self-report;depression;0;Post-second dose 2;Week 8;4,00;28,000;1;0;13;4,800;2,90000000000000;11;18,800;4,30000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,500;3,10000000000000;13;17,900;3,30000000000000;11;Low;Some concerns;Some concerns;Low;Low;Some concerns;2021;psilocybin;waitlist;"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;immediate treatment group;delayed treatment group;2;39,8666666666667;66,7777777777778;dep;NA;crossover;open-label;"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";NCT03181529;Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285;Davis2021_msd_phq-9_Week8_4.00_self-report_psil_wl_NA_NA;-3,75018853776688310;0,694357648017136;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;qids-sr;self-report;depression;0;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;79;-6,300;5,89523099107666;75;-5,200;5,96497089341323;NA;NA;NA;NA;16,100;4,14000000000000;79;16,300;4,16000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_qids-sr_Week3_3.00_self-report_psil_psil_25mg_10mg;-0,18460291306012985;0,161565177688826;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;qids-sr;self-report;depression;0;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;79;-6,300;5,89523099107666;79;-3,600;6,12197064457961;NA;NA;NA;NA;16,100;4,14000000000000;79;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_qids-sr_Week3_3.00_self-report_psil_psil_25mg_1mg;-0,44711245099768004;0,161106231491561;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;qids-sr;self-report;depression;0;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;75;-5,200;5,96497089341323;79;-3,600;6,12197064457961;NA;NA;NA;NA;16,300;4,16000000000000;75;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_qids-sr_Week3_3.00_self-report_psil_psil_10mg_1mg;-0,26332785116562563;0,161922629984635;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;qids-sr;self-report;depression;0;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;79;-6,500;29,24941530188038;75;-5,500;7,06959513293419;NA;NA;NA;NA;16,100;4,14000000000000;79;16,300;4,16000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_qids-sr_Week12_12.00_self-report_psil_psil_25mg_10mg;-0,04622662928049439;0,161240715280361;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;qids-sr;self-report;depression;0;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;79;-6,500;29,24941530188038;79;-5,000;7,02892925859141;NA;NA;NA;NA;16,100;4,14000000000000;79;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_qids-sr_Week12_12.00_self-report_psil_psil_25mg_1mg;-0,07017806878265766;0,159160900372791;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;qids-sr;self-report;depression;0;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;75;-5,500;7,06959513293419;79;-5,000;7,02892925859141;NA;NA;NA;NA;16,300;4,16000000000000;75;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_qids-sr_Week12_12.00_self-report_psil_psil_10mg_1mg;-0,07058391584933107;0,161269643391451;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;79;-15,026;12,05239162987994;75;-11,986;12,23693895547412;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Day2_0.29_clinician_psil_psil_25mg_10mg;-0,24912114593171114;0,161848897621857;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;79;-15,026;12,05239162987994;79;-9,078;12,05239162987994;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Day2_0.29_clinician_psil_psil_25mg_1mg;-0,49113554613926258;0,161515313598675;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;75;-11,986;12,23693895547412;79;-9,078;12,05239162987994;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Day2_0.29_clinician_psil_psil_10mg_1mg;-0,23830404354257123;0,161795477652513;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;79;-13,043;11,12801941047912;75;-8,796;11,77794549146837;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week1_1.00_clinician_psil_psil_25mg_10mg;-0,36911477037163343;0,162598654898194;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;79;-13,043;11,12801941047912;79;-6,887;11,59020552017953;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week1_1.00_clinician_psil_psil_25mg_1mg;-0,53922249061526439;0,162004663914633;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;75;-8,796;11,77794549146837;79;-6,887;11,59020552017953;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week1_1.00_clinician_psil_psil_10mg_1mg;-0,16260640126933609;0,161487655787320;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;79;-12,000;12,01720163565628;75;-7,900;11,92994178682645;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week3_3.00_clinician_psil_psil_25mg_10mg;-0,34069351044301460;0,162395109096660;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;79;-12,000;12,01720163565628;79;-5,400;12,24394128915923;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week3_3.00_clinician_psil_psil_25mg_1mg;-0,54143627865238364;0,162028254630371;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;75;-7,900;11,92994178682645;79;-5,400;12,24394128915923;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week3_3.00_clinician_psil_psil_10mg_1mg;-0,20572488372314504;0,161648820099789;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;79;-11,530;13,44783815339848;75;-5,991;13,58793858537784;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week6_6.00_clinician_psil_psil_25mg_10mg;-0,40777834306524813;0,162901252285212;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;79;-11,530;13,44783815339848;79;-6,261;12,98565204369808;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week6_6.00_clinician_psil_psil_25mg_1mg;-0,39668059044808601;0,160683685359775;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;75;-5,991;13,58793858537784;79;-6,261;12,98565204369808;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week6_6.00_clinician_psil_psil_10mg_1mg;0,02022736455153360;0,161223146003312;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;79;-9,339;14,37221037279931;75;-6,109;14,49726525935150;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week9_9.00_clinician_psil_psil_25mg_10mg;-0,22268312464111339;0,161722489932522;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;79;-9,339;14,37221037279931;79;-5,322;14,38109856721662;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week9_9.00_clinician_psil_psil_25mg_1mg;-0,27806582665982427;0,159885943110615;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;75;-6,109;14,49726525935150;79;-5,322;14,38109856721662;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week9_9.00_clinician_psil_psil_10mg_1mg;-0,05424039656402192;0,161248901762607;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;79;-9,496;14,38109856721662;75;-5,651;14,04693204938360;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week12_12.00_clinician_psil_psil_25mg_10mg;-0,26906891465809013;0,161953575769648;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;79;-9,496;14,38109856721662;79;-6,000;14,84328467691703;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week12_12.00_clinician_psil_psil_25mg_1mg;-0,23807040049667147;0,159679538002117;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;75;-5,651;14,04693204938360;79;-6,000;14,84328467691703;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week12_12.00_clinician_psil_psil_10mg_1mg;0,02401449041642934;0,161224849872201;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;response;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;42;79;24;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Day2_0.29_clinician_psil_psil_25mg_10mg;-0,48305875461703568;0,184601397856223;0,5076560490047115;0,198707396175270;42;24;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;42;79;18;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Day2_0.29_clinician_psil_psil_25mg_1mg;-0,73920316646147111;0,193189884520747;0,8472978603872034;0,232483598709408;42;18;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24;75;18;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Day2_0.29_clinician_psil_psil_10mg_1mg;-0,25605013073695237;0,201233919986895;0,3396418113824921;0,266890728652735;24;18;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;response;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35;79;17;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week1_1.00_clinician_psil_psil_25mg_10mg;-0,54771974280242786;0,196758469095511;0,6701749785024865;0,247797087960611;35;17;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35;79;12;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week1_1.00_clinician_psil_psil_25mg_1mg;-0,81804245767283490;0,213213509731684;1,0704414117014134;0,294258910160014;35;12;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;75;12;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week1_1.00_clinician_psil_psil_10mg_1mg;-0,27021837826529371;0,230191279338547;0,4002664331989267;0,340830311978943;17;12;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;response;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;29;79;14;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week3_3.00_clinician_psil_psil_25mg_10mg;-0,50860496869956251;0,207979479793817;0,6762787614405044;0,282700846952793;29;14;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;29;79;14;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week3_3.00_clinician_psil_psil_25mg_1mg;-0,54351800232260727;0,207240964352298;0,7282385003712155;0,283892364027387;29;14;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14;75;14;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week3_3.00_clinician_psil_psil_10mg_1mg;-0,03484371103147465;0,230396909206025;0,0519597389307112;0,341856083280243;14;14;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;response;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;79;11;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week6_6.00_clinician_psil_psil_25mg_10mg;-0,57537176793779310;0,223178286826114;0,8082415262924004;0,321526154751359;26;11;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;79;16;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week6_6.00_clinician_psil_psil_25mg_1mg;-0,36121988671638899;0,203097531606742;0,4855078157817008;0,275036511694967;26;16;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;11;75;16;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week6_6.00_clinician_psil_psil_10mg_1mg;0,21419795273801784;0,237075981004254;-0,3227337105106995;0,356955921267117;11;16;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;response;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;79;12;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week9_9.00_clinician_psil_psil_25mg_10mg;-0,31622793564509760;0,224733656397081;0,4588658848352796;0,327630542153656;20;12;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;79;12;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week9_9.00_clinician_psil_psil_25mg_1mg;-0,35004349052636913;0,224091872823937;0,5108256237659907;0,328659212007104;20;12;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;75;12;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week9_9.00_clinician_psil_psil_10mg_1mg;-0,03377090884963717;0,244994243823549;0,0519597389307110;0,375066801363746;12;12;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;response;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;79;12;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week12_12.00_clinician_psil_psil_25mg_10mg;-0,51899736264531959;0,218131110395555;0,7212301493027706;0,309521098817895;26;12;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;79;13;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week12_12.00_clinician_psil_psil_25mg_1mg;-0,50067053597456312;0,213104169598532;0,6931471805599453;0,300113577980759;26;13;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;75;13;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week12_12.00_clinician_psil_psil_10mg_1mg;0,01839068431471346;0,241127423028606;-0,0280829687428252;0,366421682048123;12;13;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;response;madrs;clinician;depression;1;Post-first dose 7;Week 3-12 Sustained Response;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;79;3;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week3-12SustainedResponse_12.00_clinician_psil_psil_25mg_10mg;-0,99160609743480599;0,359674074446653;1,6220166946409604;0,608146176631818;16;3;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 7;Week 3-12 Sustained Response;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;79;6;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week3-12SustainedResponse_12.00_clinician_psil_psil_25mg_1mg;-0,61898877394486473;0,280440753604151;0,9808292530117262;0,451497741932852;16;6;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 7;Week 3-12 Sustained Response;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;3;75;6;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week3-12SustainedResponse_12.00_clinician_psil_psil_10mg_1mg;0,37269627194386418;0,400458956333702;-0,6411874416292344;0,688482707712086;3;6;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;remission;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;30;79;16;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Day2_0.29_clinician_psil_psil_25mg_10mg;-0,44674242736280145;0,201209101839793;0,5766489204916631;0,264275939411628;30;16;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;30;79;15;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Day2_0.29_clinician_psil_psil_25mg_1mg;-0,52684226306569792;0,203344838513193;0,6931471805599453;0,273282901594296;30;15;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;75;15;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Day2_0.29_clinician_psil_psil_10mg_1mg;-0,08003264000584821;0,221728017482283;0,1164982600682823;0,321208819127421;16;15;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;remission;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;25;79;8;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week1_1.00_clinician_psil_psil_25mg_10mg;-0,74343684682551936;0,245600712471635;1,0874745442576539;0,372838354811526;25;8;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;25;79;9;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week1_1.00_clinician_psil_psil_25mg_1mg;-0,70294054932581040;0,236439338957101;1,0216512475319814;0,354675422625967;25;9;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;8;75;9;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week1_1.00_clinician_psil_psil_10mg_1mg;0,04058595351917987;0,283986403909221;-0,0658232967256723;0,458387990603677;8;9;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;remission;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;23;79;7;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week3_3.00_clinician_psil_psil_25mg_10mg;-0,75912540018388175;0,257947947756852;1,1376243279431253;0,400429572515909;23;7;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;23;79;6;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week3_3.00_clinician_psil_psil_25mg_1mg;-0,88273008225015182;0,271050185749346;1,3437347467010947;0,429916819675655;23;6;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;7;75;6;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week3_3.00_clinician_psil_psil_10mg_1mg;-0,12349209492711938;0,320496322472041;0,2061104187579694;0,532477462755350;7;6;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;remission;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;79;7;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week6_6.00_clinician_psil_psil_25mg_10mg;-0,65382211876337593;0,261234604859298;0,9978623855679666;0,408491837954822;20;7;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;79;10;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week6_6.00_clinician_psil_psil_25mg_1mg;-0,46621722690354056;0,234844046305309;0,6931471805599453;0,353105571046107;20;10;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;7;75;10;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week6_6.00_clinician_psil_psil_10mg_1mg;0,18766435518260557;0,287567453972760;-0,3047152050080214;0,465688288102362;7;10;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;remission;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;79;9;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week9_9.00_clinician_psil_psil_25mg_10mg;-0,34116816345177042;0,249402839658612;0,5234044059728509;0,384212896620710;16;9;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;79;9;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week9_9.00_clinician_psil_psil_25mg_1mg;-0,37349593678986254;0,248874676341758;0,5753641449035619;0,385090450952641;16;9;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;75;9;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week9_9.00_clinician_psil_psil_10mg_1mg;-0,03228013608197812;0,276577838141005;0,0519597389307110;0,442979300916857;9;9;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;remission;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21;79;5;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week12_12.00_clinician_psil_psil_25mg_10mg;-0,89045938373218436;0,291290666364917;1,3831247863586114;0,470773285603180;21;5;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21;79;9;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week12_12.00_clinician_psil_psil_25mg_1mg;-0,56806969819056030;0,240481329850560;0,8472978603872034;0,365258405836137;21;9;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;75;9;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week12_12.00_clinician_psil_psil_10mg_1mg;0,32246213956063119;0,321327108955673;-0,5358269259714080;0,533965869629957;5;9;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;79;16,874;10,53912408759124;75;21,014;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Day2_0.29_clinician_psil_psil_25mg_10mg;-0,39654492550867360;0,162810289829870;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;79;16,874;10,53912408759124;79;23,622;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Day2_0.29_clinician_psil_psil_25mg_1mg;-0,64668668511676197;0,163256618223517;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;75;21,014;10,53912408759124;79;23,622;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Day2_0.29_clinician_psil_psil_10mg_1mg;-0,25000147259605821;0,161853348627889;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;79;18,857;10,53912408759124;75;24,204;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week1_1.00_clinician_psil_psil_25mg_10mg;-0,51215597021615411;0,163864815195660;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;79;18,857;10,53912408759124;79;25,813;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week1_1.00_clinician_psil_psil_25mg_1mg;-0,66662012176529273;0,163512602249458;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;75;24,204;10,53912408759124;79;25,813;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week1_1.00_clinician_psil_psil_10mg_1mg;-0,15423787170516007;0,161460733330932;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;79;19,900;10,53912408759124;75;25,100;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week3_3.00_clinician_psil_psil_25mg_10mg;-0,49807575184664338;0,163722432833855;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;79;19,900;10,53912408759124;79;27,300;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week3_3.00_clinician_psil_psil_25mg_1mg;-0,70917034230350318;0,164083582263683;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;75;25,100;10,53912408759124;79;27,300;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week3_3.00_clinician_psil_psil_10mg_1mg;-0,21089081277274843;0,161670647650147;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;79;20,370;10,53912408759124;75;27,009;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week6_6.00_clinician_psil_psil_25mg_10mg;-0,63590863779035878;0,165280238538101;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;79;20,370;10,53912408759124;79;26,439;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week6_6.00_clinician_psil_psil_25mg_1mg;-0,58161551451891369;0,162472569947978;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;75;27,009;10,53912408759124;79;26,439;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week6_6.00_clinician_psil_psil_10mg_1mg;0,05463989240021171;0,161249344032070;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;79;22,561;10,53912408759124;75;26,891;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week9_9.00_clinician_psil_psil_25mg_10mg;-0,41474384721076230;0,162958905257691;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;79;22,561;10,53912408759124;79;27,378;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week9_9.00_clinician_psil_psil_25mg_1mg;-0,46163155930756411;0,161237019689574;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;75;26,891;10,53912408759124;79;27,378;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week9_9.00_clinician_psil_psil_10mg_1mg;-0,04668355719105886;0,161241146956967;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;79;22,404;10,53912408759124;75;27,349;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week12_12.00_clinician_psil_psil_25mg_10mg;-0,47365088324647153;0,163484580987544;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;79;22,404;10,53912408759124;79;26,700;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week12_12.00_clinician_psil_psil_25mg_1mg;-0,41170213385619620;0,160804375658786;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;75;27,349;10,53912408759124;79;26,700;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week12_12.00_clinician_psil_psil_10mg_1mg;0,06221278976796046;0,161258341358482;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;qids-sr;self-report;depression;0;Post-first dose 3;Week 3;3,00;21,000;1;NA;79;9,800;5,20465116279070;75;11,100;5,22250000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,100;4,14000000000000;79;16,300;4,16000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_qids-sr_Week3_3.00_self-report_psil_psil_25mg_10mg;-0,24812747376470318;0,161843892248539;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;qids-sr;self-report;depression;0;Post-first dose 3;Week 3;3,00;21,000;1;NA;79;9,800;5,20465116279070;79;12,200;5,22250000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,100;4,14000000000000;79;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_qids-sr_Week3_3.00_self-report_psil_psil_25mg_1mg;-0,45811928515047246;0,161205007705512;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;qids-sr;self-report;depression;0;Post-first dose 3;Week 3;3,00;21,000;1;NA;75;11,100;5,20465116279070;79;12,200;5,22250000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,300;4,16000000000000;75;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_qids-sr_Week3_3.00_self-report_psil_psil_10mg_1mg;-0,20993510179968158;0,161666568909026;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;qids-sr;self-report;depression;0;Post-first dose 6;Week 12;12,00;84,000;0;NA;79;9,600;5,20465116279070;75;10,800;5,22250000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,100;4,14000000000000;79;16,300;4,16000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_qids-sr_Week12_12.00_self-report_psil_psil_25mg_10mg;-0,22904074501357188;0,161751602527394;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;qids-sr;self-report;depression;0;Post-first dose 6;Week 12;12,00;84,000;0;NA;79;9,600;5,20465116279070;79;10,800;5,22250000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,100;4,14000000000000;79;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_qids-sr_Week12_12.00_self-report_psil_psil_25mg_1mg;-0,22905964257523606;0,159637418544292;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;qids-sr;self-report;depression;0;Post-first dose 6;Week 12;12,00;84,000;0;NA;75;10,800;5,20465116279070;79;10,800;5,22250000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,300;4,16000000000000;75;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;NA;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_qids-sr_Week12_12.00_self-report_psil_psil_10mg_1mg;0,00000000000000000;0,161218985176792;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;bdi;self-report;depression;0;Post-first dose 1;5 weeks after session 1;5,00;35,000;1;0;26;7,000;7,08763712389397;25;12,920;7,90000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17,770;8,20942141688438;26;18,400;5,45000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;NA;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_bdi_5weeksaftersession1_5.00_self-report_psil_psil_22mg/kg_1mg/kg;-0,77754880367406609;0,290818652815185;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;bdi;self-report;depression;0;Post-second dose 1;5 weeks after session 2;5,00;35,000;0;1;25;5,800;7,05000000000000;24;8,170;6,07473456210228;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17,770;8,20942141688438;26;18,400;5,45000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;NA;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_bdi_5weeksaftersession2_5.00_self-report_psil_psil_22mg/kg_1mg/kg;-0,35382339575641347;0,288073118615127;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;bdi;self-report;depression;0;Follow-up 1;6 months;26,09;182,625;0;1;24;6,170;6,17271415181361;22;8,000;7,03562363973514;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17,770;8,20942141688438;26;18,400;5,45000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;NA;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_bdi_6months_26.09_self-report_psil_psil_22mg/kg_1mg/kg;-0,27257529146759862;0,296575805493764;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;grid-ham-d;clinician;depression;1;Post-first dose 1;5 weeks after session 1;5,00;35,000;1;0;25;6,640;5,20000000000000;25;14,800;7,25000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;NA;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_grid-ham-d_5weeksaftersession1_5.00_clinician_psil_psil_22mg/kg_1mg/kg;-1,27311104197224201;0,311013705206831;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;grid-ham-d;clinician;depression;1;Post-second dose 1;5 weeks after session 2;5,00;35,000;0;1;25;6,520;7,20000000000000;24;6,500;4,21312235758707;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;NA;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_grid-ham-d_5weeksaftersession2_5.00_clinician_psil_psil_22mg/kg_1mg/kg;0,00331890655475999;0,285774006447645;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;grid-ham-d;clinician;depression;1;Follow-up 1;6 months;26,09;182,625;0;1;24;6,230;6,36867333123626;22;6,950;5,81611554218105;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;NA;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_grid-ham-d_6months_26.09_clinician_psil_psil_22mg/kg_1mg/kg;-0,11579698553577734;0,295418499944029;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;hads-d;self-report;depression;0;Post-first dose 1;5 weeks after session 1;5,00;35,000;1;0;26;3,920;3,77327444005866;25;6,040;3,95000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,810;3,51832346437902;26;9,480;3,55000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;NA;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_hads-d_5weeksaftersession1_5.00_self-report_psil_psil_22mg/kg_1mg/kg;-0,54065489082500096;0,285337615889013;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;hads-d;self-report;depression;0;Post-second dose 1;5 weeks after session 2;5,00;35,000;0;1;25;4,280;4,45000000000000;24;4,570;3,57625502446344;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,810;3,51832346437902;26;9,480;3,55000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;NA;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_hads-d_5weeksaftersession2_5.00_self-report_psil_psil_22mg/kg_1mg/kg;-0,07052468938737315;0,285865505950152;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;hads-d;self-report;depression;0;Follow-up 1;6 months;26,09;182,625;0;1;24;3,460;3,23332646047380;22;4,640;3,37709934707287;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,810;3,51832346437902;26;9,480;3,55000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;NA;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_hads-d_6months_26.09_self-report_psil_psil_22mg/kg_1mg/kg;-0,35115579586740397;0,297504127606758;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;response;grid-ham-d;clinician;depression;1;Post-first dose 1;5 weeks after session 1;5,00;35,000;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;23;25;8;25;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;NA;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_response_grid-ham-d_5weeksaftersession1_5.00_clinician_psil_psil_22mg/kg_1mg/kg;-1,73443550611936326;0,470184256190578;1,0560526742493137;0,297452955725044;23;8;25;25
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;response;grid-ham-d;clinician;depression;1;Post-second dose 1;5 weeks after session 2;5,00;35,000;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21;25;18;24;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;NA;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_response_grid-ham-d_5weeksaftersession2_5.00_clinician_psil_psil_22mg/kg_1mg/kg;-0,30358263731036345;0,397508236769202;0,1133286853070031;0,146655843756519;21;18;25;24
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;response;grid-ham-d;clinician;depression;1;Follow-up 1;6 months;26,09;182,625;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;19;24;17;22;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;NA;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_response_grid-ham-d_6months_26.09_clinician_psil_psil_22mg/kg_1mg/kg;-0,06027067386422890;0,394288867299855;0,0242142581205945;0,155993257027094;19;17;24;22
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;remission;grid-ham-d;clinician;depression;1;Post-first dose 1;5 weeks after session 1;5,00;35,000;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15;25;4;25;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;NA;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_remission_grid-ham-d_5weeksaftersession1_5.00_clinician_psil_psil_22mg/kg_1mg/kg;-1,11990289316815228;0,375667318726251;1,3217558399823195;0,486483983977547;15;4;25;25
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;remission;grid-ham-d;clinician;depression;1;Post-second dose 1;5 weeks after session 2;5,00;35,000;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;25;14;24;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;NA;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_remission_grid-ham-d_5weeksaftersession2_5.00_clinician_psil_psil_22mg/kg_1mg/kg;-0,22637835717215685;0,328608718760945;0,1533340199207023;0,220421038409834;17;14;25;24
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;remission;grid-ham-d;clinician;depression;1;Follow-up 1;6 months;26,09;182,625;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;24;13;22;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;NA;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_remission_grid-ham-d_6months_26.09_clinician_psil_psil_22mg/kg_1mg/kg;-0,28154787481164734;0,344178896486629;0,1812526096050495;0,220511664574982;17;13;24;22
Grob 2011;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Pre-first dose 1;1 day before experimental session;-0,14;-1,000;0;1;12;16,090;12,70978882594042;12;14,369;13,64856036364275;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;Low;Some concerns;Low;Some concerns;High;High;2011;psilocybin;niacin;0.2 mg/kg;250 mg;psilocybin;niacin placebo;1;NA;NA;cancer;NA;crossover;double-blind;10.1001/archgenpsychiatry.2010.116;NCT00302744;Grob, C., Danforth, A., Chopra, G., Hagerty, M., McKay, C., Halberstadt, A., & Greer, G. (2011). Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. ARCHIVES OF GENERAL PSYCHIATRY, 68(1), 71–78. https://doi.org/10.1001/archgenpsychiatry.2010.116;Grob2011_msd_bdi_1daybeforeexperimentalsession_-0.14_self-report_psil_ncn_NA_NA;0,12600199461443884;0,408682608848014;NA;NA;NA;NA;NA;NA
Grob 2011;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 1;1 day after experimental session;0,14;1,000;0;1;12;11,442;10,04243058228435;12;13,208;11,76755318662295;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;Low;Some concerns;Low;Some concerns;High;High;2011;psilocybin;niacin;0.2 mg/kg;250 mg;psilocybin;niacin placebo;1;NA;NA;cancer;NA;crossover;double-blind;10.1001/archgenpsychiatry.2010.116;NCT00302744;Grob, C., Danforth, A., Chopra, G., Hagerty, M., McKay, C., Halberstadt, A., & Greer, G. (2011). Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. ARCHIVES OF GENERAL PSYCHIATRY, 68(1), 71–78. https://doi.org/10.1001/archgenpsychiatry.2010.116;Grob2011_msd_bdi_1dayafterexperimentalsession_0.14_self-report_psil_ncn_NA_NA;-0,15587305359912776;0,408912757018787;NA;NA;NA;NA;NA;NA
Grob 2011;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 2;2 weeks after experimental session;2,00;14,000;1;1;12;10,054;9,25607951564808;12;13,270;10,98120211998668;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;Low;Some concerns;Low;Some concerns;High;High;2011;psilocybin;niacin;0.2 mg/kg;250 mg;psilocybin;niacin placebo;1;NA;NA;cancer;NA;crossover;double-blind;10.1001/archgenpsychiatry.2010.116;NCT00302744;Grob, C., Danforth, A., Chopra, G., Hagerty, M., McKay, C., Halberstadt, A., & Greer, G. (2011). Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. ARCHIVES OF GENERAL PSYCHIATRY, 68(1), 71–78. https://doi.org/10.1001/archgenpsychiatry.2010.116;Grob2011_msd_bdi_2weeksafterexperimentalsession_2.00_self-report_psil_ncn_NA_NA;-0,30576069806097955;0,410799187568030;NA;NA;NA;NA;NA;NA
Krempien 2023;psil-d;psil-d;16 mg;12 mg;msd;madrs;clinician;depression;1;Post-first dose 4;Day 21;3,00;21,000;1;NA;9;16,556;6,14600000000000;15;15,867;8,68400000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,444;4,03500000000000;9;32,611;3,66400000000000;18;NA;NA;NA;NA;NA;NA;2023;CYB003 deuterated psilocin;CYB003 deuterated psilocin;16 mg;12 mg;16 mg group;12 mg group;1;NA;NA;dep;NA;parallel;double-blind;10.1038/s41386-023-01755-5;NCT05385783;Krempien, S., Inamdar, A., Shenouda, M., Johnson, K., Maass-Robinsin, S., Johnson, M., Kelman, A., Nathan, P., Belser, A., Pathare, P., House-Gecewicz, A., Sorie, A., Bartlone, A., Varty, G., Morgan, M., Avery, K., Muhammad, A., Nivorozhkin, A., & Palfreyman, M. (2023). Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CYB003, a Deuterated Psilocybin Analog in Patients With Major Depressive Disorder. NEUROPSYCHOPHARMACOLOGY, 48, 195–196;Krempien2023_msd_madrs_Day21_3.00_clinician_psil-d_psil-d_16mg_12mg;0,08467365452156889;0,421826984238059;NA;NA;NA;NA;NA;NA
Krempien 2023;psil-d;pcb;16 mg;NA;msd;madrs;clinician;depression;1;Post-first dose 4;Day 21;3,00;21,000;1;NA;9;16,556;6,14600000000000;9;29,000;5,31500000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,444;4,03500000000000;9;31,556;4,92700000000000;9;NA;NA;NA;NA;NA;NA;2023;CYB003 deuterated psilocin;placebo;16 mg;NA;16 mg group;placebo;1;NA;NA;dep;NA;parallel;double-blind;10.1038/s41386-023-01755-5;NCT05385783;Krempien, S., Inamdar, A., Shenouda, M., Johnson, K., Maass-Robinsin, S., Johnson, M., Kelman, A., Nathan, P., Belser, A., Pathare, P., House-Gecewicz, A., Sorie, A., Bartlone, A., Varty, G., Morgan, M., Avery, K., Muhammad, A., Nivorozhkin, A., & Palfreyman, M. (2023). Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CYB003, a Deuterated Psilocybin Analog in Patients With Major Depressive Disorder. NEUROPSYCHOPHARMACOLOGY, 48, 195–196;Krempien2023_msd_madrs_Day21_3.00_clinician_psil-d_pcb_16mg_NA;-2,06271669538168512;0,593738559711083;NA;NA;NA;NA;NA;NA
Krempien 2023;psil-d;pcb;12 mg;NA;msd;madrs;clinician;depression;1;Post-first dose 4;Day 21;3,00;21,000;1;NA;15;15,867;8,68400000000000;9;29,000;5,31500000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;32,611;3,66400000000000;18;31,556;4,92700000000000;9;NA;NA;NA;NA;NA;NA;2023;CYB003 deuterated psilocin;placebo;12 mg;NA;12 mg group;placebo;1;NA;NA;dep;NA;parallel;double-blind;10.1038/s41386-023-01755-5;NCT05385783;Krempien, S., Inamdar, A., Shenouda, M., Johnson, K., Maass-Robinsin, S., Johnson, M., Kelman, A., Nathan, P., Belser, A., Pathare, P., House-Gecewicz, A., Sorie, A., Bartlone, A., Varty, G., Morgan, M., Avery, K., Muhammad, A., Nivorozhkin, A., & Palfreyman, M. (2023). Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CYB003, a Deuterated Psilocybin Analog in Patients With Major Depressive Disorder. NEUROPSYCHOPHARMACOLOGY, 48, 195–196;Krempien2023_msd_madrs_Day21_3.00_clinician_psil-d_pcb_12mg_NA;-1,66123853816432954;0,489338185039199;NA;NA;NA;NA;NA;NA
Lewis 2025;psil-mbsr;mbsr;NA;NA;msd;qids-sr;self-report;depression;1;Post-first dose 1;2 weeks;2,00;14,000;1;NA;12;4,800;2,50000000000000;10;9,900;3,20000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;Low;Low;Low;Some concerns;Low;Some concerns;2025;mbsr-psilocybin;mbsr;25 mg;NA;MBSR-PAP;MBSR;1;43,6400000000000;71,8400000000000;dep;NA;parallel;open-label;10.1371/journal.pmed.1004519;NCT05557643;"Lewis, B.R.; Hendrick, J.; Byrne, K.; Odette, M.; Wu, C.; Garland, E.L. (2025). Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial. PLOS Medicine, 22. https://doi.org/10.1371/journal.pmed.1004519";Lewis2025_msd_qids-sr_2weeks_2.00_self-report_psil-mbsr_mbsr_NA_NA;-1,72973732736908947;0,506761772923200;NA;NA;NA;NA;NA;NA
Lewis 2025;psil-mbsr;mbsr;NA;NA;msd;qids-sr;self-report;depression;1;Post-first dose 2;6 months;26,09;183,000;0;NA;12;6,100;3,30000000000000;10;8,000;2,90000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;Low;Low;Low;Some concerns;Low;Some concerns;2025;mbsr-psilocybin;mbsr;25 mg;NA;MBSR-PAP;MBSR;1;43,6400000000000;71,8400000000000;dep;NA;parallel;open-label;10.1371/journal.pmed.1004519;NCT05557643;"Lewis, B.R.; Hendrick, J.; Byrne, K.; Odette, M.; Wu, C.; Garland, E.L. (2025). Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial. PLOS Medicine, 22. https://doi.org/10.1371/journal.pmed.1004519";Lewis2025_msd_qids-sr_6months_26.09_self-report_psil-mbsr_mbsr_NA_NA;-0,58466074360579112;0,437867090525376;NA;NA;NA;NA;NA;NA
Lewis 2025;psil-mbsr;mbsr;NA;NA;remission;qids-sr;self-report;depression;1;Post-first dose 2;2 weeks;2,00;14,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;7;13;2;12;NA;NA;NA;NA;NA;NA;Low;Low;Low;Some concerns;Low;Some concerns;2025;mbsr-psilocybin;mbsr;25 mg;NA;MBSR-PAP;MBSR;1;43,6400000000000;71,8400000000000;dep;NA;parallel;open-label;10.1371/journal.pmed.1004519;NCT05557643;"Lewis, B.R.; Hendrick, J.; Byrne, K.; Odette, M.; Wu, C.; Garland, E.L. (2025). Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial. PLOS Medicine, 22. https://doi.org/10.1371/journal.pmed.1004519";Lewis2025_remission_qids-sr_2weeks_2.00_self-report_psil-mbsr_mbsr_NA_NA;-0,94026293239993042;0,525796621133611;1,1727202608218317;0,694694704601045;7;2;13;12
Luquiens 2025;psil;psil;25 mg;1 mg;msd;bdi-ii;self-report;depression;1;Post-first dose 1;Week 3;0,00;0,000;0;NA;20;15,000;12,00000000000000;10;14,000;9,00000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;11,00000000000000;20;31,000;9,00000000000000;10;Low;High;Low;Some concerns;Low;High;2025;psilocybin;psilocybin;25 mg;1 mg;25 mg group;10 mg group;2;49,6666666666667;43,3333333333333;aud;NA;parallel;double-blind;10.1111/add.70152;NCT06235411;"Luquiens, A.; Belahda, D.; Graux, C.; Igounenc, N.; Serrand, C.; Rochefort, P.; Mura, T.; Sergent, F. (2025). Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial. Addiction. https://doi.org/10.1111/add.70152";Luquiens2025_msd_bdi-ii_Week3_0.00_self-report_psil_psil_25mg_1mg;0,08746376594117736;0,387472166916128;NA;NA;NA;NA;NA;NA
Luquiens 2025;psil;psil;25 mg;1 mg;msd;bdi-ii;self-report;depression;1;Post-second dose 1;Week 6;3,00;21,000;1;NA;20;12,000;13,00000000000000;10;16,000;8,00000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;11,00000000000000;20;31,000;9,00000000000000;10;Low;High;Low;Some concerns;Low;High;2025;psilocybin;psilocybin;25 mg;1 mg;25 mg group;10 mg group;2;49,6666666666667;43,3333333333333;aud;NA;parallel;double-blind;10.1111/add.70152;NCT06235411;"Luquiens, A.; Belahda, D.; Graux, C.; Igounenc, N.; Serrand, C.; Rochefort, P.; Mura, T.; Sergent, F. (2025). Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial. Addiction. https://doi.org/10.1111/add.70152";Luquiens2025_msd_bdi-ii_Week6_3.00_self-report_psil_psil_25mg_1mg;-0,33465100311620588;0,389835423511669;NA;NA;NA;NA;NA;NA
Luquiens 2025;psil;psil;25 mg;1 mg;msd;bdi-ii;self-report;depression;1;Follow-up 1;Week 12;9,00;63,000;0;NA;20;15,000;14,00000000000000;9;16,000;10,00000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;11,00000000000000;20;31,000;9,00000000000000;10;Low;High;Low;Some concerns;Low;High;2025;psilocybin;psilocybin;25 mg;1 mg;25 mg group;10 mg group;2;49,6666666666667;43,3333333333333;aud;NA;parallel;double-blind;10.1111/add.70152;NCT06235411;"Luquiens, A.; Belahda, D.; Graux, C.; Igounenc, N.; Serrand, C.; Rochefort, P.; Mura, T.; Sergent, F. (2025). Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial. Addiction. https://doi.org/10.1111/add.70152";Luquiens2025_msd_bdi-ii_Week12_9.00_self-report_psil_psil_25mg_1mg;-0,07508793234526946;0,401514645548271;NA;NA;NA;NA;NA;NA
Luquiens 2025;psil;psil;25 mg;1 mg;response;bdi-ii;self-report;depression;1;Follow-up 1;Week 12;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;10;20;6;9;33,000;11,00000000000000;20;31,000;9,00000000000000;10;Low;High;Low;Some concerns;Low;High;2025;psilocybin;psilocybin;25 mg;1 mg;25 mg group;10 mg group;2;49,6666666666667;43,3333333333333;aud;NA;parallel;double-blind;10.1111/add.70152;NCT06235411;"Luquiens, A.; Belahda, D.; Graux, C.; Igounenc, N.; Serrand, C.; Rochefort, P.; Mura, T.; Sergent, F. (2025). Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial. Addiction. https://doi.org/10.1111/add.70152";Luquiens2025_response_bdi-ii_Week12_9.00_self-report_psil_psil_25mg_1mg;0,37143752542033442;0,461274848272599;-0,2876820724517809;0,324893144826965;10;6;20;9
Raison 2023;psil;ncn;NA;NA;change;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;51;-2,700;5,10102030610204;53;-2,700;5,20007849234323;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;dep;NA;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_change_madrs_Day2_0.29_clinician_psil_ncn_NA_NA;0,00000000000000000;0,196152409277982;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;change;madrs;clinician;depression;1;Post-first dose 2;Day 8;1,14;8,000;0;NA;NA;NA;NA;NA;NA;NA;51;-17,800;11,84165428202259;53;-5,800;12,07161078579678;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;dep;NA;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_change_madrs_Day8_1.14_clinician_psil_ncn_NA_NA;-0,99599549798874898;0,208125264900041;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;change;madrs;clinician;depression;1;Post-first dose 3;Day 15;2,14;15,000;0;NA;NA;NA;NA;NA;NA;NA;51;-18,000;12,02383357866909;53;-6,900;12,62876205283355;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;dep;NA;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_change_madrs_Day15_2.14_clinician_psil_ncn_NA_NA;-0,89317763251304971;0,205835749047960;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;change;madrs;clinician;depression;1;Post-first dose 4;Day 29;4,14;29,000;0;NA;NA;NA;NA;NA;NA;NA;51;-19,200;12,38819217196209;53;-5,500;13,00019623085807;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;dep;NA;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_change_madrs_Day29_4.14_clinician_psil_ncn_NA_NA;-1,07046182341651752;0,209921339689726;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;change;madrs;clinician;depression;1;Post-first dose 5;Day 43;6,14;43,000;1;NA;NA;NA;NA;NA;NA;NA;51;-19,100;13,11690935854809;53;-6,800;13,74306458690710;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;dep;NA;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_change_madrs_Day43_6.14_clinician_psil_ncn_NA_NA;-0,90844823571866895;0,206161577613683;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;change;smdds;self-report;depression;0;Post-first dose 2;Day 8;1,14;8,000;0;NA;NA;NA;NA;NA;NA;NA;51;-21,100;14,39216443507360;48;-9,600;14,31593014419174;NA;NA;NA;NA;43,200;8,70000000000000;51;44,300;5,90000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;dep;NA;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_change_smdds_Day8_1.14_self-report_psil_ncn_NA_NA;-0,79488908013194914;0,209003320149336;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;change;smdds;self-report;depression;0;Post-first dose 5;Day 43;6,14;43,000;1;NA;NA;NA;NA;NA;NA;NA;50;-21,800;14,79151940237166;42;-10,800;14,38327655003785;NA;NA;NA;NA;43,200;8,70000000000000;51;44,300;5,90000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;dep;NA;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_change_smdds_Day43_6.14_self-report_psil_ncn_NA_NA;-0,74677278098618760;0,216544760098465;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;msd;madrs;clinician;depression;1;Post-first dose 5;Day 43;6,14;43,000;1;NA;50;16,100;13,00000000000000;44;27,300;12,50000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;dep;NA;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_msd_madrs_Day43_6.14_clinician_psil_ncn_NA_NA;-0,86997194043111481;0,216378625859585;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;response;madrs;clinician;depression;1;Post-first dose 2;Day 8;1,14;8,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;27;51;5;50;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;dep;NA;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_response_madrs_Day8_1.14_clinician_psil_ncn_NA_NA;-1,26663694011237071;0,302440924827385;1,6665963262740489;0,444330050637791;27;5;51;50
Raison 2023;psil;ncn;NA;NA;response;madrs;clinician;depression;1;Post-first dose 3;Day 15;2,14;15,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;25;50;8;45;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;dep;NA;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_response_madrs_Day15_2.14_clinician_psil_ncn_NA_NA;-0,83751957077186134;0,265570629110550;1,0340737675305385;0,350396600693811;25;8;50;45
Raison 2023;psil;ncn;NA;NA;response;madrs;clinician;depression;1;Post-first dose 4;Day 29;4,14;29,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;49;7;44;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;dep;NA;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_response_madrs_Day29_4.14_clinician_psil_ncn_NA_NA;-0,97741596097536709;0,276668227108227;1,2045557247738035;0,371730070516366;26;7;49;44
Raison 2023;psil;ncn;NA;NA;response;madrs;clinician;depression;1;Post-first dose 5;Day 43;6,14;43,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;29;50;9;44;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;dep;NA;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_response_madrs_Day43_6.14_clinician_psil_ncn_NA_NA;-0,91915159297567650;0,259642749420353;1,0422378811403696;0,320728229198067;29;9;50;44
Raison 2023;psil;ncn;NA;NA;response;madrs;clinician;depression;1;Follow-up 1;Days 8-43 Sustained Response;6,14;43,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;48;5;44;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;dep;NA;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_response_madrs_Days8-43SustainedResponse_6.14_clinician_psil_ncn_NA_NA;-0,93907732959933798;0,307637231231115;1,2992829841302609;0,454356021132541;20;5;48;44
Raison 2023;psil;ncn;NA;NA;remission;madrs;clinician;depression;1;Post-first dose 2;Day 8;1,14;8,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;18;51;4;50;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;dep;NA;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_remission_madrs_Day8_1.14_clinician_psil_ncn_NA_NA;-1,00466752808606996;0,329691782803155;1,4842747694800944;0,515701185201567;18;4;51;50
Raison 2023;psil;ncn;NA;NA;remission;madrs;clinician;depression;1;Post-first dose 3;Day 15;2,14;15,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;50;6;45;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;dep;NA;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_remission_madrs_Day15_2.14_clinician_psil_ncn_NA_NA;-0,80189679432624872;0,289456084639812;1,0986122886681098;0,417665469538056;20;6;50;45
Raison 2023;psil;ncn;NA;NA;remission;madrs;clinician;depression;1;Post-first dose 4;Day 29;4,14;29,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;18;49;5;44;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;dep;NA;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_remission_madrs_Day29_4.14_clinician_psil_ncn_NA_NA;-0,82590432937777714;0,308672621340806;1,1733031812696990;0,460890572221842;18;5;49;44
Raison 2023;psil;ncn;NA;NA;remission;madrs;clinician;depression;1;Post-first dose 5;Day 43;6,14;43,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22;50;5;44;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;dep;NA;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_remission_madrs_Day43_6.14_clinician_psil_ncn_NA_NA;-0,99136754710359765;0,305383387785473;1,3537711694143306;0,450252454437811;22;5;50;44
Raison 2023;psil;ncn;NA;NA;remission;madrs;clinician;depression;1;Follow-up 1;Days 8-43 Sustained Response;6,14;43,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;48;4;44;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;dep;NA;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_remission_madrs_Days8-43SustainedResponse_6.14_clinician_psil_ncn_NA_NA;-0,65823804649686590;0,342583864748047;1,0116009116784799;0,538305421923955;12;4;48;44
Raison 2023;psil;ncn;NA;NA;imsd;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;51;32,800;13,00000000000000;53;32,300;12,50000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;dep;NA;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_imsd_madrs_Day2_0.29_clinician_psil_ncn_NA_NA;0,03893411233210140;0,196171262205403;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;imsd;madrs;clinician;depression;1;Post-first dose 2;Day 8;1,14;8,000;0;NA;51;17,700;13,00000000000000;53;29,200;12,50000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;dep;NA;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_imsd_madrs_Day8_1.14_clinician_psil_ncn_NA_NA;-0,89548458363833217;0,205884651101164;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;imsd;madrs;clinician;depression;1;Post-first dose 3;Day 15;2,14;15,000;0;NA;51;17,500;13,00000000000000;53;28,100;12,50000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;dep;NA;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_imsd_madrs_Day15_2.14_clinician_psil_ncn_NA_NA;-0,82540318144054980;0,204450551529181;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;imsd;madrs;clinician;depression;1;Post-first dose 4;Day 29;4,14;29,000;0;NA;51;16,300;13,00000000000000;53;29,500;12,50000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;dep;NA;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_imsd_madrs_Day29_4.14_clinician_psil_ncn_NA_NA;-1,02786056556747685;0,208879863202166;NA;NA;NA;NA;NA;NA
Rieser 2025;psil;pcb;NA;NA;msd;bdi;self-report;depression;1;Flexible Timepoint 1;Day -14;-2,00;-14,000;0;NA;18;12,720;8,37000000000000;19;12,210;7,75000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,060;8,99000000000000;18;11,050;8,02000000000000;19;Low;Low;Some concerns;Some concerns;Low;Some concerns;2025;psilocybin;mannitol;25 mg;100% mannitol;psilocybin;placebo;1;37,2675000000000;37,7975000000000;aud;NA;parallel;double-blind;10.1016/j.eclinm.2025.103149;NCT04141501;Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Rotz, R. von, Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: A phase 2 randomized clinical trial. eClinicalMedicine, 82. https://doi.org/10.1016/j.eclinm.2025.103149;Rieser2025_msd_bdi_Day-14_-2.00_self-report_psil_pcb_NA_NA;0,06193203084870311;0,329000423326536;NA;NA;NA;NA;NA;NA
Rieser 2025;psil;pcb;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 1;Day 1;0,14;1,000;0;NA;18;6,110;5,61000000000000;19;8,610;10,80000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,060;8,99000000000000;18;11,050;8,02000000000000;19;Low;Low;Some concerns;Some concerns;Low;Some concerns;2025;psilocybin;mannitol;25 mg;100% mannitol;psilocybin;placebo;1;37,2675000000000;37,7975000000000;aud;NA;parallel;double-blind;10.1016/j.eclinm.2025.103149;NCT04141501;Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Rotz, R. von, Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: A phase 2 randomized clinical trial. eClinicalMedicine, 82. https://doi.org/10.1016/j.eclinm.2025.103149;Rieser2025_msd_bdi_Day1_0.14_self-report_psil_pcb_NA_NA;-0,28193258331105392;0,330619388961670;NA;NA;NA;NA;NA;NA
Rieser 2025;psil;pcb;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 2;Day 14;2,00;14,000;0;NA;18;7,170;7,13000000000000;18;10,790;10,97000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,060;8,99000000000000;18;11,050;8,02000000000000;19;Low;Low;Some concerns;Some concerns;Low;Some concerns;2025;psilocybin;mannitol;25 mg;100% mannitol;psilocybin;placebo;1;37,2675000000000;37,7975000000000;aud;NA;parallel;double-blind;10.1016/j.eclinm.2025.103149;NCT04141501;Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Rotz, R. von, Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: A phase 2 randomized clinical trial. eClinicalMedicine, 82. https://doi.org/10.1016/j.eclinm.2025.103149;Rieser2025_msd_bdi_Day14_2.00_self-report_psil_pcb_NA_NA;-0,38259563495698945;0,336507979084192;NA;NA;NA;NA;NA;NA
Rieser 2025;psil;pcb;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 3;Day 30;4,29;30,000;1;NA;18;7,170;7,13000000000000;19;10,790;10,97000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,060;8,99000000000000;18;11,050;8,02000000000000;19;Low;Low;Some concerns;Some concerns;Low;Some concerns;2025;psilocybin;mannitol;25 mg;100% mannitol;psilocybin;placebo;1;37,2675000000000;37,7975000000000;aud;NA;parallel;double-blind;10.1016/j.eclinm.2025.103149;NCT04141501;Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Rotz, R. von, Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: A phase 2 randomized clinical trial. eClinicalMedicine, 82. https://doi.org/10.1016/j.eclinm.2025.103149;Rieser2025_msd_bdi_Day30_4.29_self-report_psil_pcb_NA_NA;-0,38064430600023824;0,332012714527199;NA;NA;NA;NA;NA;NA
Rieser 2025;psil;pcb;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 4;Day 96;13,71;96,000;0;NA;17;7,760;7,97000000000000;18;14,000;12,77000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,060;8,99000000000000;18;11,050;8,02000000000000;19;Low;Low;Some concerns;Some concerns;Low;Some concerns;2025;psilocybin;mannitol;25 mg;100% mannitol;psilocybin;placebo;1;37,2675000000000;37,7975000000000;aud;NA;parallel;double-blind;10.1016/j.eclinm.2025.103149;NCT04141501;Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Rotz, R. von, Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: A phase 2 randomized clinical trial. eClinicalMedicine, 82. https://doi.org/10.1016/j.eclinm.2025.103149;Rieser2025_msd_bdi_Day96_13.71_self-report_psil_pcb_NA_NA;-0,56903943380207367;0,345288659722553;NA;NA;NA;NA;NA;NA
Rieser 2025;psil;pcb;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 5;Day 190;27,14;190,000;0;NA;17;9,470;10,26000000000000;17;11,410;9,68000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,060;8,99000000000000;18;11,050;8,02000000000000;19;Low;Low;Some concerns;Some concerns;Low;Some concerns;2025;psilocybin;mannitol;25 mg;100% mannitol;psilocybin;placebo;1;37,2675000000000;37,7975000000000;aud;NA;parallel;double-blind;10.1016/j.eclinm.2025.103149;NCT04141501;Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Rotz, R. von, Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: A phase 2 randomized clinical trial. eClinicalMedicine, 82. https://doi.org/10.1016/j.eclinm.2025.103149;Rieser2025_msd_bdi_Day190_27.14_self-report_psil_pcb_NA_NA;-0,18990696449561470;0,343807205481078;NA;NA;NA;NA;NA;NA
Rosenblat 2024;psil;wl;NA;NA;change;madrs;clinician;depression;1;Post-first dose 1;Day 1;0,14;1,000;0;0;NA;NA;NA;NA;NA;NA;16;-13,277;6,30000000000000;14;-1,064;6,20740960465797;NA;NA;NA;NA;33,000;3,86000000000000;16;27,570;6,64000000000000;15;Some concerns;Low;Low;High;Low;High;2024;psilocybin;waitlist;25 mg;NA;immediate group;delayed group;1;44,1266666666667;39,1333333333333;trd;NA;crossover;open-label;10.1016/j.medj.2024.01.005;NCT05029466;Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., … McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005;Rosenblat2024_change_madrs_Day1_0.14_clinician_psil_wl_NA_NA;-1,89908475272569666;0,444323125248803;NA;NA;NA;NA;NA;NA
Rosenblat 2024;psil;wl;NA;NA;change;madrs;clinician;depression;1;Post-first dose 2;Day 7;1,00;7,000;0;0;NA;NA;NA;NA;NA;NA;16;-11,319;7,82800000000000;14;-3,021;7,48331477354788;NA;NA;NA;NA;33,000;3,86000000000000;16;27,570;6,64000000000000;15;Some concerns;Low;Low;High;Low;High;2024;psilocybin;waitlist;25 mg;NA;immediate group;delayed group;1;44,1266666666667;39,1333333333333;trd;NA;crossover;open-label;10.1016/j.medj.2024.01.005;NCT05029466;Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., … McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005;Rosenblat2024_change_madrs_Day7_1.00_clinician_psil_wl_NA_NA;-1,05265203301188959;0,391710041145542;NA;NA;NA;NA;NA;NA
Rosenblat 2024;psil;wl;NA;NA;change;madrs;clinician;depression;1;Post-first dose 3;Day 14;2,00;14,000;1;0;NA;NA;NA;NA;NA;NA;16;-9,600;7,60000000000000;14;-3,000;3,36749164809655;NA;NA;NA;NA;33,000;3,86000000000000;16;27,570;6,64000000000000;15;Some concerns;Low;Low;High;Low;High;2024;psilocybin;waitlist;25 mg;NA;immediate group;delayed group;1;44,1266666666667;39,1333333333333;trd;NA;crossover;open-label;10.1016/j.medj.2024.01.005;NCT05029466;Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., … McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005;Rosenblat2024_change_madrs_Day14_2.00_clinician_psil_wl_NA_NA;-1,06719381767744292;0,392402176392330;NA;NA;NA;NA;NA;NA
Rosenblat 2024;psil;wl;NA;NA;msd;madrs;clinician;depression;1;Post-first dose 3;Day 14;2,00;14,000;1;0;16;23,440;8,69000000000000;14;24,570;6,52000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;3,86000000000000;16;27,570;6,64000000000000;15;Some concerns;Low;Low;High;Low;High;2024;psilocybin;waitlist;25 mg;NA;immediate group;delayed group;1;44,1266666666667;39,1333333333333;trd;NA;crossover;open-label;10.1016/j.medj.2024.01.005;NCT05029466;Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., … McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005;Rosenblat2024_msd_madrs_Day14_2.00_clinician_psil_wl_NA_NA;-0,14171301667713440;0,366445267842868;NA;NA;NA;NA;NA;NA
Rosenblat 2024;psil;wl;NA;NA;imsd;madrs;clinician;depression;1;Post-first dose 1;Day 1;0,14;1,000;0;0;16;19,723;8,69000000000000;14;26,506;6,52000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;3,86000000000000;16;27,570;6,64000000000000;15;Some concerns;Low;Low;High;Low;High;2024;psilocybin;waitlist;25 mg;NA;immediate group;delayed group;1;44,1266666666667;39,1333333333333;trd;NA;crossover;open-label;10.1016/j.medj.2024.01.005;NCT05029466;Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., … McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005;Rosenblat2024_imsd_madrs_Day1_0.14_clinician_psil_wl_NA_NA;-0,85065432931062279;0,382972717203476;NA;NA;NA;NA;NA;NA
Rosenblat 2024;psil;wl;NA;NA;imsd;madrs;clinician;depression;1;Post-first dose 2;Day 7;1,00;7,000;0;0;16;21,681;8,69000000000000;14;24,549;6,52000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;3,86000000000000;16;27,570;6,64000000000000;15;Some concerns;Low;Low;High;Low;High;2024;psilocybin;waitlist;25 mg;NA;immediate group;delayed group;1;44,1266666666667;39,1333333333333;trd;NA;crossover;open-label;10.1016/j.medj.2024.01.005;NCT05029466;Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., … McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005;Rosenblat2024_imsd_madrs_Day7_1.00_clinician_psil_wl_NA_NA;-0,35967516091152402;0,369061136286049;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Pre-first dose 1;1 day pre-dose 1;-0,14;-1,000;0;0;14;10,400;6,90709953598470;15;16,247;7,54457155841205;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_bdi_1daypre-dose1_-0.14_self-report_psil_ncn_NA_NA;-0,78445040415340850;0,386427045543218;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 1;1 day post-dose 1;0,14;1,000;0;0;14;4,188;6,90709953598470;15;12,034;6,95200510644231;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_bdi_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA;-1,10036887261461747;0,400241252699935;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 2;2 weeks post-dose 1;2,00;14,000;0;0;14;6,636;7,15404892351178;14;13,449;7,52073134741562;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_bdi_2weekspost-dose1_2.00_self-report_psil_ncn_NA_NA;-0,90120587945026109;0,397798255450695;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 3;6 weeks post-dose 1;6,00;42,000;0;0;14;6,438;6,71627500925922;14;14,181;6,90709953598470;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_bdi_6weekspost-dose1_6.00_self-report_psil_ncn_NA_NA;-1,10350608761990276;0,407340792292258;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 4;7 weeks post-dose 1 and 1 day pre-dose 2;7,00;49,000;1;0;12;7,097;6,39473158154429;14;12,841;7,48331477354788;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_bdi_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA;-0,79404494658719260;0,409500561347812;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-second dose 2;6 weeks post-dose 2;6,00;42,000;0;1;12;6,212;6,57486486553146;11;9,545;6,80571406980928;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_bdi_6weekspost-dose2_6.00_self-report_psil_ncn_NA_NA;-0,48050139960509808;0,423845590912223;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-second dose 3;26 weeks post-dose 2;26,00;182,000;0;1;11;6,410;6,46078509161232;12;8,974;6,92820323027551;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_bdi_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA;-0,36832208305530018;0,421208871873938;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;hads-d;self-report;depression;0;Pre-first dose 1;1 day pre-dose 1;-0,14;-1,000;0;0;14;3,859;3,47974136969977;15;5,945;3,40435236131632;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_hads-d_1daypre-dose1_-0.14_self-report_psil_ncn_NA_NA;-0,58924681792804900;0,380042102654754;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;hads-d;self-report;depression;0;Post-first dose 1;1 day post-dose 1;0,14;1,000;0;0;14;2,019;3,38245827764364;15;6,164;3,21070319400595;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_hads-d_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA;-1,22287540277370277;0,406678447909128;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;hads-d;self-report;depression;0;Post-first dose 2;2 weeks post-dose 1;2,00;14,000;0;0;14;2,109;3,43484148105848;14;5,831;3,43484148105848;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_hads-d_2weekspost-dose1_2.00_self-report_psil_ncn_NA_NA;-1,05204046618656388;0,404752847895918;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;hads-d;self-report;depression;0;Post-first dose 3;6 weeks post-dose 1;6,00;42,000;0;0;14;2,263;3,47974136969977;14;6,761;3,10183397363560;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_hads-d_6weekspost-dose1_6.00_self-report_psil_ncn_NA_NA;-1,32485277849217686;0,419653953725893;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;hads-d;self-report;depression;0;Post-first dose 4;7 weeks post-dose 1 and 1 day pre-dose 2;7,00;49,000;1;0;12;2,734;3,30821704245656;14;6,101;3,28891684297429;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_hads-d_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA;-0,98874905515037670;0,418101050737959;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;hads-d;self-report;depression;0;Post-second dose 2;6 weeks post-dose 2;6,00;42,000;0;1;12;1,791;3,30821704245656;11;4,906;3,16737667478941;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_hads-d_6weekspost-dose2_6.00_self-report_psil_ncn_NA_NA;-0,92612271955594216;0,440809253309700;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;hads-d;self-report;depression;0;Post-second dose 3;26 weeks post-dose 2;26,00;182,000;0;1;11;1,960;3,33320791430718;12;4,271;3,30821704245656;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_hads-d_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA;-0,67089618622880953;0,429854469566899;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;response;bdi;self-report;depression;1;Post-first dose 1;1 day post-dose 1;0,14;1,000;0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;14;4;15;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_response_bdi_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA;-1,50223974351905665;0,530033969845441;1,1676051601550610;0,441857550844268;12;4;14;15
Ross 2016;psil;ncn;NA;NA;response;bdi;self-report;depression;1;Post-first dose 4;7 weeks post-dose 1 and 1 day pre-dose 2;7,00;49,000;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;10;12;2;14;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_response_bdi_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA;-1,81596223568402571;0,599741779377007;1,7635885922613588;0,667261639267608;10;2;12;14
Ross 2016;psil;ncn;NA;NA;response;bdi;self-report;depression;1;Post-second dose 3;26 weeks post-dose 2;26,00;182,000;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;11;7;12;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_response_bdi_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA;-0,62046695251766215;0,538490090853892;0,3383258052705359;0,282357627355504;9;7;11;12
Ross 2016;psil;ncn;NA;NA;remission;hads-d;self-report;depression;0;Post-first dose 1;1 day post-dose 1;0,14;1,000;0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;11;14;3;15;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_remission_hads-d_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA;-1,43912322147627747;0,505574636705140;1,3682758556172123;0,534927271829719;11;3;14;15
Ross 2016;psil;ncn;NA;NA;remission;hads-d;self-report;depression;0;Post-first dose 4;7 weeks post-dose 1 and 1 day pre-dose 2;7,00;49,000;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;8;12;6;14;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_remission_hads-d_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA;-0,52368289259737844;0,450158158078553;0,4418327522790392;0,370006434950477;8;6;12;14
Ross 2016;psil;ncn;NA;NA;remission;hads-d;self-report;depression;0;Post-second dose 3;26 weeks post-dose 2;26,00;182,000;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;11;7;12;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_remission_hads-d_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA;-0,62046695251766215;0,538490090853892;0,3383258052705359;0,282357627355504;9;7;11;12
Ross 2016;psil;ncn;NA;NA;response;hads-d;self-report;depression;0;Post-first dose 1;1 day post-dose 1;0,14;1,000;0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;11;14;3;15;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_response_hads-d_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA;-1,43912322147627747;0,505574636705140;1,3682758556172123;0,534927271829719;11;3;14;15
Ross 2016;psil;ncn;NA;NA;response;hads-d;self-report;depression;0;Post-first dose 4;7 weeks post-dose 1 and 1 day pre-dose 2;7,00;49,000;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;8;12;6;14;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_response_hads-d_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA;-0,52368289259737844;0,450158158078553;0,4418327522790392;0,370006434950477;8;6;12;14
Ross 2016;psil;ncn;NA;NA;response;hads-d;self-report;depression;0;Post-second dose 3;26 weeks post-dose 2;26,00;182,000;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;11;7;12;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_response_hads-d_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA;-0,62046695251766215;0,538490090853892;0,3383258052705359;0,282357627355504;9;7;11;12
Ross 2016;psil;ncn;NA;NA;remission;bdi;self-report;depression;1;Post-first dose 1;1 day post-dose 1;0,14;1,000;0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;14;4;15;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_remission_bdi_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA;-1,50223974351905665;0,530033969845441;1,1676051601550610;0,441857550844268;12;4;14;15
Ross 2016;psil;ncn;NA;NA;remission;bdi;self-report;depression;1;Post-first dose 4;7 weeks post-dose 1 and 1 day pre-dose 2;7,00;49,000;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;10;12;2;14;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_remission_bdi_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA;-1,81596223568402571;0,599741779377007;1,7635885922613588;0,667261639267608;10;2;12;14
Ross 2016;psil;ncn;NA;NA;remission;bdi;self-report;depression;1;Post-second dose 3;26 weeks post-dose 2;26,00;182,000;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;11;7;12;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;NA;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_remission_bdi_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA;-0,62046695251766215;0,538490090853892;0,3383258052705359;0,282357627355504;9;7;11;12
Ross 2025;psil;ncn;NA;NA;msd;hads-d;self-report;depression;1;Post-first dose 1;Day 1;0,14;1,000;0;NA;17;6,590;4,46000000000000;18;8,500;3,57000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,880;3,48000000000000;17;11,670;3,27000000000000;18;Low;Low;Low;Some concerns;Low;Some concerns;2025;psilocybin;niacin;25 mg;100 mg;psilocybin;placebo;1;55,9628571428571;54,5428571428571;cancer;NA;parallel;double-blind;10.1016/j.genhosppsych.2025.08.001;ACTRN12619001225101;"Ross, M.L.; Iyer, R.; Williams, M.L.; Boughey, M.; O'Callaghan, C.; Hiscock, R.; Dwyer, J. (2025). Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial. General Hospital Psychiatry, 96. https://doi.org/10.1016/j.genhosppsych.2025.08.001";Ross2025_msd_hads-d_Day1_0.14_self-report_psil_ncn_NA_NA;-0,46353334402311136;0,342919999984711;NA;NA;NA;NA;NA;NA
Ross 2025;psil;ncn;NA;NA;msd;hads-d;self-report;depression;1;Post-first dose 2;Week 3;3,00;21,000;0;NA;17;6,570;4,70000000000000;18;9,280;3,92000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,880;3,48000000000000;17;11,670;3,27000000000000;18;Low;Low;Low;Some concerns;Low;Some concerns;2025;psilocybin;niacin;25 mg;100 mg;psilocybin;placebo;1;55,9628571428571;54,5428571428571;cancer;NA;parallel;double-blind;10.1016/j.genhosppsych.2025.08.001;ACTRN12619001225101;"Ross, M.L.; Iyer, R.; Williams, M.L.; Boughey, M.; O'Callaghan, C.; Hiscock, R.; Dwyer, J. (2025). Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial. General Hospital Psychiatry, 96. https://doi.org/10.1016/j.genhosppsych.2025.08.001";Ross2025_msd_hads-d_Week3_3.00_self-report_psil_ncn_NA_NA;-0,61354207410417083;0,346427109292292;NA;NA;NA;NA;NA;NA
Ross 2025;psil;ncn;NA;NA;msd;hads-d;self-report;depression;1;Post-first dose 3;Week 6-7;6,00;42,000;1;NA;14;4,840;4,26000000000000;18;8,380;4,10000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,880;3,48000000000000;17;11,670;3,27000000000000;18;Low;Low;Low;Some concerns;Low;Some concerns;2025;psilocybin;niacin;25 mg;100 mg;psilocybin;placebo;1;55,9628571428571;54,5428571428571;cancer;NA;parallel;double-blind;10.1016/j.genhosppsych.2025.08.001;ACTRN12619001225101;"Ross, M.L.; Iyer, R.; Williams, M.L.; Boughey, M.; O'Callaghan, C.; Hiscock, R.; Dwyer, J. (2025). Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial. General Hospital Psychiatry, 96. https://doi.org/10.1016/j.genhosppsych.2025.08.001";Ross2025_msd_hads-d_Week6-7_6.00_self-report_psil_ncn_NA_NA;-0,82750220689741383;0,371811877928267;NA;NA;NA;NA;NA;NA
Ross 2025;psil;ncn;NA;NA;msd;bdi-ii;self-report;depression;0;Post-first dose 1;Day 1;0,14;1,000;0;NA;17;11,900;9,31000000000000;18;17,200;8,26000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21,000;7,18000000000000;17;22,700;7,61000000000000;18;Low;Low;Low;Some concerns;Low;Some concerns;2025;psilocybin;niacin;25 mg;100 mg;psilocybin;placebo;1;55,9628571428571;54,5428571428571;cancer;NA;parallel;double-blind;10.1016/j.genhosppsych.2025.08.001;ACTRN12619001225101;"Ross, M.L.; Iyer, R.; Williams, M.L.; Boughey, M.; O'Callaghan, C.; Hiscock, R.; Dwyer, J. (2025). Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial. General Hospital Psychiatry, 96. https://doi.org/10.1016/j.genhosppsych.2025.08.001";Ross2025_msd_bdi-ii_Day1_0.14_self-report_psil_ncn_NA_NA;-0,58949991240284649;0,345801894681828;NA;NA;NA;NA;NA;NA
Ross 2025;psil;ncn;NA;NA;msd;bdi-ii;self-report;depression;0;Post-first dose 2;Week 3;3,00;21,000;0;NA;17;12,400;8,09000000000000;18;18,800;9,61000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21,000;7,18000000000000;17;22,700;7,61000000000000;18;Low;Low;Low;Some concerns;Low;Some concerns;2025;psilocybin;niacin;25 mg;100 mg;psilocybin;placebo;1;55,9628571428571;54,5428571428571;cancer;NA;parallel;double-blind;10.1016/j.genhosppsych.2025.08.001;ACTRN12619001225101;"Ross, M.L.; Iyer, R.; Williams, M.L.; Boughey, M.; O'Callaghan, C.; Hiscock, R.; Dwyer, J. (2025). Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial. General Hospital Psychiatry, 96. https://doi.org/10.1016/j.genhosppsych.2025.08.001";Ross2025_msd_bdi-ii_Week3_3.00_self-report_psil_ncn_NA_NA;-0,70220007394235073;0,348937266321390;NA;NA;NA;NA;NA;NA
Ross 2025;psil;ncn;NA;NA;msd;bdi-ii;self-report;depression;0;Post-first dose 3;Week 6-7;6,00;42,000;1;NA;14;9,230;5,72000000000000;18;19,100;7,10000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21,000;7,18000000000000;17;22,700;7,61000000000000;18;Low;Low;Low;Some concerns;Low;Some concerns;2025;psilocybin;niacin;25 mg;100 mg;psilocybin;placebo;1;55,9628571428571;54,5428571428571;cancer;NA;parallel;double-blind;10.1016/j.genhosppsych.2025.08.001;ACTRN12619001225101;"Ross, M.L.; Iyer, R.; Williams, M.L.; Boughey, M.; O'Callaghan, C.; Hiscock, R.; Dwyer, J. (2025). Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial. General Hospital Psychiatry, 96. https://doi.org/10.1016/j.genhosppsych.2025.08.001";Ross2025_msd_bdi-ii_Week6-7_6.00_self-report_psil_ncn_NA_NA;-1,47160897825765136;0,403230724263689;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;bdi;self-report;depression;0;Pre-first dose 1;Day -1;-0,14;-1,000;0;NA;26;25,695;6,31768517734146;26;24,798;10,01957334420982;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,900;10,02467236372342;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;dep;NA;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_bdi_Day-1_-0.14_self-report_psil_pcb_NA_NA;0,10548091002400753;0,277548842334483;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;bdi;self-report;depression;0;DOSE 1;Day 0;0,00;0,000;0;NA;26;12,242;7,18961751416583;26;20,191;10,89150568103419;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,900;10,02467236372342;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;dep;NA;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_bdi_Day0_0.00_self-report_psil_pcb_NA_NA;-0,84840536845533920;0,289926959286354;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;bdi;self-report;depression;0;Post-first dose 1;Day 2;0,29;2,000;0;NA;26;11,823;8,93348218781456;26;22,293;11,76853703737215;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,900;10,02467236372342;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;dep;NA;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_bdi_Day2_0.29_self-report_psil_pcb_NA_NA;-0,98703435264889661;0,294244283502394;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;bdi;self-report;depression;0;Post-first dose 2;Day 8;1,14;8,000;0;NA;26;13,584;11,54927919828766;26;21,148;11,54927919828766;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,900;10,02467236372342;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;dep;NA;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_bdi_Day8_1.14_self-report_psil_pcb_NA_NA;-0,64505929083009739;0,284688371674402;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;bdi;self-report;depression;0;Post-first dose 3;Day 14;2,00;14,000;1;NA;26;13,379;10,23883118329431;26;20,729;11,33002135920317;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,900;10,02467236372342;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;dep;NA;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_bdi_Day14_2.00_self-report_psil_pcb_NA_NA;-0,67040650657638035;0,285268239079986;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;madrs;clinician;depression;1;Pre-first dose 1;Day -1;-0,14;-1,000;0;NA;26;23,534;4,18629502065968;26;24,948;7,44456848984546;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;dep;NA;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_madrs_Day-1_-0.14_clinician_psil_pcb_NA_NA;-0,23060285431836317;0,278298712350879;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;madrs;clinician;depression;1;DOSE 1;Day 0;0,00;0,000;0;NA;26;11,727;7,21511261173379;26;21,034;9,53516649041851;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;dep;NA;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_madrs_Day0_0.00_clinician_psil_pcb_NA_NA;-1,08416213909409986;0,297613339412923;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;26;9,775;7,90857926558241;26;20,632;11,16685273476820;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;dep;NA;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_madrs_Day2_0.29_clinician_psil_pcb_NA_NA;-1,10515607016573902;0,298377744492480;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;madrs;clinician;depression;1;Post-first dose 2;Day 8;1,14;8,000;0;NA;26;12,065;8,83660081705630;26;19,957;10,46828706140599;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;dep;NA;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_madrs_Day8_1.14_clinician_psil_pcb_NA_NA;-0,80242972515504940;0,288626644278412;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;madrs;clinician;depression;1;Post-first dose 3;Day 14;2,00;14,000;1;NA;26;11,162;9,76972138804378;26;20,696;10,23883118329431;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;dep;NA;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_madrs_Day14_2.00_clinician_psil_pcb_NA_NA;-0,93836788231098855;0,292661784694183;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;response;madrs;clinician;depression;1;Post-first dose 3;Day 14;2,00;14,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15;26;4;26;24,118;5,11431657213356;26;24,528;6,74600281648325;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;dep;NA;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_response_madrs_Day14_2.00_clinician_psil_pcb_NA_NA;-1,09412740860668056;0,371085838569234;1,3217558399823193;0,489636180999311;15;4;26;26
von Rotz 2023;psil;pcb;NA;NA;remission;madrs;clinician;depression;1;Post-first dose 3;Day 14;2,00;14,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14;26;3;26;24,118;5,11431657213356;26;24,528;6,74600281648325;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;dep;NA;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_remission_madrs_Day14_2.00_clinician_psil_pcb_NA_NA;-1,18976883955491308;0,401968864868958;1,5404450409471488;0,572572115841165;14;3;26;26
von Rotz 2023;psil;pcb;NA;NA;response;bdi;self-report;depression;0;Post-first dose 3;Day 14;2,00;14,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14;26;3;26;26,541;6,31768517734146;26;25,900;10,02467236372342;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;dep;NA;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_response_bdi_Day14_2.00_self-report_psil_pcb_NA_NA;-1,18976883955491308;0,401968864868958;1,5404450409471488;0,572572115841165;14;3;26;26
von Rotz 2023;psil;pcb;NA;NA;remission;bdi;self-report;depression;0;Post-first dose 3;Day 14;2,00;14,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;26;3;26;26,541;6,31768517734146;26;25,900;10,02467236372342;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;dep;NA;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_remission_bdi_Day14_2.00_self-report_psil_pcb_NA_NA;-1,02235583542038633;0,401968864868958;1,3862943611198906;0,582875278034323;12;3;26;26
=======
<<<<<<< Updated upstream
"";"study";"condition_arm1";"condition_arm2";"multi_arm1";"multi_arm2";"outcome_type";"instrument";"rating";"instrument_symptom";"primary_instrument";"cov_time_point";"time";"time_weeks";"time_days";"primary_timepoint";"post_crossover";"n_arm1";"mean_arm1";"sd_arm1";"n_arm2";"mean_arm2";"sd_arm2";"n_change_arm1";"mean_change_arm1";"sd_change_arm1";"n_change_arm2";"mean_change_arm2";"sd_change_arm2";"event_arm1";"totaln_arm1";"event_arm2";"totaln_arm2";"baseline_m_arm1";"baseline_sd_arm1";"baseline_n_arm1";"baseline_m_arm2";"baseline_sd_arm2";"baseline_n_arm2";"rob_rand";"rob_dev";"rob_miss";"rob_meas";"rob_sel";"rob";"year";"drug_arm1";"drug_arm2";"dose_arm1";"dose_arm2";"name_arm1";"name_arm2";"n_dosing_sessions";"mean_age";"percent_women";"diagnosis";"target_group";"design";"blinding";"doi";"registration_number";".id";".g";".g_se";".log_rr";".log_rr_se";".event_arm1";".event_arm2";".totaln_arm1";".totaln_arm2"
"1";"Back 2024";"psil";"ncn";NA;NA;"msd";"madrs";"clinician";"depression";1;"Pre-first dose 1";"Day -8";-1,14;-8;0;NA;15;27,67;5,27;15;28,4;7,39;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;"Low";"Low";"Low";"Low";"Low";"Low";2024;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin arm";"niacin arm";1;38;50;"dep";NA;"parallel";"double-blind";"10.1001/jamanetworkopen.2024.49026";"NCT05163496";"Back2024_msd_madrs_Day-8_-1.14_clinician_psil_ncn_NA_NA";-0,110666088903096;0,365443493603394;NA;NA;NA;NA;NA;NA
"2";"Back 2024";"psil";"ncn";NA;NA;"msd";"madrs";"clinician";"depression";1;"Post-first dose 4";"Day 28";4;28;1;NA;15;6,33;6,72;15;19,07;10,34;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;"Low";"Low";"Low";"Low";"Low";"Low";2024;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin arm";"niacin arm";1;38;50;"dep";NA;"parallel";"double-blind";"10.1001/jamanetworkopen.2024.49026";"NCT05163496";"Back2024_msd_madrs_Day28_4.00_clinician_psil_ncn_NA_NA";-1,42153552640956;0,410986356401838;NA;NA;NA;NA;NA;NA
"3";"Carhart-Harris 2021";"psil";"esc";NA;NA;"change";"qids-sr";"self-report";"depression";0;"Post-second dose 1";"Week 6";3;21;1;NA;NA;NA;NA;NA;NA;NA;30;-8;5,47722557505166;29;-6;5,3851648071345;NA;NA;NA;NA;14,5;3,9;30;16,4;4,1;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"25 mg";"10 mg; 20 mg";"psilocybin group";"escitalopram group";2;41,235593220339;34,0508474576271;"dep";NA;"parallel";"double-blind";"10.1056/NEJMoa2032994";"NCT03429075";"Carhart-Harris2021_change_qids-sr_Week6_3.00_self-report_psil_esc_NA_NA";-0,363309361758319;0,262611586674514;NA;NA;NA;NA;NA;NA
"4";"Carhart-Harris 2021";"psil";"esc";NA;NA;"change";"bdi-1a";"self-report";"depression";0;"Post-second dose 1";"Week 6";3;21;1;NA;NA;NA;NA;NA;NA;NA;30;-18,4;12,2958125154221;29;-10,8;9,6163657270259;NA;NA;NA;NA;29,1;6,8;30;28,7;7;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"25 mg";"10 mg; 20 mg";"psilocybin group";"escitalopram group";2;41,235593220339;34,0508474576271;"dep";NA;"parallel";"double-blind";"10.1056/NEJMoa2032994";"NCT03429075";"Carhart-Harris2021_change_bdi-1a_Week6_3.00_self-report_psil_esc_NA_NA";-0,678018079704898;0,267986899585578;NA;NA;NA;NA;NA;NA
"5";"Carhart-Harris 2021";"psil";"esc";NA;NA;"change";"ham-d-17";"clinician";"depression";0;"Post-second dose 1";"Week 6";3;21;1;NA;NA;NA;NA;NA;NA;NA;30;-10,5;5,47722557505166;29;-5,1;5,3851648071345;NA;NA;NA;NA;19,2;2,3;30;18,4;3,4;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"25 mg";"10 mg; 20 mg";"psilocybin group";"escitalopram group";2;41,235593220339;34,0508474576271;"dep";NA;"parallel";"double-blind";"10.1056/NEJMoa2032994";"NCT03429075";"Carhart-Harris2021_change_ham-d-17_Week6_3.00_clinician_psil_esc_NA_NA";-0,980935276747461;0,276026275889254;NA;NA;NA;NA;NA;NA
"6";"Carhart-Harris 2021";"psil";"esc";NA;NA;"change";"madrs";"clinician";"depression";0;"Post-second dose 1";"Week 6";3;21;1;NA;NA;NA;NA;NA;NA;NA;30;-14,4;9,31128347758782;29;-7,2;9,15478017212866;NA;NA;NA;NA;27,9;4;30;26,9;5,3;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"25 mg";"10 mg; 20 mg";"psilocybin group";"escitalopram group";2;41,235593220339;34,0508474576271;"dep";NA;"parallel";"double-blind";"10.1056/NEJMoa2032994";"NCT03429075";"Carhart-Harris2021_change_madrs_Week6_3.00_clinician_psil_esc_NA_NA";-0,769361001370558;0,270125147933961;NA;NA;NA;NA;NA;NA
"7";"Carhart-Harris 2021";"psil";"esc";NA;NA;"msd";"qids-sr";"self-report";"depression";1;"Post-second dose 1";"Week 6";3;21;1;NA;30;6,9;5,9;29;10,1;5,8;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14,5;3,9;30;16,4;4,1;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"25 mg";"10 mg; 20 mg";"psilocybin group";"escitalopram group";2;41,235593220339;34,0508474576271;"dep";NA;"parallel";"double-blind";"10.1056/NEJMoa2032994";"NCT03429075";"Carhart-Harris2021_msd_qids-sr_Week6_3.00_self-report_psil_esc_NA_NA";-0,539678732925694;0,265237432013847;NA;NA;NA;NA;NA;NA
"8";"Carhart-Harris 2021";"psil";"esc";NA;NA;"msd";"bdi-1a";"self-report";"depression";0;"Post-second dose 1";"Week 6";3;21;1;NA;30;10,7;11;29;17,9;11,1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;29,1;6,8;30;28,7;7;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"25 mg";"10 mg; 20 mg";"psilocybin group";"escitalopram group";2;41,235593220339;34,0508474576271;"dep";NA;"parallel";"double-blind";"10.1056/NEJMoa2032994";"NCT03429075";"Carhart-Harris2021_msd_bdi-1a_Week6_3.00_self-report_psil_esc_NA_NA";-0,643016935967134;0,267235040715549;NA;NA;NA;NA;NA;NA
"9";"Carhart-Harris 2021";"psil";"esc";NA;NA;"msd";"ham-d-17";"clinician";"depression";0;"Post-second dose 1";"Week 6";3;21;1;NA;30;8,3;5,5;29;13,6;5,2;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;19,2;2,3;30;18,4;3,4;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"25 mg";"10 mg; 20 mg";"psilocybin group";"escitalopram group";2;41,235593220339;34,0508474576271;"dep";NA;"parallel";"double-blind";"10.1056/NEJMoa2032994";"NCT03429075";"Carhart-Harris2021_msd_ham-d-17_Week6_3.00_clinician_psil_esc_NA_NA";-0,976697930755904;0,275895471772229;NA;NA;NA;NA;NA;NA
"10";"Carhart-Harris 2021";"psil";"esc";NA;NA;"msd";"madrs";"clinician";"depression";0;"Post-second dose 1";"Week 6";3;21;1;NA;30;13;10;29;19,8;8,5;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;27,9;4;30;26,9;5,3;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"25 mg";"10 mg; 20 mg";"psilocybin group";"escitalopram group";2;41,235593220339;34,0508474576271;"dep";NA;"parallel";"double-blind";"10.1056/NEJMoa2032994";"NCT03429075";"Carhart-Harris2021_msd_madrs_Week6_3.00_clinician_psil_esc_NA_NA";-0,722027242067186;0,26898553479948;NA;NA;NA;NA;NA;NA
"11";"Carhart-Harris 2021";"psil";"esc";NA;NA;"response";"qids-sr";"self-report";"depression";0;"Post-second dose 1";"Week 6";3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21;30;14;29;14,5;3,9;30;16,4;4,1;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"25 mg";"10 mg; 20 mg";"psilocybin group";"escitalopram group";2;41,235593220339;34,0508474576271;"dep";NA;"parallel";"double-blind";"10.1056/NEJMoa2032994";"NCT03429075";"Carhart-Harris2021_response_qids-sr_Week6_3.00_self-report_psil_esc_NA_NA";-0,498501201709367;0,300373270489182;0,371563556432483;0,226343824951325;21;14;30;29
"12";"Carhart-Harris 2021";"psil";"esc";NA;NA;"remission";"qids-sr";"self-report";"depression";0;"Post-second dose 1";"Week 6";3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;30;8;29;14,5;3,9;30;16,4;4,1;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"25 mg";"10 mg; 20 mg";"psilocybin group";"escitalopram group";2;41,235593220339;34,0508474576271;"dep";NA;"parallel";"double-blind";"10.1056/NEJMoa2032994";"NCT03429075";"Carhart-Harris2021_remission_qids-sr_Week6_3.00_self-report_psil_esc_NA_NA";-0,670992169548338;0,306156690535671;0,719870250700699;0,340598645707439;17;8;30;29
"13";"Carhart-Harris 2021";"psil";"esc";NA;NA;"response";"bdi-1a";"self-report";"depression";0;"Post-second dose 1";"Week 6";3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;23;30;12;29;29,1;6,8;30;28,7;7;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"25 mg";"10 mg; 20 mg";"psilocybin group";"escitalopram group";2;41,235593220339;34,0508474576271;"dep";NA;"parallel";"double-blind";"10.1056/NEJMoa2032994";"NCT03429075";"Carhart-Harris2021_response_bdi-1a_Week6_3.00_self-report_psil_esc_NA_NA";-0,836678104294455;0,31598999314667;0,616686014465468;0,242889897379194;23;12;30;29
"14";"Carhart-Harris 2021";"psil";"esc";NA;NA;"remission";"bdi-1a";"self-report";"depression";0;"Post-second dose 1";"Week 6";3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;30;5;29;29,1;6,8;30;28,7;7;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"25 mg";"10 mg; 20 mg";"psilocybin group";"escitalopram group";2;41,235593220339;34,0508474576271;"dep";NA;"parallel";"double-blind";"10.1056/NEJMoa2032994";"NCT03429075";"Carhart-Harris2021_remission_bdi-1a_Week6_3.00_self-report_psil_esc_NA_NA";-0,99934093835083;0,338703230909486;1,18987387994643;0,437043976571857;17;5;30;29
"15";"Carhart-Harris 2021";"psil";"esc";NA;NA;"response";"ham-d-17";"clinician";"depression";0;"Post-second dose 1";"Week 6";3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22;30;7;29;19,2;2,3;30;18,4;3,4;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"25 mg";"10 mg; 20 mg";"psilocybin group";"escitalopram group";2;41,235593220339;34,0508474576271;"dep";NA;"parallel";"double-blind";"10.1056/NEJMoa2032994";"NCT03429075";"Carhart-Harris2021_response_ham-d-17_Week6_3.00_clinician_psil_esc_NA_NA";-1,17335476888894;0,330230008279525;1,11123075262732;0,347124756186685;22;7;30;29
"16";"Carhart-Harris 2021";"psil";"esc";NA;NA;"response";"madrs";"clinician";"depression";0;"Post-second dose 1";"Week 6";3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;30;6;29;27,9;4;30;26,9;5,3;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"25 mg";"10 mg; 20 mg";"psilocybin group";"escitalopram group";2;41,235593220339;34,0508474576271;"dep";NA;"parallel";"double-blind";"10.1056/NEJMoa2032994";"NCT03429075";"Carhart-Harris2021_response_madrs_Week6_3.00_clinician_psil_esc_NA_NA";-1,10815056090644;0,330863916168362;1,17007125265025;0,385811579287926;20;6;30;29
"17";"Carhart-Harris 2021";"psil";"esc";NA;NA;"remission";"ham-d-17";"clinician";"depression";0;"Post-second dose 1";"Week 6";3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15;30;3;29;19,2;2,3;30;18,4;3,4;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"25 mg";"10 mg; 20 mg";"psilocybin group";"escitalopram group";2;41,235593220339;34,0508474576271;"dep";NA;"parallel";"double-blind";"10.1056/NEJMoa2032994";"NCT03429075";"Carhart-Harris2021_remission_ham-d-17_Week6_3.00_clinician_psil_esc_NA_NA";-1,17485144826605;0,391842523093344;1,57553636075842;0,576353978077689;15;3;30;29
"18";"Carhart-Harris 2021";"psil";"esc";NA;NA;"remission";"madrs";"clinician";"depression";0;"Post-second dose 1";"Week 6";3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;30;2;29;27,9;4;30;26,9;5,3;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"25 mg";"10 mg; 20 mg";"psilocybin group";"escitalopram group";2;41,235593220339;34,0508474576271;"dep";NA;"parallel";"double-blind";"10.1056/NEJMoa2032994";"NCT03429075";"Carhart-Harris2021_remission_madrs_Week6_3.00_clinician_psil_esc_NA_NA";-0,955007950884727;0,459878100635296;1,47017584510059;0,737085489720893;9;2;30;29
"19";"Davis 2021";"psil";"wl";NA;NA;"msd";"bdi";"self-report";"depression";0;"Post-second dose 1";"Week 5";1;7;0;0;13;8,2;8,9;11;35,2;9,1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;7;13;34,5;10;11;"Low";"Some concerns";"Some concerns";"Low";"Low";"Some concerns";2021;"psilocybin";"waitlist";"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;"immediate treatment group";"delayed treatment group";2;39,8666666666667;66,7777777777778;"dep";NA;"crossover";"open-label";"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";"NCT03181529";"Davis2021_msd_bdi_Week5_1.00_self-report_psil_wl_NA_NA";-2,8993026484422;0,596396246972318;NA;NA;NA;NA;NA;NA
"20";"Davis 2021";"psil";"wl";NA;NA;"msd";"bdi";"self-report";"depression";0;"Post-second dose 2";"Week 8";4;28;1;0;13;8,2;7;11;35,9;8,4;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;7;13;34,5;10;11;"Low";"Some concerns";"Some concerns";"Low";"Low";"Some concerns";2021;"psilocybin";"waitlist";"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;"immediate treatment group";"delayed treatment group";2;39,8666666666667;66,7777777777778;"dep";NA;"crossover";"open-label";"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";"NCT03181529";"Davis2021_msd_bdi_Week8_4.00_self-report_psil_wl_NA_NA";-3,48779651560761;0,663090832701423;NA;NA;NA;NA;NA;NA
"21";"Davis 2021";"psil";"wl";NA;NA;"msd";"qids-sr";"self-report";"depression";0;"Post-second dose 1";"Week 5";1;7;0;0;13;5,2;4,6;11;31,9;5,6;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,2;3,6;13;17,4;3,6;11;"Low";"Some concerns";"Some concerns";"Low";"Low";"Some concerns";2021;"psilocybin";"waitlist";"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;"immediate treatment group";"delayed treatment group";2;39,8666666666667;66,7777777777778;"dep";NA;"crossover";"open-label";"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";"NCT03181529";"Davis2021_msd_qids-sr_Week5_1.00_self-report_psil_wl_NA_NA";-5,07565447275227;0,862303533688809;NA;NA;NA;NA;NA;NA
"22";"Davis 2021";"psil";"wl";NA;NA;"msd";"qids-sr";"self-report";"depression";0;"Post-second dose 2";"Week 8";4;28;1;0;13;5,5;3,6;11;17,7;3,7;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,2;3,6;13;17,4;3,6;11;"Low";"Some concerns";"Some concerns";"Low";"Low";"Some concerns";2021;"psilocybin";"waitlist";"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;"immediate treatment group";"delayed treatment group";2;39,8666666666667;66,7777777777778;"dep";NA;"crossover";"open-label";"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";"NCT03181529";"Davis2021_msd_qids-sr_Week8_4.00_self-report_psil_wl_NA_NA";-3,23093088729085;0,63334117548284;NA;NA;NA;NA;NA;NA
"23";"Davis 2021";"psil";"wl";NA;NA;"msd";"grid-ham-d";"clinician";"depression";1;"Post-second dose 1";"Week 5";1;7;0;0;13;8;7,1;11;23,8;5,4;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,9;3,6;13;22,5;4,4;11;"Low";"Some concerns";"Some concerns";"Low";"Low";"Some concerns";2021;"psilocybin";"waitlist";"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;"immediate treatment group";"delayed treatment group";2;39,8666666666667;66,7777777777778;"dep";NA;"crossover";"open-label";"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";"NCT03181529";"Davis2021_msd_grid-ham-d_Week5_1.00_clinician_psil_wl_NA_NA";-2,3897279858468;0,543559686244671;NA;NA;NA;NA;NA;NA
"24";"Davis 2021";"psil";"wl";NA;NA;"msd";"grid-ham-d";"clinician";"depression";1;"Post-second dose 2";"Week 8";4;28;1;0;13;8,5;5,7;11;23,5;6;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,9;3,6;13;22,5;4,4;11;"Low";"Some concerns";"Some concerns";"Low";"Low";"Some concerns";2021;"psilocybin";"waitlist";"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;"immediate treatment group";"delayed treatment group";2;39,8666666666667;66,7777777777778;"dep";NA;"crossover";"open-label";"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";"NCT03181529";"Davis2021_msd_grid-ham-d_Week8_4.00_clinician_psil_wl_NA_NA";-2,48065716535765;0,552588609503246;NA;NA;NA;NA;NA;NA
"25";"Davis 2021";"psil";"wl";NA;NA;"msd";"phq-9";"self-report";"depression";0;"Post-second dose 2";"Week 8";4;28;1;0;13;4,8;2,9;11;18,8;4,3;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,5;3,1;13;17,9;3,3;11;"Low";"Some concerns";"Some concerns";"Low";"Low";"Some concerns";2021;"psilocybin";"waitlist";"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;"immediate treatment group";"delayed treatment group";2;39,8666666666667;66,7777777777778;"dep";NA;"crossover";"open-label";"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";"NCT03181529";"Davis2021_msd_phq-9_Week8_4.00_self-report_psil_wl_NA_NA";-3,75018853776688;0,694357648017136;NA;NA;NA;NA;NA;NA
"26";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"change";"qids-sr";"self-report";"depression";0;"Post-first dose 3";"Week 3";3;21;1;NA;NA;NA;NA;NA;NA;NA;79;-6,3;5,89523099107666;75;-5,2;5,96497089341323;NA;NA;NA;NA;16,1;4,14;79;16,3;4,16;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_qids-sr_Week3_3.00_self-report_psil_psil_25mg_10mg";-0,18460291306013;0,161565177688826;NA;NA;NA;NA;NA;NA
"27";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"change";"qids-sr";"self-report";"depression";0;"Post-first dose 3";"Week 3";3;21;1;NA;NA;NA;NA;NA;NA;NA;79;-6,3;5,89523099107666;79;-3,6;6,12197064457961;NA;NA;NA;NA;16,1;4,14;79;15,8;3,96;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_qids-sr_Week3_3.00_self-report_psil_psil_25mg_1mg";-0,44711245099768;0,161106231491561;NA;NA;NA;NA;NA;NA
"28";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"change";"qids-sr";"self-report";"depression";0;"Post-first dose 3";"Week 3";3;21;1;NA;NA;NA;NA;NA;NA;NA;75;-5,2;5,96497089341323;79;-3,6;6,12197064457961;NA;NA;NA;NA;16,3;4,16;75;15,8;3,96;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_qids-sr_Week3_3.00_self-report_psil_psil_10mg_1mg";-0,263327851165626;0,161922629984635;NA;NA;NA;NA;NA;NA
"29";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"change";"qids-sr";"self-report";"depression";0;"Post-first dose 6";"Week 12";12;84;0;NA;NA;NA;NA;NA;NA;NA;79;-6,5;29,2494153018804;75;-5,5;7,06959513293419;NA;NA;NA;NA;16,1;4,14;79;16,3;4,16;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_qids-sr_Week12_12.00_self-report_psil_psil_25mg_10mg";-0,0462266292804944;0,161240715280361;NA;NA;NA;NA;NA;NA
"30";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"change";"qids-sr";"self-report";"depression";0;"Post-first dose 6";"Week 12";12;84;0;NA;NA;NA;NA;NA;NA;NA;79;-6,5;29,2494153018804;79;-5;7,02892925859141;NA;NA;NA;NA;16,1;4,14;79;15,8;3,96;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_qids-sr_Week12_12.00_self-report_psil_psil_25mg_1mg";-0,0701780687826577;0,159160900372791;NA;NA;NA;NA;NA;NA
"31";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"change";"qids-sr";"self-report";"depression";0;"Post-first dose 6";"Week 12";12;84;0;NA;NA;NA;NA;NA;NA;NA;75;-5,5;7,06959513293419;79;-5;7,02892925859141;NA;NA;NA;NA;16,3;4,16;75;15,8;3,96;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_qids-sr_Week12_12.00_self-report_psil_psil_10mg_1mg";-0,0705839158493311;0,161269643391451;NA;NA;NA;NA;NA;NA
"32";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"change";"madrs";"clinician";"depression";1;"Post-first dose 1";"Day 2";0,29;2;0;NA;NA;NA;NA;NA;NA;NA;79;-15,026;12,0523916298799;75;-11,986;12,2369389554741;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_madrs_Day2_0.29_clinician_psil_psil_25mg_10mg";-0,249121145931711;0,161848897621857;NA;NA;NA;NA;NA;NA
"33";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"change";"madrs";"clinician";"depression";1;"Post-first dose 1";"Day 2";0,29;2;0;NA;NA;NA;NA;NA;NA;NA;79;-15,026;12,0523916298799;79;-9,078;12,0523916298799;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_madrs_Day2_0.29_clinician_psil_psil_25mg_1mg";-0,491135546139263;0,161515313598675;NA;NA;NA;NA;NA;NA
"34";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"change";"madrs";"clinician";"depression";1;"Post-first dose 1";"Day 2";0,29;2;0;NA;NA;NA;NA;NA;NA;NA;75;-11,986;12,2369389554741;79;-9,078;12,0523916298799;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_madrs_Day2_0.29_clinician_psil_psil_10mg_1mg";-0,238304043542571;0,161795477652513;NA;NA;NA;NA;NA;NA
"35";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"change";"madrs";"clinician";"depression";1;"Post-first dose 2";"Week 1";1;7;0;NA;NA;NA;NA;NA;NA;NA;79;-13,043;11,1280194104791;75;-8,796;11,7779454914684;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_madrs_Week1_1.00_clinician_psil_psil_25mg_10mg";-0,369114770371633;0,162598654898194;NA;NA;NA;NA;NA;NA
"36";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"change";"madrs";"clinician";"depression";1;"Post-first dose 2";"Week 1";1;7;0;NA;NA;NA;NA;NA;NA;NA;79;-13,043;11,1280194104791;79;-6,887;11,5902055201795;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_madrs_Week1_1.00_clinician_psil_psil_25mg_1mg";-0,539222490615264;0,162004663914633;NA;NA;NA;NA;NA;NA
"37";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"change";"madrs";"clinician";"depression";1;"Post-first dose 2";"Week 1";1;7;0;NA;NA;NA;NA;NA;NA;NA;75;-8,796;11,7779454914684;79;-6,887;11,5902055201795;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_madrs_Week1_1.00_clinician_psil_psil_10mg_1mg";-0,162606401269336;0,16148765578732;NA;NA;NA;NA;NA;NA
"38";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"change";"madrs";"clinician";"depression";1;"Post-first dose 3";"Week 3";3;21;1;NA;NA;NA;NA;NA;NA;NA;79;-12;12,0172016356563;75;-7,9;11,9299417868265;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_madrs_Week3_3.00_clinician_psil_psil_25mg_10mg";-0,340693510443015;0,16239510909666;NA;NA;NA;NA;NA;NA
"39";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"change";"madrs";"clinician";"depression";1;"Post-first dose 3";"Week 3";3;21;1;NA;NA;NA;NA;NA;NA;NA;79;-12;12,0172016356563;79;-5,4;12,2439412891592;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_madrs_Week3_3.00_clinician_psil_psil_25mg_1mg";-0,541436278652384;0,162028254630371;NA;NA;NA;NA;NA;NA
"40";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"change";"madrs";"clinician";"depression";1;"Post-first dose 3";"Week 3";3;21;1;NA;NA;NA;NA;NA;NA;NA;75;-7,9;11,9299417868265;79;-5,4;12,2439412891592;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_madrs_Week3_3.00_clinician_psil_psil_10mg_1mg";-0,205724883723145;0,161648820099789;NA;NA;NA;NA;NA;NA
"41";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"change";"madrs";"clinician";"depression";1;"Post-first dose 4";"Week 6";6;42;0;NA;NA;NA;NA;NA;NA;NA;79;-11,53;13,4478381533985;75;-5,991;13,5879385853778;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_madrs_Week6_6.00_clinician_psil_psil_25mg_10mg";-0,407778343065248;0,162901252285212;NA;NA;NA;NA;NA;NA
"42";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"change";"madrs";"clinician";"depression";1;"Post-first dose 4";"Week 6";6;42;0;NA;NA;NA;NA;NA;NA;NA;79;-11,53;13,4478381533985;79;-6,261;12,9856520436981;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_madrs_Week6_6.00_clinician_psil_psil_25mg_1mg";-0,396680590448086;0,160683685359775;NA;NA;NA;NA;NA;NA
"43";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"change";"madrs";"clinician";"depression";1;"Post-first dose 4";"Week 6";6;42;0;NA;NA;NA;NA;NA;NA;NA;75;-5,991;13,5879385853778;79;-6,261;12,9856520436981;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_madrs_Week6_6.00_clinician_psil_psil_10mg_1mg";0,0202273645515336;0,161223146003312;NA;NA;NA;NA;NA;NA
"44";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"change";"madrs";"clinician";"depression";1;"Post-first dose 5";"Week 9";9;63;0;NA;NA;NA;NA;NA;NA;NA;79;-9,339;14,3722103727993;75;-6,109;14,4972652593515;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_madrs_Week9_9.00_clinician_psil_psil_25mg_10mg";-0,222683124641113;0,161722489932522;NA;NA;NA;NA;NA;NA
"45";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"change";"madrs";"clinician";"depression";1;"Post-first dose 5";"Week 9";9;63;0;NA;NA;NA;NA;NA;NA;NA;79;-9,339;14,3722103727993;79;-5,322;14,3810985672166;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_madrs_Week9_9.00_clinician_psil_psil_25mg_1mg";-0,278065826659824;0,159885943110615;NA;NA;NA;NA;NA;NA
"46";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"change";"madrs";"clinician";"depression";1;"Post-first dose 5";"Week 9";9;63;0;NA;NA;NA;NA;NA;NA;NA;75;-6,109;14,4972652593515;79;-5,322;14,3810985672166;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_madrs_Week9_9.00_clinician_psil_psil_10mg_1mg";-0,0542403965640219;0,161248901762607;NA;NA;NA;NA;NA;NA
"47";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"change";"madrs";"clinician";"depression";1;"Post-first dose 6";"Week 12";12;84;0;NA;NA;NA;NA;NA;NA;NA;79;-9,496;14,3810985672166;75;-5,651;14,0469320493836;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_madrs_Week12_12.00_clinician_psil_psil_25mg_10mg";-0,26906891465809;0,161953575769648;NA;NA;NA;NA;NA;NA
"48";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"change";"madrs";"clinician";"depression";1;"Post-first dose 6";"Week 12";12;84;0;NA;NA;NA;NA;NA;NA;NA;79;-9,496;14,3810985672166;79;-6;14,843284676917;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_madrs_Week12_12.00_clinician_psil_psil_25mg_1mg";-0,238070400496671;0,159679538002117;NA;NA;NA;NA;NA;NA
"49";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"change";"madrs";"clinician";"depression";1;"Post-first dose 6";"Week 12";12;84;0;NA;NA;NA;NA;NA;NA;NA;75;-5,651;14,0469320493836;79;-6;14,843284676917;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_change_madrs_Week12_12.00_clinician_psil_psil_10mg_1mg";0,0240144904164293;0,161224849872201;NA;NA;NA;NA;NA;NA
"50";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"response";"madrs";"clinician";"depression";1;"Post-first dose 1";"Day 2";0,29;2;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;42;79;24;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_response_madrs_Day2_0.29_clinician_psil_psil_25mg_10mg";-0,483058754617036;0,184601397856223;0,507656049004712;0,19870739617527;42;24;79;75
"51";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"response";"madrs";"clinician";"depression";1;"Post-first dose 1";"Day 2";0,29;2;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;42;79;18;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_response_madrs_Day2_0.29_clinician_psil_psil_25mg_1mg";-0,739203166461471;0,193189884520747;0,847297860387203;0,232483598709408;42;18;79;79
"52";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"response";"madrs";"clinician";"depression";1;"Post-first dose 1";"Day 2";0,29;2;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24;75;18;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_response_madrs_Day2_0.29_clinician_psil_psil_10mg_1mg";-0,256050130736952;0,201233919986895;0,339641811382492;0,266890728652735;24;18;75;79
"53";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"response";"madrs";"clinician";"depression";1;"Post-first dose 2";"Week 1";1;7;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35;79;17;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_response_madrs_Week1_1.00_clinician_psil_psil_25mg_10mg";-0,547719742802428;0,196758469095511;0,670174978502487;0,247797087960611;35;17;79;75
"54";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"response";"madrs";"clinician";"depression";1;"Post-first dose 2";"Week 1";1;7;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35;79;12;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_response_madrs_Week1_1.00_clinician_psil_psil_25mg_1mg";-0,818042457672835;0,213213509731684;1,07044141170141;0,294258910160014;35;12;79;79
"55";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"response";"madrs";"clinician";"depression";1;"Post-first dose 2";"Week 1";1;7;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;75;12;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_response_madrs_Week1_1.00_clinician_psil_psil_10mg_1mg";-0,270218378265294;0,230191279338547;0,400266433198927;0,340830311978943;17;12;75;79
"56";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"response";"madrs";"clinician";"depression";1;"Post-first dose 3";"Week 3";3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;29;79;14;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_response_madrs_Week3_3.00_clinician_psil_psil_25mg_10mg";-0,508604968699563;0,207979479793817;0,676278761440504;0,282700846952793;29;14;79;75
"57";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"response";"madrs";"clinician";"depression";1;"Post-first dose 3";"Week 3";3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;29;79;14;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_response_madrs_Week3_3.00_clinician_psil_psil_25mg_1mg";-0,543518002322607;0,207240964352298;0,728238500371216;0,283892364027387;29;14;79;79
"58";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"response";"madrs";"clinician";"depression";1;"Post-first dose 3";"Week 3";3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14;75;14;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_response_madrs_Week3_3.00_clinician_psil_psil_10mg_1mg";-0,0348437110314746;0,230396909206025;0,0519597389307112;0,341856083280243;14;14;75;79
"59";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"response";"madrs";"clinician";"depression";1;"Post-first dose 4";"Week 6";6;42;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;79;11;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_response_madrs_Week6_6.00_clinician_psil_psil_25mg_10mg";-0,575371767937793;0,223178286826114;0,8082415262924;0,321526154751359;26;11;79;75
"60";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"response";"madrs";"clinician";"depression";1;"Post-first dose 4";"Week 6";6;42;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;79;16;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_response_madrs_Week6_6.00_clinician_psil_psil_25mg_1mg";-0,361219886716389;0,203097531606742;0,485507815781701;0,275036511694967;26;16;79;79
"61";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"response";"madrs";"clinician";"depression";1;"Post-first dose 4";"Week 6";6;42;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;11;75;16;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_response_madrs_Week6_6.00_clinician_psil_psil_10mg_1mg";0,214197952738018;0,237075981004254;-0,3227337105107;0,356955921267117;11;16;75;79
"62";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"response";"madrs";"clinician";"depression";1;"Post-first dose 5";"Week 9";9;63;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;79;12;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_response_madrs_Week9_9.00_clinician_psil_psil_25mg_10mg";-0,316227935645098;0,224733656397081;0,45886588483528;0,327630542153656;20;12;79;75
"63";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"response";"madrs";"clinician";"depression";1;"Post-first dose 5";"Week 9";9;63;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;79;12;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_response_madrs_Week9_9.00_clinician_psil_psil_25mg_1mg";-0,350043490526369;0,224091872823937;0,510825623765991;0,328659212007104;20;12;79;79
"64";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"response";"madrs";"clinician";"depression";1;"Post-first dose 5";"Week 9";9;63;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;75;12;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_response_madrs_Week9_9.00_clinician_psil_psil_10mg_1mg";-0,0337709088496372;0,244994243823549;0,051959738930711;0,375066801363746;12;12;75;79
"65";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"response";"madrs";"clinician";"depression";1;"Post-first dose 6";"Week 12";12;84;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;79;12;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_response_madrs_Week12_12.00_clinician_psil_psil_25mg_10mg";-0,51899736264532;0,218131110395555;0,721230149302771;0,309521098817895;26;12;79;75
"66";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"response";"madrs";"clinician";"depression";1;"Post-first dose 6";"Week 12";12;84;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;79;13;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_response_madrs_Week12_12.00_clinician_psil_psil_25mg_1mg";-0,500670535974563;0,213104169598532;0,693147180559945;0,300113577980759;26;13;79;79
"67";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"response";"madrs";"clinician";"depression";1;"Post-first dose 6";"Week 12";12;84;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;75;13;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_response_madrs_Week12_12.00_clinician_psil_psil_10mg_1mg";0,0183906843147135;0,241127423028606;-0,0280829687428252;0,366421682048123;12;13;75;79
"68";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"response";"madrs";"clinician";"depression";1;"Post-first dose 7";"Week 3-12 Sustained Response";12;84;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;79;3;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_response_madrs_Week3-12SustainedResponse_12.00_clinician_psil_psil_25mg_10mg";-0,991606097434806;0,359674074446653;1,62201669464096;0,608146176631818;16;3;79;75
"69";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"response";"madrs";"clinician";"depression";1;"Post-first dose 7";"Week 3-12 Sustained Response";12;84;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;79;6;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_response_madrs_Week3-12SustainedResponse_12.00_clinician_psil_psil_25mg_1mg";-0,618988773944865;0,280440753604151;0,980829253011726;0,451497741932852;16;6;79;79
"70";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"response";"madrs";"clinician";"depression";1;"Post-first dose 7";"Week 3-12 Sustained Response";12;84;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;3;75;6;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_response_madrs_Week3-12SustainedResponse_12.00_clinician_psil_psil_10mg_1mg";0,372696271943864;0,400458956333702;-0,641187441629234;0,688482707712086;3;6;75;79
"71";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"remission";"madrs";"clinician";"depression";1;"Post-first dose 1";"Day 2";0,29;2;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;30;79;16;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_remission_madrs_Day2_0.29_clinician_psil_psil_25mg_10mg";-0,446742427362801;0,201209101839793;0,576648920491663;0,264275939411628;30;16;79;75
"72";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"remission";"madrs";"clinician";"depression";1;"Post-first dose 1";"Day 2";0,29;2;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;30;79;15;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_remission_madrs_Day2_0.29_clinician_psil_psil_25mg_1mg";-0,526842263065698;0,203344838513193;0,693147180559945;0,273282901594296;30;15;79;79
"73";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"remission";"madrs";"clinician";"depression";1;"Post-first dose 1";"Day 2";0,29;2;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;75;15;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_remission_madrs_Day2_0.29_clinician_psil_psil_10mg_1mg";-0,0800326400058482;0,221728017482283;0,116498260068282;0,321208819127421;16;15;75;79
"74";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"remission";"madrs";"clinician";"depression";1;"Post-first dose 2";"Week 1";1;7;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;25;79;8;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_remission_madrs_Week1_1.00_clinician_psil_psil_25mg_10mg";-0,743436846825519;0,245600712471635;1,08747454425765;0,372838354811526;25;8;79;75
"75";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"remission";"madrs";"clinician";"depression";1;"Post-first dose 2";"Week 1";1;7;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;25;79;9;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_remission_madrs_Week1_1.00_clinician_psil_psil_25mg_1mg";-0,70294054932581;0,236439338957101;1,02165124753198;0,354675422625967;25;9;79;79
"76";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"remission";"madrs";"clinician";"depression";1;"Post-first dose 2";"Week 1";1;7;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;8;75;9;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_remission_madrs_Week1_1.00_clinician_psil_psil_10mg_1mg";0,0405859535191799;0,283986403909221;-0,0658232967256723;0,458387990603677;8;9;75;79
"77";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"remission";"madrs";"clinician";"depression";1;"Post-first dose 3";"Week 3";3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;23;79;7;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_remission_madrs_Week3_3.00_clinician_psil_psil_25mg_10mg";-0,759125400183882;0,257947947756852;1,13762432794313;0,400429572515909;23;7;79;75
"78";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"remission";"madrs";"clinician";"depression";1;"Post-first dose 3";"Week 3";3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;23;79;6;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_remission_madrs_Week3_3.00_clinician_psil_psil_25mg_1mg";-0,882730082250152;0,271050185749346;1,34373474670109;0,429916819675655;23;6;79;79
"79";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"remission";"madrs";"clinician";"depression";1;"Post-first dose 3";"Week 3";3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;7;75;6;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_remission_madrs_Week3_3.00_clinician_psil_psil_10mg_1mg";-0,123492094927119;0,320496322472041;0,206110418757969;0,53247746275535;7;6;75;79
"80";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"remission";"madrs";"clinician";"depression";1;"Post-first dose 4";"Week 6";6;42;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;79;7;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_remission_madrs_Week6_6.00_clinician_psil_psil_25mg_10mg";-0,653822118763376;0,261234604859298;0,997862385567967;0,408491837954822;20;7;79;75
"81";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"remission";"madrs";"clinician";"depression";1;"Post-first dose 4";"Week 6";6;42;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;79;10;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_remission_madrs_Week6_6.00_clinician_psil_psil_25mg_1mg";-0,466217226903541;0,234844046305309;0,693147180559945;0,353105571046107;20;10;79;79
"82";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"remission";"madrs";"clinician";"depression";1;"Post-first dose 4";"Week 6";6;42;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;7;75;10;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_remission_madrs_Week6_6.00_clinician_psil_psil_10mg_1mg";0,187664355182606;0,28756745397276;-0,304715205008021;0,465688288102362;7;10;75;79
"83";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"remission";"madrs";"clinician";"depression";1;"Post-first dose 5";"Week 9";9;63;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;79;9;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_remission_madrs_Week9_9.00_clinician_psil_psil_25mg_10mg";-0,34116816345177;0,249402839658612;0,523404405972851;0,38421289662071;16;9;79;75
"84";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"remission";"madrs";"clinician";"depression";1;"Post-first dose 5";"Week 9";9;63;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;79;9;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_remission_madrs_Week9_9.00_clinician_psil_psil_25mg_1mg";-0,373495936789863;0,248874676341758;0,575364144903562;0,385090450952641;16;9;79;79
"85";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"remission";"madrs";"clinician";"depression";1;"Post-first dose 5";"Week 9";9;63;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;75;9;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_remission_madrs_Week9_9.00_clinician_psil_psil_10mg_1mg";-0,0322801360819781;0,276577838141005;0,051959738930711;0,442979300916857;9;9;75;79
"86";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"remission";"madrs";"clinician";"depression";1;"Post-first dose 6";"Week 12";12;84;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21;79;5;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_remission_madrs_Week12_12.00_clinician_psil_psil_25mg_10mg";-0,890459383732184;0,291290666364917;1,38312478635861;0,47077328560318;21;5;79;75
"87";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"remission";"madrs";"clinician";"depression";1;"Post-first dose 6";"Week 12";12;84;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21;79;9;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_remission_madrs_Week12_12.00_clinician_psil_psil_25mg_1mg";-0,56806969819056;0,24048132985056;0,847297860387203;0,365258405836137;21;9;79;79
"88";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"remission";"madrs";"clinician";"depression";1;"Post-first dose 6";"Week 12";12;84;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;75;9;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_remission_madrs_Week12_12.00_clinician_psil_psil_10mg_1mg";0,322462139560631;0,321327108955673;-0,535826925971408;0,533965869629957;5;9;75;79
"89";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"imsd";"madrs";"clinician";"depression";1;"Post-first dose 1";"Day 2";0,29;2;0;NA;79;16,874;10,5391240875912;75;21,014;10,2275;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_imsd_madrs_Day2_0.29_clinician_psil_psil_25mg_10mg";-0,396544925508674;0,16281028982987;NA;NA;NA;NA;NA;NA
"90";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"imsd";"madrs";"clinician";"depression";1;"Post-first dose 1";"Day 2";0,29;2;0;NA;79;16,874;10,5391240875912;79;23,622;10,2275;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_imsd_madrs_Day2_0.29_clinician_psil_psil_25mg_1mg";-0,646686685116762;0,163256618223517;NA;NA;NA;NA;NA;NA
"91";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"imsd";"madrs";"clinician";"depression";1;"Post-first dose 1";"Day 2";0,29;2;0;NA;75;21,014;10,5391240875912;79;23,622;10,2275;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_imsd_madrs_Day2_0.29_clinician_psil_psil_10mg_1mg";-0,250001472596058;0,161853348627889;NA;NA;NA;NA;NA;NA
"92";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"imsd";"madrs";"clinician";"depression";1;"Post-first dose 2";"Week 1";1;7;0;NA;79;18,857;10,5391240875912;75;24,204;10,2275;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_imsd_madrs_Week1_1.00_clinician_psil_psil_25mg_10mg";-0,512155970216154;0,16386481519566;NA;NA;NA;NA;NA;NA
"93";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"imsd";"madrs";"clinician";"depression";1;"Post-first dose 2";"Week 1";1;7;0;NA;79;18,857;10,5391240875912;79;25,813;10,2275;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_imsd_madrs_Week1_1.00_clinician_psil_psil_25mg_1mg";-0,666620121765293;0,163512602249458;NA;NA;NA;NA;NA;NA
"94";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"imsd";"madrs";"clinician";"depression";1;"Post-first dose 2";"Week 1";1;7;0;NA;75;24,204;10,5391240875912;79;25,813;10,2275;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_imsd_madrs_Week1_1.00_clinician_psil_psil_10mg_1mg";-0,15423787170516;0,161460733330932;NA;NA;NA;NA;NA;NA
"95";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"imsd";"madrs";"clinician";"depression";1;"Post-first dose 3";"Week 3";3;21;1;NA;79;19,9;10,5391240875912;75;25,1;10,2275;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_imsd_madrs_Week3_3.00_clinician_psil_psil_25mg_10mg";-0,498075751846643;0,163722432833855;NA;NA;NA;NA;NA;NA
"96";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"imsd";"madrs";"clinician";"depression";1;"Post-first dose 3";"Week 3";3;21;1;NA;79;19,9;10,5391240875912;79;27,3;10,2275;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_imsd_madrs_Week3_3.00_clinician_psil_psil_25mg_1mg";-0,709170342303503;0,164083582263683;NA;NA;NA;NA;NA;NA
"97";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"imsd";"madrs";"clinician";"depression";1;"Post-first dose 3";"Week 3";3;21;1;NA;75;25,1;10,5391240875912;79;27,3;10,2275;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_imsd_madrs_Week3_3.00_clinician_psil_psil_10mg_1mg";-0,210890812772748;0,161670647650147;NA;NA;NA;NA;NA;NA
"98";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"imsd";"madrs";"clinician";"depression";1;"Post-first dose 4";"Week 6";6;42;0;NA;79;20,37;10,5391240875912;75;27,009;10,2275;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_imsd_madrs_Week6_6.00_clinician_psil_psil_25mg_10mg";-0,635908637790359;0,165280238538101;NA;NA;NA;NA;NA;NA
"99";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"imsd";"madrs";"clinician";"depression";1;"Post-first dose 4";"Week 6";6;42;0;NA;79;20,37;10,5391240875912;79;26,439;10,2275;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_imsd_madrs_Week6_6.00_clinician_psil_psil_25mg_1mg";-0,581615514518914;0,162472569947978;NA;NA;NA;NA;NA;NA
"100";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"imsd";"madrs";"clinician";"depression";1;"Post-first dose 4";"Week 6";6;42;0;NA;75;27,009;10,5391240875912;79;26,439;10,2275;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_imsd_madrs_Week6_6.00_clinician_psil_psil_10mg_1mg";0,0546398924002117;0,16124934403207;NA;NA;NA;NA;NA;NA
"101";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"imsd";"madrs";"clinician";"depression";1;"Post-first dose 5";"Week 9";9;63;0;NA;79;22,561;10,5391240875912;75;26,891;10,2275;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_imsd_madrs_Week9_9.00_clinician_psil_psil_25mg_10mg";-0,414743847210762;0,162958905257691;NA;NA;NA;NA;NA;NA
"102";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"imsd";"madrs";"clinician";"depression";1;"Post-first dose 5";"Week 9";9;63;0;NA;79;22,561;10,5391240875912;79;27,378;10,2275;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_imsd_madrs_Week9_9.00_clinician_psil_psil_25mg_1mg";-0,461631559307564;0,161237019689574;NA;NA;NA;NA;NA;NA
"103";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"imsd";"madrs";"clinician";"depression";1;"Post-first dose 5";"Week 9";9;63;0;NA;75;26,891;10,5391240875912;79;27,378;10,2275;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_imsd_madrs_Week9_9.00_clinician_psil_psil_10mg_1mg";-0,0466835571910589;0,161241146956967;NA;NA;NA;NA;NA;NA
"104";"Goodwin 2022";"psil";"psil";"25 mg";"10 mg";"imsd";"madrs";"clinician";"depression";1;"Post-first dose 6";"Week 12";12;84;0;NA;79;22,404;10,5391240875912;75;27,349;10,2275;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"10 mg";"25-mg group";"10-mg group";1;40,3948051948052;55,512987012987;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_imsd_madrs_Week12_12.00_clinician_psil_psil_25mg_10mg";-0,473650883246472;0,163484580987544;NA;NA;NA;NA;NA;NA
"105";"Goodwin 2022";"psil";"psil";"25 mg";"1 mg";"imsd";"madrs";"clinician";"depression";1;"Post-first dose 6";"Week 12";12;84;0;NA;79;22,404;10,5391240875912;79;26,7;10,2275;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"25 mg";"1 mg";"25-mg group";"1-mg group";1;39,45;51;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_imsd_madrs_Week12_12.00_clinician_psil_psil_25mg_1mg";-0,411702133856196;0,160804375658786;NA;NA;NA;NA;NA;NA
"106";"Goodwin 2022";"psil";"psil";"10 mg";"1 mg";"imsd";"madrs";"clinician";"depression";1;"Post-first dose 6";"Week 12";12;84;0;NA;75;27,349;10,5391240875912;79;26,7;10,2275;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"10 mg";"1 mg";"10-mg group";"1-mg group";1;39,6253246753247;50,3831168831169;"trd";NA;"parallel";"double-blind";"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";"NCT03775200";"Goodwin2022_imsd_madrs_Week12_12.00_clinician_psil_psil_10mg_1mg";0,0622127897679605;0,161258341358482;NA;NA;NA;NA;NA;NA
"107";"Griffiths 2016";"psil";"psil";"22 mg/kg";"1 mg/kg";"msd";"bdi";"self-report";"depression";0;"Post-first dose 1";"5 weeks after session 1";5;35;1;0;26;7;7,08763712389397;25;12,92;7,9;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17,77;8,20942141688438;26;18,4;5,45;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"22 mg/kg";"1 mg/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;49,0357142857143;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675513";"NCT00465595";"Griffiths2016_msd_bdi_5weeksaftersession1_5.00_self-report_psil_psil_22mg/kg_1mg/kg";-0,777548803674066;0,290818652815185;NA;NA;NA;NA;NA;NA
"108";"Griffiths 2016";"psil";"psil";"22 mg/kg";"1 mg/kg";"msd";"bdi";"self-report";"depression";0;"Post-second dose 1";"5 weeks after session 2";5;35;0;1;25;5,8;7,05;24;8,17;6,07473456210228;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17,77;8,20942141688438;26;18,4;5,45;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"22 mg/kg";"1 mg/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;49,0357142857143;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675513";"NCT00465595";"Griffiths2016_msd_bdi_5weeksaftersession2_5.00_self-report_psil_psil_22mg/kg_1mg/kg";-0,353823395756413;0,288073118615127;NA;NA;NA;NA;NA;NA
"109";"Griffiths 2016";"psil";"psil";"22 mg/kg";"1 mg/kg";"msd";"bdi";"self-report";"depression";0;"Follow-up 1";"6 months";26,09;182,625;0;1;24;6,17;6,17271415181361;22;8;7,03562363973514;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17,77;8,20942141688438;26;18,4;5,45;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"22 mg/kg";"1 mg/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;49,0357142857143;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675513";"NCT00465595";"Griffiths2016_msd_bdi_6months_26.09_self-report_psil_psil_22mg/kg_1mg/kg";-0,272575291467599;0,296575805493764;NA;NA;NA;NA;NA;NA
"110";"Griffiths 2016";"psil";"psil";"22 mg/kg";"1 mg/kg";"msd";"grid-ham-d";"clinician";"depression";1;"Post-first dose 1";"5 weeks after session 1";5;35;1;0;25;6,64;5,2;25;14,8;7,25;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,84;4,946048928185;26;22,32;4,4;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"22 mg/kg";"1 mg/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;49,0357142857143;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675513";"NCT00465595";"Griffiths2016_msd_grid-ham-d_5weeksaftersession1_5.00_clinician_psil_psil_22mg/kg_1mg/kg";-1,27311104197224;0,311013705206831;NA;NA;NA;NA;NA;NA
"111";"Griffiths 2016";"psil";"psil";"22 mg/kg";"1 mg/kg";"msd";"grid-ham-d";"clinician";"depression";1;"Post-second dose 1";"5 weeks after session 2";5;35;0;1;25;6,52;7,2;24;6,5;4,21312235758707;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,84;4,946048928185;26;22,32;4,4;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"22 mg/kg";"1 mg/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;49,0357142857143;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675513";"NCT00465595";"Griffiths2016_msd_grid-ham-d_5weeksaftersession2_5.00_clinician_psil_psil_22mg/kg_1mg/kg";0,00331890655475998;0,285774006447645;NA;NA;NA;NA;NA;NA
"112";"Griffiths 2016";"psil";"psil";"22 mg/kg";"1 mg/kg";"msd";"grid-ham-d";"clinician";"depression";1;"Follow-up 1";"6 months";26,09;182,625;0;1;24;6,23;6,36867333123626;22;6,95;5,81611554218105;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,84;4,946048928185;26;22,32;4,4;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"22 mg/kg";"1 mg/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;49,0357142857143;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675513";"NCT00465595";"Griffiths2016_msd_grid-ham-d_6months_26.09_clinician_psil_psil_22mg/kg_1mg/kg";-0,115796985535777;0,295418499944029;NA;NA;NA;NA;NA;NA
"113";"Griffiths 2016";"psil";"psil";"22 mg/kg";"1 mg/kg";"msd";"hads-d";"self-report";"depression";0;"Post-first dose 1";"5 weeks after session 1";5;35;1;0;26;3,92;3,77327444005866;25;6,04;3,95;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,81;3,51832346437902;26;9,48;3,55;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"22 mg/kg";"1 mg/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;49,0357142857143;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675513";"NCT00465595";"Griffiths2016_msd_hads-d_5weeksaftersession1_5.00_self-report_psil_psil_22mg/kg_1mg/kg";-0,540654890825001;0,285337615889013;NA;NA;NA;NA;NA;NA
"114";"Griffiths 2016";"psil";"psil";"22 mg/kg";"1 mg/kg";"msd";"hads-d";"self-report";"depression";0;"Post-second dose 1";"5 weeks after session 2";5;35;0;1;25;4,28;4,45;24;4,57;3,57625502446344;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,81;3,51832346437902;26;9,48;3,55;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"22 mg/kg";"1 mg/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;49,0357142857143;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675513";"NCT00465595";"Griffiths2016_msd_hads-d_5weeksaftersession2_5.00_self-report_psil_psil_22mg/kg_1mg/kg";-0,0705246893873731;0,285865505950152;NA;NA;NA;NA;NA;NA
"115";"Griffiths 2016";"psil";"psil";"22 mg/kg";"1 mg/kg";"msd";"hads-d";"self-report";"depression";0;"Follow-up 1";"6 months";26,09;182,625;0;1;24;3,46;3,2333264604738;22;4,64;3,37709934707287;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,81;3,51832346437902;26;9,48;3,55;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"22 mg/kg";"1 mg/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;49,0357142857143;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675513";"NCT00465595";"Griffiths2016_msd_hads-d_6months_26.09_self-report_psil_psil_22mg/kg_1mg/kg";-0,351155795867404;0,297504127606758;NA;NA;NA;NA;NA;NA
"116";"Griffiths 2016";"psil";"psil";"22 mg/kg";"1 mg/kg";"response";"grid-ham-d";"clinician";"depression";1;"Post-first dose 1";"5 weeks after session 1";5;35;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;23;25;8;25;22,84;4,946048928185;26;22,32;4,4;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"22 mg/kg";"1 mg/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;49,0357142857143;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675513";"NCT00465595";"Griffiths2016_response_grid-ham-d_5weeksaftersession1_5.00_clinician_psil_psil_22mg/kg_1mg/kg";-1,73443550611936;0,470184256190578;1,05605267424931;0,297452955725044;23;8;25;25
"117";"Griffiths 2016";"psil";"psil";"22 mg/kg";"1 mg/kg";"response";"grid-ham-d";"clinician";"depression";1;"Post-second dose 1";"5 weeks after session 2";5;35;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21;25;18;24;22,84;4,946048928185;26;22,32;4,4;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"22 mg/kg";"1 mg/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;49,0357142857143;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675513";"NCT00465595";"Griffiths2016_response_grid-ham-d_5weeksaftersession2_5.00_clinician_psil_psil_22mg/kg_1mg/kg";-0,303582637310363;0,397508236769202;0,113328685307003;0,146655843756519;21;18;25;24
"118";"Griffiths 2016";"psil";"psil";"22 mg/kg";"1 mg/kg";"response";"grid-ham-d";"clinician";"depression";1;"Follow-up 1";"6 months";26,09;182,625;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;19;24;17;22;22,84;4,946048928185;26;22,32;4,4;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"22 mg/kg";"1 mg/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;49,0357142857143;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675513";"NCT00465595";"Griffiths2016_response_grid-ham-d_6months_26.09_clinician_psil_psil_22mg/kg_1mg/kg";-0,0602706738642289;0,394288867299855;0,0242142581205945;0,155993257027094;19;17;24;22
"119";"Griffiths 2016";"psil";"psil";"22 mg/kg";"1 mg/kg";"remission";"grid-ham-d";"clinician";"depression";1;"Post-first dose 1";"5 weeks after session 1";5;35;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15;25;4;25;22,84;4,946048928185;26;22,32;4,4;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"22 mg/kg";"1 mg/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;49,0357142857143;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675513";"NCT00465595";"Griffiths2016_remission_grid-ham-d_5weeksaftersession1_5.00_clinician_psil_psil_22mg/kg_1mg/kg";-1,11990289316815;0,375667318726251;1,32175583998232;0,486483983977547;15;4;25;25
"120";"Griffiths 2016";"psil";"psil";"22 mg/kg";"1 mg/kg";"remission";"grid-ham-d";"clinician";"depression";1;"Post-second dose 1";"5 weeks after session 2";5;35;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;25;14;24;22,84;4,946048928185;26;22,32;4,4;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"22 mg/kg";"1 mg/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;49,0357142857143;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675513";"NCT00465595";"Griffiths2016_remission_grid-ham-d_5weeksaftersession2_5.00_clinician_psil_psil_22mg/kg_1mg/kg";-0,226378357172157;0,328608718760945;0,153334019920702;0,220421038409834;17;14;25;24
"121";"Griffiths 2016";"psil";"psil";"22 mg/kg";"1 mg/kg";"remission";"grid-ham-d";"clinician";"depression";1;"Follow-up 1";"6 months";26,09;182,625;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;24;13;22;22,84;4,946048928185;26;22,32;4,4;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"22 mg/kg";"1 mg/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;49,0357142857143;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675513";"NCT00465595";"Griffiths2016_remission_grid-ham-d_6months_26.09_clinician_psil_psil_22mg/kg_1mg/kg";-0,281547874811647;0,344178896486629;0,18125260960505;0,220511664574982;17;13;24;22
"122";"Grob 2011";"psil";"ncn";NA;NA;"msd";"bdi";"self-report";"depression";1;"Pre-first dose 1";"1 day before experimental session";-0,14;-1;0;1;12;16,09;12,7097888259404;12;14,369;13,6485603636428;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;"Low";"Some concerns";"Low";"Some concerns";"High";"High";2011;"psilocybin";"niacin";"0.2 mg/kg";"250 mg";"psilocybin";"niacin placebo";1;NA;NA;"cancer";NA;"crossover";"double-blind";"10.1001/archgenpsychiatry.2010.116";"NCT00302744";"Grob2011_msd_bdi_1daybeforeexperimentalsession_-0.14_self-report_psil_ncn_NA_NA";0,126001994614439;0,408682608848014;NA;NA;NA;NA;NA;NA
"123";"Grob 2011";"psil";"ncn";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-first dose 1";"1 day after experimental session";0,14;1;0;1;12;11,442;10,0424305822844;12;13,208;11,767553186623;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;"Low";"Some concerns";"Low";"Some concerns";"High";"High";2011;"psilocybin";"niacin";"0.2 mg/kg";"250 mg";"psilocybin";"niacin placebo";1;NA;NA;"cancer";NA;"crossover";"double-blind";"10.1001/archgenpsychiatry.2010.116";"NCT00302744";"Grob2011_msd_bdi_1dayafterexperimentalsession_0.14_self-report_psil_ncn_NA_NA";-0,155873053599128;0,408912757018787;NA;NA;NA;NA;NA;NA
"124";"Grob 2011";"psil";"ncn";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-first dose 2";"2 weeks after experimental session";2;14;1;1;12;10,054;9,25607951564808;12;13,27;10,9812021199867;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;"Low";"Some concerns";"Low";"Some concerns";"High";"High";2011;"psilocybin";"niacin";"0.2 mg/kg";"250 mg";"psilocybin";"niacin placebo";1;NA;NA;"cancer";NA;"crossover";"double-blind";"10.1001/archgenpsychiatry.2010.116";"NCT00302744";"Grob2011_msd_bdi_2weeksafterexperimentalsession_2.00_self-report_psil_ncn_NA_NA";-0,30576069806098;0,41079918756803;NA;NA;NA;NA;NA;NA
"125";"Krempien 2023";"psil-d";"psil-d";"16 mg";"12 mg";"msd";"madrs";"clinician";"depression";1;"Post-first dose 4";"Day 21";3;21;1;NA;9;16,556;6,146;15;15,867;8,684;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,444;4,035;9;32,611;3,664;18;NA;NA;NA;NA;NA;NA;2023;"CYB003 deuterated psilocin";"CYB003 deuterated psilocin";"16 mg";"12 mg";"16 mg group";"12 mg group";1;NA;NA;"dep";NA;"parallel";"double-blind";"10.1038/s41386-023-01755-5";"NCT05385783";"Krempien2023_msd_madrs_Day21_3.00_clinician_psil-d_psil-d_16mg_12mg";0,0846736545215689;0,421826984238059;NA;NA;NA;NA;NA;NA
"126";"Krempien 2023";"psil-d";"pcb";"16 mg";NA;"msd";"madrs";"clinician";"depression";1;"Post-first dose 4";"Day 21";3;21;1;NA;9;16,556;6,146;9;29;5,315;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,444;4,035;9;31,556;4,927;9;NA;NA;NA;NA;NA;NA;2023;"CYB003 deuterated psilocin";"placebo";"16 mg";NA;"16 mg group";"placebo";1;NA;NA;"dep";NA;"parallel";"double-blind";"10.1038/s41386-023-01755-5";"NCT05385783";"Krempien2023_msd_madrs_Day21_3.00_clinician_psil-d_pcb_16mg_NA";-2,06271669538169;0,593738559711083;NA;NA;NA;NA;NA;NA
"127";"Krempien 2023";"psil-d";"pcb";"12 mg";NA;"msd";"madrs";"clinician";"depression";1;"Post-first dose 4";"Day 21";3;21;1;NA;15;15,867;8,684;9;29;5,315;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;32,611;3,664;18;31,556;4,927;9;NA;NA;NA;NA;NA;NA;2023;"CYB003 deuterated psilocin";"placebo";"12 mg";NA;"12 mg group";"placebo";1;NA;NA;"dep";NA;"parallel";"double-blind";"10.1038/s41386-023-01755-5";"NCT05385783";"Krempien2023_msd_madrs_Day21_3.00_clinician_psil-d_pcb_12mg_NA";-1,66123853816433;0,489338185039199;NA;NA;NA;NA;NA;NA
"128";"Raison 2023";"psil";"ncn";NA;NA;"change";"madrs";"clinician";"depression";1;"Post-first dose 1";"Day 2";0,29;2;0;NA;NA;NA;NA;NA;NA;NA;51;-2,7;5,10102030610204;53;-2,7;5,20007849234323;NA;NA;NA;NA;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin";"niacin";1;41,1134615384615;50,0576923076923;"dep";NA;"parallel";"double-blind";"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";"NCT03866174";"Raison2023_change_madrs_Day2_0.29_clinician_psil_ncn_NA_NA";0;0,196152409277982;NA;NA;NA;NA;NA;NA
"129";"Raison 2023";"psil";"ncn";NA;NA;"change";"madrs";"clinician";"depression";1;"Post-first dose 2";"Day 8";1,14;8;0;NA;NA;NA;NA;NA;NA;NA;51;-17,8;11,8416542820226;53;-5,8;12,0716107857968;NA;NA;NA;NA;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin";"niacin";1;41,1134615384615;50,0576923076923;"dep";NA;"parallel";"double-blind";"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";"NCT03866174";"Raison2023_change_madrs_Day8_1.14_clinician_psil_ncn_NA_NA";-0,995995497988749;0,208125264900041;NA;NA;NA;NA;NA;NA
"130";"Raison 2023";"psil";"ncn";NA;NA;"change";"madrs";"clinician";"depression";1;"Post-first dose 3";"Day 15";2,14;15;0;NA;NA;NA;NA;NA;NA;NA;51;-18;12,0238335786691;53;-6,9;12,6287620528336;NA;NA;NA;NA;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin";"niacin";1;41,1134615384615;50,0576923076923;"dep";NA;"parallel";"double-blind";"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";"NCT03866174";"Raison2023_change_madrs_Day15_2.14_clinician_psil_ncn_NA_NA";-0,89317763251305;0,20583574904796;NA;NA;NA;NA;NA;NA
"131";"Raison 2023";"psil";"ncn";NA;NA;"change";"madrs";"clinician";"depression";1;"Post-first dose 4";"Day 29";4,14;29;0;NA;NA;NA;NA;NA;NA;NA;51;-19,2;12,3881921719621;53;-5,5;13,0001962308581;NA;NA;NA;NA;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin";"niacin";1;41,1134615384615;50,0576923076923;"dep";NA;"parallel";"double-blind";"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";"NCT03866174";"Raison2023_change_madrs_Day29_4.14_clinician_psil_ncn_NA_NA";-1,07046182341652;0,209921339689726;NA;NA;NA;NA;NA;NA
"132";"Raison 2023";"psil";"ncn";NA;NA;"change";"madrs";"clinician";"depression";1;"Post-first dose 5";"Day 43";6,14;43;1;NA;NA;NA;NA;NA;NA;NA;51;-19,1;13,1169093585481;53;-6,8;13,7430645869071;NA;NA;NA;NA;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin";"niacin";1;41,1134615384615;50,0576923076923;"dep";NA;"parallel";"double-blind";"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";"NCT03866174";"Raison2023_change_madrs_Day43_6.14_clinician_psil_ncn_NA_NA";-0,908448235718669;0,206161577613683;NA;NA;NA;NA;NA;NA
"133";"Raison 2023";"psil";"ncn";NA;NA;"change";"smdds";"self-report";"depression";0;"Post-first dose 2";"Day 8";1,14;8;0;NA;NA;NA;NA;NA;NA;NA;51;-21,1;14,3921644350736;48;-9,6;14,3159301441917;NA;NA;NA;NA;43,2;8,7;51;44,3;5,9;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin";"niacin";1;41,1134615384615;50,0576923076923;"dep";NA;"parallel";"double-blind";"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";"NCT03866174";"Raison2023_change_smdds_Day8_1.14_self-report_psil_ncn_NA_NA";-0,794889080131949;0,209003320149336;NA;NA;NA;NA;NA;NA
"134";"Raison 2023";"psil";"ncn";NA;NA;"change";"smdds";"self-report";"depression";0;"Post-first dose 5";"Day 43";6,14;43;1;NA;NA;NA;NA;NA;NA;NA;50;-21,8;14,7915194023717;42;-10,8;14,3832765500379;NA;NA;NA;NA;43,2;8,7;51;44,3;5,9;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin";"niacin";1;41,1134615384615;50,0576923076923;"dep";NA;"parallel";"double-blind";"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";"NCT03866174";"Raison2023_change_smdds_Day43_6.14_self-report_psil_ncn_NA_NA";-0,746772780986188;0,216544760098465;NA;NA;NA;NA;NA;NA
"135";"Raison 2023";"psil";"ncn";NA;NA;"msd";"madrs";"clinician";"depression";1;"Post-first dose 5";"Day 43";6,14;43;1;NA;50;16,1;13;44;27,3;12,5;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin";"niacin";1;41,1134615384615;50,0576923076923;"dep";NA;"parallel";"double-blind";"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";"NCT03866174";"Raison2023_msd_madrs_Day43_6.14_clinician_psil_ncn_NA_NA";-0,869971940431115;0,216378625859585;NA;NA;NA;NA;NA;NA
"136";"Raison 2023";"psil";"ncn";NA;NA;"response";"madrs";"clinician";"depression";1;"Post-first dose 2";"Day 8";1,14;8;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;27;51;5;50;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin";"niacin";1;41,1134615384615;50,0576923076923;"dep";NA;"parallel";"double-blind";"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";"NCT03866174";"Raison2023_response_madrs_Day8_1.14_clinician_psil_ncn_NA_NA";-1,26663694011237;0,302440924827385;1,66659632627405;0,444330050637791;27;5;51;50
"137";"Raison 2023";"psil";"ncn";NA;NA;"response";"madrs";"clinician";"depression";1;"Post-first dose 3";"Day 15";2,14;15;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;25;50;8;45;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin";"niacin";1;41,1134615384615;50,0576923076923;"dep";NA;"parallel";"double-blind";"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";"NCT03866174";"Raison2023_response_madrs_Day15_2.14_clinician_psil_ncn_NA_NA";-0,837519570771861;0,26557062911055;1,03407376753054;0,350396600693811;25;8;50;45
"138";"Raison 2023";"psil";"ncn";NA;NA;"response";"madrs";"clinician";"depression";1;"Post-first dose 4";"Day 29";4,14;29;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;49;7;44;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin";"niacin";1;41,1134615384615;50,0576923076923;"dep";NA;"parallel";"double-blind";"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";"NCT03866174";"Raison2023_response_madrs_Day29_4.14_clinician_psil_ncn_NA_NA";-0,977415960975367;0,276668227108227;1,2045557247738;0,371730070516366;26;7;49;44
"139";"Raison 2023";"psil";"ncn";NA;NA;"response";"madrs";"clinician";"depression";1;"Post-first dose 5";"Day 43";6,14;43;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;29;50;9;44;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin";"niacin";1;41,1134615384615;50,0576923076923;"dep";NA;"parallel";"double-blind";"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";"NCT03866174";"Raison2023_response_madrs_Day43_6.14_clinician_psil_ncn_NA_NA";-0,919151592975676;0,259642749420353;1,04223788114037;0,320728229198067;29;9;50;44
"140";"Raison 2023";"psil";"ncn";NA;NA;"response";"madrs";"clinician";"depression";1;"Follow-up 1";"Days 8-43 Sustained Response";6,14;43;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;48;5;44;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin";"niacin";1;41,1134615384615;50,0576923076923;"dep";NA;"parallel";"double-blind";"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";"NCT03866174";"Raison2023_response_madrs_Days8-43SustainedResponse_6.14_clinician_psil_ncn_NA_NA";-0,939077329599338;0,307637231231115;1,29928298413026;0,454356021132541;20;5;48;44
"141";"Raison 2023";"psil";"ncn";NA;NA;"remission";"madrs";"clinician";"depression";1;"Post-first dose 2";"Day 8";1,14;8;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;18;51;4;50;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin";"niacin";1;41,1134615384615;50,0576923076923;"dep";NA;"parallel";"double-blind";"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";"NCT03866174";"Raison2023_remission_madrs_Day8_1.14_clinician_psil_ncn_NA_NA";-1,00466752808607;0,329691782803155;1,48427476948009;0,515701185201567;18;4;51;50
"142";"Raison 2023";"psil";"ncn";NA;NA;"remission";"madrs";"clinician";"depression";1;"Post-first dose 3";"Day 15";2,14;15;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;50;6;45;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin";"niacin";1;41,1134615384615;50,0576923076923;"dep";NA;"parallel";"double-blind";"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";"NCT03866174";"Raison2023_remission_madrs_Day15_2.14_clinician_psil_ncn_NA_NA";-0,801896794326249;0,289456084639812;1,09861228866811;0,417665469538056;20;6;50;45
"143";"Raison 2023";"psil";"ncn";NA;NA;"remission";"madrs";"clinician";"depression";1;"Post-first dose 4";"Day 29";4,14;29;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;18;49;5;44;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin";"niacin";1;41,1134615384615;50,0576923076923;"dep";NA;"parallel";"double-blind";"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";"NCT03866174";"Raison2023_remission_madrs_Day29_4.14_clinician_psil_ncn_NA_NA";-0,825904329377777;0,308672621340806;1,1733031812697;0,460890572221842;18;5;49;44
"144";"Raison 2023";"psil";"ncn";NA;NA;"remission";"madrs";"clinician";"depression";1;"Post-first dose 5";"Day 43";6,14;43;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22;50;5;44;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin";"niacin";1;41,1134615384615;50,0576923076923;"dep";NA;"parallel";"double-blind";"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";"NCT03866174";"Raison2023_remission_madrs_Day43_6.14_clinician_psil_ncn_NA_NA";-0,991367547103598;0,305383387785473;1,35377116941433;0,450252454437811;22;5;50;44
"145";"Raison 2023";"psil";"ncn";NA;NA;"remission";"madrs";"clinician";"depression";1;"Follow-up 1";"Days 8-43 Sustained Response";6,14;43;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;48;4;44;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin";"niacin";1;41,1134615384615;50,0576923076923;"dep";NA;"parallel";"double-blind";"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";"NCT03866174";"Raison2023_remission_madrs_Days8-43SustainedResponse_6.14_clinician_psil_ncn_NA_NA";-0,658238046496866;0,342583864748047;1,01160091167848;0,538305421923955;12;4;48;44
"146";"Raison 2023";"psil";"ncn";NA;NA;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 1";"Day 2";0,29;2;0;NA;51;32,8;13;53;32,3;12,5;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin";"niacin";1;41,1134615384615;50,0576923076923;"dep";NA;"parallel";"double-blind";"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";"NCT03866174";"Raison2023_imsd_madrs_Day2_0.29_clinician_psil_ncn_NA_NA";0,0389341123321014;0,196171262205403;NA;NA;NA;NA;NA;NA
"147";"Raison 2023";"psil";"ncn";NA;NA;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 2";"Day 8";1,14;8;0;NA;51;17,7;13;53;29,2;12,5;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin";"niacin";1;41,1134615384615;50,0576923076923;"dep";NA;"parallel";"double-blind";"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";"NCT03866174";"Raison2023_imsd_madrs_Day8_1.14_clinician_psil_ncn_NA_NA";-0,895484583638332;0,205884651101164;NA;NA;NA;NA;NA;NA
"148";"Raison 2023";"psil";"ncn";NA;NA;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 3";"Day 15";2,14;15;0;NA;51;17,5;13;53;28,1;12,5;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin";"niacin";1;41,1134615384615;50,0576923076923;"dep";NA;"parallel";"double-blind";"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";"NCT03866174";"Raison2023_imsd_madrs_Day15_2.14_clinician_psil_ncn_NA_NA";-0,82540318144055;0,204450551529181;NA;NA;NA;NA;NA;NA
"149";"Raison 2023";"psil";"ncn";NA;NA;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 4";"Day 29";4,14;29;0;NA;51;16,3;13;53;29,5;12,5;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"25 mg";"100 mg";"psilocybin";"niacin";1;41,1134615384615;50,0576923076923;"dep";NA;"parallel";"double-blind";"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";"NCT03866174";"Raison2023_imsd_madrs_Day29_4.14_clinician_psil_ncn_NA_NA";-1,02786056556748;0,208879863202166;NA;NA;NA;NA;NA;NA
"150";"Rieser 2025";"psil";"pcb";NA;NA;"msd";"bdi";"self-report";"depression";1;"Flexible Timepoint 1";"Day -14";-2;-14;0;NA;18;12,72;8,37;19;12,21;7,75;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,06;8,99;18;11,05;8,02;19;"Low";"Low";"Some concerns";"Some concerns";"Low";"Some concerns";2025;"psilocybin";"mannitol";"25 mg";"100% mannitol";"psilocybin";"placebo";1;37,2675;37,7975;"aud";NA;"parallel";"double-blind";"10.1016/j.eclinm.2025.103149";"NCT04141501";"Rieser2025_msd_bdi_Day-14_-2.00_self-report_psil_pcb_NA_NA";0,0619320308487031;0,329000423326536;NA;NA;NA;NA;NA;NA
"151";"Rieser 2025";"psil";"pcb";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-first dose 1";"Day 1";0,14;1;0;NA;18;6,11;5,61;19;8,61;10,8;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,06;8,99;18;11,05;8,02;19;"Low";"Low";"Some concerns";"Some concerns";"Low";"Some concerns";2025;"psilocybin";"mannitol";"25 mg";"100% mannitol";"psilocybin";"placebo";1;37,2675;37,7975;"aud";NA;"parallel";"double-blind";"10.1016/j.eclinm.2025.103149";"NCT04141501";"Rieser2025_msd_bdi_Day1_0.14_self-report_psil_pcb_NA_NA";-0,281932583311054;0,33061938896167;NA;NA;NA;NA;NA;NA
"152";"Rieser 2025";"psil";"pcb";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-first dose 2";"Day 14";2;14;0;NA;18;7,17;7,13;18;10,79;10,97;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,06;8,99;18;11,05;8,02;19;"Low";"Low";"Some concerns";"Some concerns";"Low";"Some concerns";2025;"psilocybin";"mannitol";"25 mg";"100% mannitol";"psilocybin";"placebo";1;37,2675;37,7975;"aud";NA;"parallel";"double-blind";"10.1016/j.eclinm.2025.103149";"NCT04141501";"Rieser2025_msd_bdi_Day14_2.00_self-report_psil_pcb_NA_NA";-0,382595634956989;0,336507979084192;NA;NA;NA;NA;NA;NA
"153";"Rieser 2025";"psil";"pcb";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-first dose 3";"Day 30";4,29;30;1;NA;18;7,17;7,13;19;10,79;10,97;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,06;8,99;18;11,05;8,02;19;"Low";"Low";"Some concerns";"Some concerns";"Low";"Some concerns";2025;"psilocybin";"mannitol";"25 mg";"100% mannitol";"psilocybin";"placebo";1;37,2675;37,7975;"aud";NA;"parallel";"double-blind";"10.1016/j.eclinm.2025.103149";"NCT04141501";"Rieser2025_msd_bdi_Day30_4.29_self-report_psil_pcb_NA_NA";-0,380644306000238;0,332012714527199;NA;NA;NA;NA;NA;NA
"154";"Rieser 2025";"psil";"pcb";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-first dose 4";"Day 96";13,71;96;0;NA;17;7,76;7,97;18;14;12,77;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,06;8,99;18;11,05;8,02;19;"Low";"Low";"Some concerns";"Some concerns";"Low";"Some concerns";2025;"psilocybin";"mannitol";"25 mg";"100% mannitol";"psilocybin";"placebo";1;37,2675;37,7975;"aud";NA;"parallel";"double-blind";"10.1016/j.eclinm.2025.103149";"NCT04141501";"Rieser2025_msd_bdi_Day96_13.71_self-report_psil_pcb_NA_NA";-0,569039433802074;0,345288659722553;NA;NA;NA;NA;NA;NA
"155";"Rieser 2025";"psil";"pcb";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-first dose 5";"Day 190";27,14;190;0;NA;17;9,47;10,26;17;11,41;9,68;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,06;8,99;18;11,05;8,02;19;"Low";"Low";"Some concerns";"Some concerns";"Low";"Some concerns";2025;"psilocybin";"mannitol";"25 mg";"100% mannitol";"psilocybin";"placebo";1;37,2675;37,7975;"aud";NA;"parallel";"double-blind";"10.1016/j.eclinm.2025.103149";"NCT04141501";"Rieser2025_msd_bdi_Day190_27.14_self-report_psil_pcb_NA_NA";-0,189906964495615;0,343807205481078;NA;NA;NA;NA;NA;NA
"156";"Rosenblat 2024";"psil";"wl";NA;NA;"change";"madrs";"clinician";"depression";1;"Post-first dose 1";"Day 1";0,14;1;0;0;NA;NA;NA;NA;NA;NA;16;-13,277;6,3;14;-1,064;6,20740960465797;NA;NA;NA;NA;33;3,86;16;27,57;6,64;15;"Some concerns";"Low";"Low";"High";"Low";"High";2024;"psilocybin";"waitlist";"25 mg";NA;"immediate group";"delayed group";1;44,1266666666667;39,1333333333333;"trd";NA;"crossover";"open-label";"10.1016/j.medj.2024.01.005";"NCT05029466";"Rosenblat2024_change_madrs_Day1_0.14_clinician_psil_wl_NA_NA";-1,8990847527257;0,444323125248803;NA;NA;NA;NA;NA;NA
"157";"Rosenblat 2024";"psil";"wl";NA;NA;"change";"madrs";"clinician";"depression";1;"Post-first dose 2";"Day 7";1;7;0;0;NA;NA;NA;NA;NA;NA;16;-11,319;7,828;14;-3,021;7,48331477354788;NA;NA;NA;NA;33;3,86;16;27,57;6,64;15;"Some concerns";"Low";"Low";"High";"Low";"High";2024;"psilocybin";"waitlist";"25 mg";NA;"immediate group";"delayed group";1;44,1266666666667;39,1333333333333;"trd";NA;"crossover";"open-label";"10.1016/j.medj.2024.01.005";"NCT05029466";"Rosenblat2024_change_madrs_Day7_1.00_clinician_psil_wl_NA_NA";-1,05265203301189;0,391710041145542;NA;NA;NA;NA;NA;NA
"158";"Rosenblat 2024";"psil";"wl";NA;NA;"change";"madrs";"clinician";"depression";1;"Post-first dose 3";"Day 14";2;14;1;0;NA;NA;NA;NA;NA;NA;16;-9,6;7,6;14;-3;3,36749164809655;NA;NA;NA;NA;33;3,86;16;27,57;6,64;15;"Some concerns";"Low";"Low";"High";"Low";"High";2024;"psilocybin";"waitlist";"25 mg";NA;"immediate group";"delayed group";1;44,1266666666667;39,1333333333333;"trd";NA;"crossover";"open-label";"10.1016/j.medj.2024.01.005";"NCT05029466";"Rosenblat2024_change_madrs_Day14_2.00_clinician_psil_wl_NA_NA";-1,06719381767744;0,392402176392329;NA;NA;NA;NA;NA;NA
"159";"Rosenblat 2024";"psil";"wl";NA;NA;"msd";"madrs";"clinician";"depression";1;"Post-first dose 3";"Day 14";2;14;1;0;16;23,44;8,69;14;24,57;6,52;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;3,86;16;27,57;6,64;15;"Some concerns";"Low";"Low";"High";"Low";"High";2024;"psilocybin";"waitlist";"25 mg";NA;"immediate group";"delayed group";1;44,1266666666667;39,1333333333333;"trd";NA;"crossover";"open-label";"10.1016/j.medj.2024.01.005";"NCT05029466";"Rosenblat2024_msd_madrs_Day14_2.00_clinician_psil_wl_NA_NA";-0,141713016677134;0,366445267842868;NA;NA;NA;NA;NA;NA
"160";"Rosenblat 2024";"psil";"wl";NA;NA;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 1";"Day 1";0,14;1;0;0;16;19,723;8,69;14;26,506;6,52;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;3,86;16;27,57;6,64;15;"Some concerns";"Low";"Low";"High";"Low";"High";2024;"psilocybin";"waitlist";"25 mg";NA;"immediate group";"delayed group";1;44,1266666666667;39,1333333333333;"trd";NA;"crossover";"open-label";"10.1016/j.medj.2024.01.005";"NCT05029466";"Rosenblat2024_imsd_madrs_Day1_0.14_clinician_psil_wl_NA_NA";-0,850654329310623;0,382972717203476;NA;NA;NA;NA;NA;NA
"161";"Rosenblat 2024";"psil";"wl";NA;NA;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 2";"Day 7";1;7;0;0;16;21,681;8,69;14;24,549;6,52;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;3,86;16;27,57;6,64;15;"Some concerns";"Low";"Low";"High";"Low";"High";2024;"psilocybin";"waitlist";"25 mg";NA;"immediate group";"delayed group";1;44,1266666666667;39,1333333333333;"trd";NA;"crossover";"open-label";"10.1016/j.medj.2024.01.005";"NCT05029466";"Rosenblat2024_imsd_madrs_Day7_1.00_clinician_psil_wl_NA_NA";-0,359675160911524;0,369061136286049;NA;NA;NA;NA;NA;NA
"162";"Ross 2016";"psil";"ncn";NA;NA;"msd";"bdi";"self-report";"depression";1;"Pre-first dose 1";"1 day pre-dose 1";-0,14;-1;0;0;14;10,4;6,9070995359847;15;16,247;7,54457155841205;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_msd_bdi_1daypre-dose1_-0.14_self-report_psil_ncn_NA_NA";-0,784450404153408;0,386427045543218;NA;NA;NA;NA;NA;NA
"163";"Ross 2016";"psil";"ncn";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-first dose 1";"1 day post-dose 1";0,14;1;0;0;14;4,188;6,9070995359847;15;12,034;6,95200510644231;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_msd_bdi_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA";-1,10036887261462;0,400241252699935;NA;NA;NA;NA;NA;NA
"164";"Ross 2016";"psil";"ncn";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-first dose 2";"2 weeks post-dose 1";2;14;0;0;14;6,636;7,15404892351178;14;13,449;7,52073134741562;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_msd_bdi_2weekspost-dose1_2.00_self-report_psil_ncn_NA_NA";-0,901205879450261;0,397798255450695;NA;NA;NA;NA;NA;NA
"165";"Ross 2016";"psil";"ncn";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-first dose 3";"6 weeks post-dose 1";6;42;0;0;14;6,438;6,71627500925922;14;14,181;6,9070995359847;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_msd_bdi_6weekspost-dose1_6.00_self-report_psil_ncn_NA_NA";-1,1035060876199;0,407340792292258;NA;NA;NA;NA;NA;NA
"166";"Ross 2016";"psil";"ncn";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-first dose 4";"7 weeks post-dose 1 and 1 day pre-dose 2";7;49;1;0;12;7,097;6,39473158154429;14;12,841;7,48331477354788;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_msd_bdi_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA";-0,794044946587193;0,409500561347812;NA;NA;NA;NA;NA;NA
"167";"Ross 2016";"psil";"ncn";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-second dose 2";"6 weeks post-dose 2";6;42;0;1;12;6,212;6,57486486553146;11;9,545;6,80571406980928;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_msd_bdi_6weekspost-dose2_6.00_self-report_psil_ncn_NA_NA";-0,480501399605098;0,423845590912223;NA;NA;NA;NA;NA;NA
"168";"Ross 2016";"psil";"ncn";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-second dose 3";"26 weeks post-dose 2";26;182;0;1;11;6,41;6,46078509161232;12;8,974;6,92820323027551;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_msd_bdi_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA";-0,3683220830553;0,421208871873938;NA;NA;NA;NA;NA;NA
"169";"Ross 2016";"psil";"ncn";NA;NA;"msd";"hads-d";"self-report";"depression";0;"Pre-first dose 1";"1 day pre-dose 1";-0,14;-1;0;0;14;3,859;3,47974136969977;15;5,945;3,40435236131632;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_msd_hads-d_1daypre-dose1_-0.14_self-report_psil_ncn_NA_NA";-0,589246817928049;0,380042102654754;NA;NA;NA;NA;NA;NA
"170";"Ross 2016";"psil";"ncn";NA;NA;"msd";"hads-d";"self-report";"depression";0;"Post-first dose 1";"1 day post-dose 1";0,14;1;0;0;14;2,019;3,38245827764364;15;6,164;3,21070319400595;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_msd_hads-d_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA";-1,2228754027737;0,406678447909128;NA;NA;NA;NA;NA;NA
"171";"Ross 2016";"psil";"ncn";NA;NA;"msd";"hads-d";"self-report";"depression";0;"Post-first dose 2";"2 weeks post-dose 1";2;14;0;0;14;2,109;3,43484148105848;14;5,831;3,43484148105848;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_msd_hads-d_2weekspost-dose1_2.00_self-report_psil_ncn_NA_NA";-1,05204046618656;0,404752847895918;NA;NA;NA;NA;NA;NA
"172";"Ross 2016";"psil";"ncn";NA;NA;"msd";"hads-d";"self-report";"depression";0;"Post-first dose 3";"6 weeks post-dose 1";6;42;0;0;14;2,263;3,47974136969977;14;6,761;3,1018339736356;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_msd_hads-d_6weekspost-dose1_6.00_self-report_psil_ncn_NA_NA";-1,32485277849218;0,419653953725893;NA;NA;NA;NA;NA;NA
"173";"Ross 2016";"psil";"ncn";NA;NA;"msd";"hads-d";"self-report";"depression";0;"Post-first dose 4";"7 weeks post-dose 1 and 1 day pre-dose 2";7;49;1;0;12;2,734;3,30821704245656;14;6,101;3,28891684297429;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_msd_hads-d_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA";-0,988749055150377;0,418101050737959;NA;NA;NA;NA;NA;NA
"174";"Ross 2016";"psil";"ncn";NA;NA;"msd";"hads-d";"self-report";"depression";0;"Post-second dose 2";"6 weeks post-dose 2";6;42;0;1;12;1,791;3,30821704245656;11;4,906;3,16737667478941;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_msd_hads-d_6weekspost-dose2_6.00_self-report_psil_ncn_NA_NA";-0,926122719555942;0,4408092533097;NA;NA;NA;NA;NA;NA
"175";"Ross 2016";"psil";"ncn";NA;NA;"msd";"hads-d";"self-report";"depression";0;"Post-second dose 3";"26 weeks post-dose 2";26;182;0;1;11;1,96;3,33320791430718;12;4,271;3,30821704245656;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_msd_hads-d_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA";-0,67089618622881;0,429854469566899;NA;NA;NA;NA;NA;NA
"176";"Ross 2016";"psil";"ncn";NA;NA;"response";"bdi";"self-report";"depression";1;"Post-first dose 1";"1 day post-dose 1";0,14;1;0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;14;4;15;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_response_bdi_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA";-1,50223974351906;0,530033969845441;1,16760516015506;0,441857550844268;12;4;14;15
"177";"Ross 2016";"psil";"ncn";NA;NA;"response";"bdi";"self-report";"depression";1;"Post-first dose 4";"7 weeks post-dose 1 and 1 day pre-dose 2";7;49;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;10;12;2;14;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_response_bdi_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA";-1,81596223568403;0,599741779377007;1,76358859226136;0,667261639267608;10;2;12;14
"178";"Ross 2016";"psil";"ncn";NA;NA;"response";"bdi";"self-report";"depression";1;"Post-second dose 3";"26 weeks post-dose 2";26;182;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;11;7;12;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_response_bdi_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA";-0,620466952517662;0,538490090853892;0,338325805270536;0,282357627355504;9;7;11;12
"179";"Ross 2016";"psil";"ncn";NA;NA;"remission";"hads-d";"self-report";"depression";0;"Post-first dose 1";"1 day post-dose 1";0,14;1;0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;11;14;3;15;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_remission_hads-d_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA";-1,43912322147628;0,50557463670514;1,36827585561721;0,534927271829719;11;3;14;15
"180";"Ross 2016";"psil";"ncn";NA;NA;"remission";"hads-d";"self-report";"depression";0;"Post-first dose 4";"7 weeks post-dose 1 and 1 day pre-dose 2";7;49;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;8;12;6;14;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_remission_hads-d_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA";-0,523682892597378;0,450158158078553;0,441832752279039;0,370006434950477;8;6;12;14
"181";"Ross 2016";"psil";"ncn";NA;NA;"remission";"hads-d";"self-report";"depression";0;"Post-second dose 3";"26 weeks post-dose 2";26;182;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;11;7;12;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_remission_hads-d_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA";-0,620466952517662;0,538490090853892;0,338325805270536;0,282357627355504;9;7;11;12
"182";"Ross 2016";"psil";"ncn";NA;NA;"response";"hads-d";"self-report";"depression";0;"Post-first dose 1";"1 day post-dose 1";0,14;1;0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;11;14;3;15;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_response_hads-d_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA";-1,43912322147628;0,50557463670514;1,36827585561721;0,534927271829719;11;3;14;15
"183";"Ross 2016";"psil";"ncn";NA;NA;"response";"hads-d";"self-report";"depression";0;"Post-first dose 4";"7 weeks post-dose 1 and 1 day pre-dose 2";7;49;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;8;12;6;14;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_response_hads-d_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA";-0,523682892597378;0,450158158078553;0,441832752279039;0,370006434950477;8;6;12;14
"184";"Ross 2016";"psil";"ncn";NA;NA;"response";"hads-d";"self-report";"depression";0;"Post-second dose 3";"26 weeks post-dose 2";26;182;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;11;7;12;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_response_hads-d_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA";-0,620466952517662;0,538490090853892;0,338325805270536;0,282357627355504;9;7;11;12
"185";"Ross 2016";"psil";"ncn";NA;NA;"remission";"bdi";"self-report";"depression";1;"Post-first dose 1";"1 day post-dose 1";0,14;1;0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;14;4;15;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_remission_bdi_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA";-1,50223974351906;0,530033969845441;1,16760516015506;0,441857550844268;12;4;14;15
"186";"Ross 2016";"psil";"ncn";NA;NA;"remission";"bdi";"self-report";"depression";1;"Post-first dose 4";"7 weeks post-dose 1 and 1 day pre-dose 2";7;49;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;10;12;2;14;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_remission_bdi_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA";-1,81596223568403;0,599741779377007;1,76358859226136;0,667261639267608;10;2;12;14
"187";"Ross 2016";"psil";"ncn";NA;NA;"remission";"bdi";"self-report";"depression";1;"Post-second dose 3";"26 weeks post-dose 2";26;182;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;11;7;12;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"0.3 mg/kg";"250 mg";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;61,1290322580645;"cancer";NA;"crossover";"double-blind";"10.1177/0269881116675512";"NCT00957359";"Ross2016_remission_bdi_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA";-0,620466952517662;0,538490090853892;0,338325805270536;0,282357627355504;9;7;11;12
"188";"vonRotz 2023";"psil";"pcb";NA;NA;"msd";"bdi";"self-report";"depression";0;"Pre-first dose 1";"Day -1";-0,14;-1;0;NA;26;25,695;6,31768517734146;26;24,798;10,0195733442098;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,9;10,0246723637234;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"0.215 mg/kg";NA;"psilocybin group";"placebo group";1;36,75;63,45;"dep";NA;"parallel";"double-blind";"10.1016/j.eclinm.2022.101809";"NCT03715127";"vonRotz2023_msd_bdi_Day-1_-0.14_self-report_psil_pcb_NA_NA";0,105480910024008;0,277548842334483;NA;NA;NA;NA;NA;NA
"189";"vonRotz 2023";"psil";"pcb";NA;NA;"msd";"bdi";"self-report";"depression";0;"DOSE 1";"Day 0";0;0;0;NA;26;12,242;7,18961751416583;26;20,191;10,8915056810342;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,9;10,0246723637234;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"0.215 mg/kg";NA;"psilocybin group";"placebo group";1;36,75;63,45;"dep";NA;"parallel";"double-blind";"10.1016/j.eclinm.2022.101809";"NCT03715127";"vonRotz2023_msd_bdi_Day0_0.00_self-report_psil_pcb_NA_NA";-0,848405368455339;0,289926959286354;NA;NA;NA;NA;NA;NA
"190";"vonRotz 2023";"psil";"pcb";NA;NA;"msd";"bdi";"self-report";"depression";0;"Post-first dose 1";"Day 2";0,29;2;0;NA;26;11,823;8,93348218781456;26;22,293;11,7685370373721;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,9;10,0246723637234;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"0.215 mg/kg";NA;"psilocybin group";"placebo group";1;36,75;63,45;"dep";NA;"parallel";"double-blind";"10.1016/j.eclinm.2022.101809";"NCT03715127";"vonRotz2023_msd_bdi_Day2_0.29_self-report_psil_pcb_NA_NA";-0,987034352648897;0,294244283502394;NA;NA;NA;NA;NA;NA
"191";"vonRotz 2023";"psil";"pcb";NA;NA;"msd";"bdi";"self-report";"depression";0;"Post-first dose 2";"Day 8";1,14;8;0;NA;26;13,584;11,5492791982877;26;21,148;11,5492791982877;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,9;10,0246723637234;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"0.215 mg/kg";NA;"psilocybin group";"placebo group";1;36,75;63,45;"dep";NA;"parallel";"double-blind";"10.1016/j.eclinm.2022.101809";"NCT03715127";"vonRotz2023_msd_bdi_Day8_1.14_self-report_psil_pcb_NA_NA";-0,645059290830097;0,284688371674402;NA;NA;NA;NA;NA;NA
"192";"vonRotz 2023";"psil";"pcb";NA;NA;"msd";"bdi";"self-report";"depression";0;"Post-first dose 3";"Day 14";2;14;1;NA;26;13,379;10,2388311832943;26;20,729;11,3300213592032;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,9;10,0246723637234;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"0.215 mg/kg";NA;"psilocybin group";"placebo group";1;36,75;63,45;"dep";NA;"parallel";"double-blind";"10.1016/j.eclinm.2022.101809";"NCT03715127";"vonRotz2023_msd_bdi_Day14_2.00_self-report_psil_pcb_NA_NA";-0,67040650657638;0,285268239079986;NA;NA;NA;NA;NA;NA
"193";"vonRotz 2023";"psil";"pcb";NA;NA;"msd";"madrs";"clinician";"depression";1;"Pre-first dose 1";"Day -1";-0,14;-1;0;NA;26;23,534;4,18629502065968;26;24,948;7,44456848984546;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"0.215 mg/kg";NA;"psilocybin group";"placebo group";1;36,75;63,45;"dep";NA;"parallel";"double-blind";"10.1016/j.eclinm.2022.101809";"NCT03715127";"vonRotz2023_msd_madrs_Day-1_-0.14_clinician_psil_pcb_NA_NA";-0,230602854318363;0,278298712350879;NA;NA;NA;NA;NA;NA
"194";"vonRotz 2023";"psil";"pcb";NA;NA;"msd";"madrs";"clinician";"depression";1;"DOSE 1";"Day 0";0;0;0;NA;26;11,727;7,21511261173379;26;21,034;9,53516649041851;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"0.215 mg/kg";NA;"psilocybin group";"placebo group";1;36,75;63,45;"dep";NA;"parallel";"double-blind";"10.1016/j.eclinm.2022.101809";"NCT03715127";"vonRotz2023_msd_madrs_Day0_0.00_clinician_psil_pcb_NA_NA";-1,0841621390941;0,297613339412923;NA;NA;NA;NA;NA;NA
"195";"vonRotz 2023";"psil";"pcb";NA;NA;"msd";"madrs";"clinician";"depression";1;"Post-first dose 1";"Day 2";0,29;2;0;NA;26;9,775;7,90857926558241;26;20,632;11,1668527347682;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"0.215 mg/kg";NA;"psilocybin group";"placebo group";1;36,75;63,45;"dep";NA;"parallel";"double-blind";"10.1016/j.eclinm.2022.101809";"NCT03715127";"vonRotz2023_msd_madrs_Day2_0.29_clinician_psil_pcb_NA_NA";-1,10515607016574;0,29837774449248;NA;NA;NA;NA;NA;NA
"196";"vonRotz 2023";"psil";"pcb";NA;NA;"msd";"madrs";"clinician";"depression";1;"Post-first dose 2";"Day 8";1,14;8;0;NA;26;12,065;8,8366008170563;26;19,957;10,468287061406;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"0.215 mg/kg";NA;"psilocybin group";"placebo group";1;36,75;63,45;"dep";NA;"parallel";"double-blind";"10.1016/j.eclinm.2022.101809";"NCT03715127";"vonRotz2023_msd_madrs_Day8_1.14_clinician_psil_pcb_NA_NA";-0,802429725155049;0,288626644278412;NA;NA;NA;NA;NA;NA
"197";"vonRotz 2023";"psil";"pcb";NA;NA;"msd";"madrs";"clinician";"depression";1;"Post-first dose 3";"Day 14";2;14;1;NA;26;11,162;9,76972138804378;26;20,696;10,2388311832943;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"0.215 mg/kg";NA;"psilocybin group";"placebo group";1;36,75;63,45;"dep";NA;"parallel";"double-blind";"10.1016/j.eclinm.2022.101809";"NCT03715127";"vonRotz2023_msd_madrs_Day14_2.00_clinician_psil_pcb_NA_NA";-0,938367882310989;0,292661784694183;NA;NA;NA;NA;NA;NA
"198";"vonRotz 2023";"psil";"pcb";NA;NA;"response";"madrs";"clinician";"depression";1;"Post-first dose 3";"Day 14";2;14;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15;26;4;26;24,118;5,11431657213356;26;24,528;6,74600281648325;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"0.215 mg/kg";NA;"psilocybin group";"placebo group";1;36,75;63,45;"dep";NA;"parallel";"double-blind";"10.1016/j.eclinm.2022.101809";"NCT03715127";"vonRotz2023_response_madrs_Day14_2.00_clinician_psil_pcb_NA_NA";-1,09412740860668;0,371085838569234;1,32175583998232;0,489636180999311;15;4;26;26
"199";"vonRotz 2023";"psil";"pcb";NA;NA;"remission";"madrs";"clinician";"depression";1;"Post-first dose 3";"Day 14";2;14;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14;26;3;26;24,118;5,11431657213356;26;24,528;6,74600281648325;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"0.215 mg/kg";NA;"psilocybin group";"placebo group";1;36,75;63,45;"dep";NA;"parallel";"double-blind";"10.1016/j.eclinm.2022.101809";"NCT03715127";"vonRotz2023_remission_madrs_Day14_2.00_clinician_psil_pcb_NA_NA";-1,18976883955491;0,401968864868958;1,54044504094715;0,572572115841165;14;3;26;26
"200";"vonRotz 2023";"psil";"pcb";NA;NA;"response";"bdi";"self-report";"depression";0;"Post-first dose 3";"Day 14";2;14;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14;26;3;26;26,541;6,31768517734146;26;25,9;10,0246723637234;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"0.215 mg/kg";NA;"psilocybin group";"placebo group";1;36,75;63,45;"dep";NA;"parallel";"double-blind";"10.1016/j.eclinm.2022.101809";"NCT03715127";"vonRotz2023_response_bdi_Day14_2.00_self-report_psil_pcb_NA_NA";-1,18976883955491;0,401968864868958;1,54044504094715;0,572572115841165;14;3;26;26
"201";"vonRotz 2023";"psil";"pcb";NA;NA;"remission";"bdi";"self-report";"depression";0;"Post-first dose 3";"Day 14";2;14;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;26;3;26;26,541;6,31768517734146;26;25,9;10,0246723637234;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"0.215 mg/kg";NA;"psilocybin group";"placebo group";1;36,75;63,45;"dep";NA;"parallel";"double-blind";"10.1016/j.eclinm.2022.101809";"NCT03715127";"vonRotz2023_remission_bdi_Day14_2.00_self-report_psil_pcb_NA_NA";-1,02235583542039;0,401968864868958;1,38629436111989;0,582875278034323;12;3;26;26
=======
study;condition_arm1;condition_arm2;multi_arm1;multi_arm2;outcome_type;instrument;rating;instrument_symptom;primary_instrument;cov_time_point;study_time_point;time_weeks;time_days;primary_timepoint;post_crossover;n_arm1;mean_arm1;sd_arm1;n_arm2;mean_arm2;sd_arm2;n_change_arm1;mean_change_arm1;sd_change_arm1;n_change_arm2;mean_change_arm2;sd_change_arm2;event_arm1;totaln_arm1;event_arm2;totaln_arm2;baseline_m_arm1;baseline_sd_arm1;baseline_n_arm1;baseline_m_arm2;baseline_sd_arm2;baseline_n_arm2;d1;d2;d3;d4;d5;rob;year;drug_arm1;drug_arm2;dose_arm1;dose_arm2;name_arm1;name_arm2;n_dosing_sessions;mean_age;percent_women;diagnosis;target_group;design;blinding;doi;registration_number;full_ref;.id;.g;.g_se;.log_rr;.log_rr_se;.event_arm1;.event_arm2;.totaln_arm1;.totaln_arm2
Back 2024;psil;ncn;NA;NA;msd;madrs;clinician;depression;1;Pre-first dose 1;Day -8;-1,14;-8,000;0;NA;15;27,670;5,27000000000000;15;28,400;7,39000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;Low;Low;Low;Low;Low;Low;2024;psilocybin;niacin;25 mg;100 mg;psilocybin arm;niacin arm;1;38,0000000000000;50,0000000000000;dep;covid practitioners with persistent depression symptoms;parallel;double-blind;10.1001/jamanetworkopen.2024.49026;NCT05163496;Back, A. L., Freeman-Young, T. K., Morgan, L., Sethi, T., Baker, K. K., Myers, S., McGregor, B. A., Harvey, K., Tai, M., Kollefrath, A., Thomas, B. J., Sorta, D., Kaelen, M., Kelmendi, B., & Gooley, T. A. (2024). Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial. JAMA Network Open, 7(12), e2449026. https://doi.org/10.1001/jamanetworkopen.2024.49026;Back2024_msd_madrs_Day-8_-1.14_clinician_psil_ncn_NA_NA;-0,11066608890309594;0,365443493603394;NA;NA;NA;NA;NA;NA
Back 2024;psil;ncn;NA;NA;msd;madrs;clinician;depression;1;Post-first dose 4;Day 28;4,00;28,000;1;NA;15;6,330;6,72000000000000;15;19,070;10,34000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;Low;Low;Low;Low;Low;Low;2024;psilocybin;niacin;25 mg;100 mg;psilocybin arm;niacin arm;1;38,0000000000000;50,0000000000000;dep;covid practitioners with persistent depression symptoms;parallel;double-blind;10.1001/jamanetworkopen.2024.49026;NCT05163496;Back, A. L., Freeman-Young, T. K., Morgan, L., Sethi, T., Baker, K. K., Myers, S., McGregor, B. A., Harvey, K., Tai, M., Kollefrath, A., Thomas, B. J., Sorta, D., Kaelen, M., Kelmendi, B., & Gooley, T. A. (2024). Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial. JAMA Network Open, 7(12), e2449026. https://doi.org/10.1001/jamanetworkopen.2024.49026;Back2024_msd_madrs_Day28_4.00_clinician_psil_ncn_NA_NA;-1,42153552640955994;0,410986356401838;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;change;qids-sr;self-report;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;30;-8,000;5,47722557505166;29;-6,000;5,38516480713450;NA;NA;NA;NA;14,500;3,90000000000000;30;16,400;4,10000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_change_qids-sr_Week6_3.00_self-report_psil_esc_NA_NA;-0,36330936175831902;0,262611586674514;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;change;bdi-1a;self-report;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;30;-18,400;12,29581251542210;29;-10,800;9,61636572702590;NA;NA;NA;NA;29,100;6,80000000000000;30;28,700;7,00000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_change_bdi-1a_Week6_3.00_self-report_psil_esc_NA_NA;-0,67801807970489791;0,267986899585578;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;change;ham-d-17;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;30;-10,500;5,47722557505166;29;-5,100;5,38516480713450;NA;NA;NA;NA;19,200;2,30000000000000;30;18,400;3,40000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_change_ham-d-17_Week6_3.00_clinician_psil_esc_NA_NA;-0,98093527674746128;0,276026275889254;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;change;madrs;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;30;-14,400;9,31128347758782;29;-7,200;9,15478017212866;NA;NA;NA;NA;27,900;4,00000000000000;30;26,900;5,30000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_change_madrs_Week6_3.00_clinician_psil_esc_NA_NA;-0,76936100137055774;0,270125147933961;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;msd;qids-sr;self-report;depression;1;Post-second dose 1;Week 6;3,00;21,000;1;NA;30;6,900;5,90000000000000;29;10,100;5,80000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14,500;3,90000000000000;30;16,400;4,10000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_msd_qids-sr_Week6_3.00_self-report_psil_esc_NA_NA;-0,53967873292569379;0,265237432013847;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;msd;bdi-1a;self-report;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;30;10,700;11,00000000000000;29;17,900;11,10000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;29,100;6,80000000000000;30;28,700;7,00000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_msd_bdi-1a_Week6_3.00_self-report_psil_esc_NA_NA;-0,64301693596713383;0,267235040715549;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;msd;ham-d-17;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;30;8,300;5,50000000000000;29;13,600;5,20000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;19,200;2,30000000000000;30;18,400;3,40000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_msd_ham-d-17_Week6_3.00_clinician_psil_esc_NA_NA;-0,97669793075590361;0,275895471772229;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;msd;madrs;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;30;13,000;10,00000000000000;29;19,800;8,50000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;27,900;4,00000000000000;30;26,900;5,30000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_msd_madrs_Week6_3.00_clinician_psil_esc_NA_NA;-0,72202724206718649;0,268985534799480;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;response;qids-sr;self-report;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21;30;14;29;14,500;3,90000000000000;30;16,400;4,10000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_response_qids-sr_Week6_3.00_self-report_psil_esc_NA_NA;-0,49850120170936724;0,300373270489182;0,3715635564324830;0,226343824951325;21;14;30;29
Carhart-Harris 2021;psil;esc;NA;NA;remission;qids-sr;self-report;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;30;8;29;14,500;3,90000000000000;30;16,400;4,10000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_remission_qids-sr_Week6_3.00_self-report_psil_esc_NA_NA;-0,67099216954833840;0,306156690535671;0,7198702507006988;0,340598645707439;17;8;30;29
Carhart-Harris 2021;psil;esc;NA;NA;response;bdi-1a;self-report;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;23;30;12;29;29,100;6,80000000000000;30;28,700;7,00000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_response_bdi-1a_Week6_3.00_self-report_psil_esc_NA_NA;-0,83667810429445455;0,315989993146670;0,6166860144654681;0,242889897379194;23;12;30;29
Carhart-Harris 2021;psil;esc;NA;NA;remission;bdi-1a;self-report;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;30;5;29;29,100;6,80000000000000;30;28,700;7,00000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_remission_bdi-1a_Week6_3.00_self-report_psil_esc_NA_NA;-0,99934093835083038;0,338703230909486;1,1898738799464341;0,437043976571857;17;5;30;29
Carhart-Harris 2021;psil;esc;NA;NA;response;ham-d-17;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22;30;7;29;19,200;2,30000000000000;30;18,400;3,40000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_response_ham-d-17_Week6_3.00_clinician_psil_esc_NA_NA;-1,17335476888894030;0,330230008279525;1,1112307526273211;0,347124756186685;22;7;30;29
Carhart-Harris 2021;psil;esc;NA;NA;response;madrs;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;30;6;29;27,900;4,00000000000000;30;26,900;5,30000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_response_madrs_Week6_3.00_clinician_psil_esc_NA_NA;-1,10815056090644326;0,330863916168362;1,1700712526502546;0,385811579287926;20;6;30;29
Carhart-Harris 2021;psil;esc;NA;NA;remission;ham-d-17;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15;30;3;29;19,200;2,30000000000000;30;18,400;3,40000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_remission_ham-d-17_Week6_3.00_clinician_psil_esc_NA_NA;-1,17485144826604637;0,391842523093344;1,5755363607584190;0,576353978077689;15;3;30;29
Carhart-Harris 2021;psil;esc;NA;NA;remission;madrs;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;30;2;29;27,900;4,00000000000000;30;26,900;5,30000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_remission_madrs_Week6_3.00_clinician_psil_esc_NA_NA;-0,95500795088472690;0,459878100635296;1,4701758451005926;0,737085489720893;9;2;30;29
Davis 2021;psil;wl;NA;NA;msd;bdi;self-report;depression;0;Post-second dose 1;Week 5;1,00;7,000;0;0;13;8,200;8,90000000000000;11;35,200;9,10000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;7,00000000000000;13;34,500;10,00000000000000;11;Low;Some concerns;Some concerns;Low;Low;Some concerns;2021;psilocybin;waitlist;"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;immediate treatment group;delayed treatment group;2;39,8666666666667;66,7777777777778;mdd;mdd;crossover;open-label;"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";NCT03181529;Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285;Davis2021_msd_bdi_Week5_1.00_self-report_psil_wl_NA_NA;-2,89930264844220353;0,596396246972318;NA;NA;NA;NA;NA;NA
Davis 2021;psil;wl;NA;NA;msd;bdi;self-report;depression;0;Post-second dose 2;Week 8;4,00;28,000;1;0;13;8,200;7,00000000000000;11;35,900;8,40000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;7,00000000000000;13;34,500;10,00000000000000;11;Low;Some concerns;Some concerns;Low;Low;Some concerns;2021;psilocybin;waitlist;"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;immediate treatment group;delayed treatment group;2;39,8666666666667;66,7777777777778;mdd;mdd;crossover;open-label;"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";NCT03181529;Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285;Davis2021_msd_bdi_Week8_4.00_self-report_psil_wl_NA_NA;-3,48779651560760939;0,663090832701423;NA;NA;NA;NA;NA;NA
Davis 2021;psil;wl;NA;NA;msd;qids-sr;self-report;depression;0;Post-second dose 1;Week 5;1,00;7,000;0;0;13;5,200;4,60000000000000;11;31,900;5,60000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,200;3,60000000000000;13;17,400;3,60000000000000;11;Low;Some concerns;Some concerns;Low;Low;Some concerns;2021;psilocybin;waitlist;"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;immediate treatment group;delayed treatment group;2;39,8666666666667;66,7777777777778;mdd;mdd;crossover;open-label;"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";NCT03181529;Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285;Davis2021_msd_qids-sr_Week5_1.00_self-report_psil_wl_NA_NA;-5,07565447275226678;0,862303533688809;NA;NA;NA;NA;NA;NA
Davis 2021;psil;wl;NA;NA;msd;qids-sr;self-report;depression;0;Post-second dose 2;Week 8;4,00;28,000;1;0;13;5,500;3,60000000000000;11;17,700;3,70000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,200;3,60000000000000;13;17,400;3,60000000000000;11;Low;Some concerns;Some concerns;Low;Low;Some concerns;2021;psilocybin;waitlist;"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;immediate treatment group;delayed treatment group;2;39,8666666666667;66,7777777777778;mdd;mdd;crossover;open-label;"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";NCT03181529;Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285;Davis2021_msd_qids-sr_Week8_4.00_self-report_psil_wl_NA_NA;-3,23093088729085398;0,633341175482840;NA;NA;NA;NA;NA;NA
Davis 2021;psil;wl;NA;NA;msd;grid-ham-d;clinician;depression;1;Post-second dose 1;Week 5;1,00;7,000;0;0;13;8,000;7,10000000000000;11;23,800;5,40000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,900;3,60000000000000;13;22,500;4,40000000000000;11;Low;Some concerns;Some concerns;Low;Low;Some concerns;2021;psilocybin;waitlist;"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;immediate treatment group;delayed treatment group;2;39,8666666666667;66,7777777777778;mdd;mdd;crossover;open-label;"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";NCT03181529;Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285;Davis2021_msd_grid-ham-d_Week5_1.00_clinician_psil_wl_NA_NA;-2,38972798584679724;0,543559686244671;NA;NA;NA;NA;NA;NA
Davis 2021;psil;wl;NA;NA;msd;grid-ham-d;clinician;depression;1;Post-second dose 2;Week 8;4,00;28,000;1;0;13;8,500;5,70000000000000;11;23,500;6,00000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,900;3,60000000000000;13;22,500;4,40000000000000;11;Low;Some concerns;Some concerns;Low;Low;Some concerns;2021;psilocybin;waitlist;"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;immediate treatment group;delayed treatment group;2;39,8666666666667;66,7777777777778;mdd;mdd;crossover;open-label;"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";NCT03181529;Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285;Davis2021_msd_grid-ham-d_Week8_4.00_clinician_psil_wl_NA_NA;-2,48065716535764702;0,552588609503246;NA;NA;NA;NA;NA;NA
Davis 2021;psil;wl;NA;NA;msd;phq-9;self-report;depression;0;Post-second dose 2;Week 8;4,00;28,000;1;0;13;4,800;2,90000000000000;11;18,800;4,30000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,500;3,10000000000000;13;17,900;3,30000000000000;11;Low;Some concerns;Some concerns;Low;Low;Some concerns;2021;psilocybin;waitlist;"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;immediate treatment group;delayed treatment group;2;39,8666666666667;66,7777777777778;mdd;mdd;crossover;open-label;"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";NCT03181529;Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285;Davis2021_msd_phq-9_Week8_4.00_self-report_psil_wl_NA_NA;-3,75018853776688310;0,694357648017136;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;qids-sr;self-report;depression;0;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;79;-6,300;5,89523099107666;75;-5,200;5,96497089341323;NA;NA;NA;NA;16,100;4,14000000000000;79;16,300;4,16000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_qids-sr_Week3_3.00_self-report_psil_psil_25mg_10mg;-0,18460291306012985;0,161565177688826;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;qids-sr;self-report;depression;0;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;79;-6,300;5,89523099107666;79;-3,600;6,12197064457961;NA;NA;NA;NA;16,100;4,14000000000000;79;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_qids-sr_Week3_3.00_self-report_psil_psil_25mg_1mg;-0,44711245099768004;0,161106231491561;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;qids-sr;self-report;depression;0;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;75;-5,200;5,96497089341323;79;-3,600;6,12197064457961;NA;NA;NA;NA;16,300;4,16000000000000;75;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_qids-sr_Week3_3.00_self-report_psil_psil_10mg_1mg;-0,26332785116562563;0,161922629984635;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;qids-sr;self-report;depression;0;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;79;-6,500;29,24941530188038;75;-5,500;7,06959513293419;NA;NA;NA;NA;16,100;4,14000000000000;79;16,300;4,16000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_qids-sr_Week12_12.00_self-report_psil_psil_25mg_10mg;-0,04622662928049439;0,161240715280361;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;qids-sr;self-report;depression;0;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;79;-6,500;29,24941530188038;79;-5,000;7,02892925859141;NA;NA;NA;NA;16,100;4,14000000000000;79;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_qids-sr_Week12_12.00_self-report_psil_psil_25mg_1mg;-0,07017806878265766;0,159160900372791;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;qids-sr;self-report;depression;0;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;75;-5,500;7,06959513293419;79;-5,000;7,02892925859141;NA;NA;NA;NA;16,300;4,16000000000000;75;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_qids-sr_Week12_12.00_self-report_psil_psil_10mg_1mg;-0,07058391584933107;0,161269643391451;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;79;-15,026;12,05239162987994;75;-11,986;12,23693895547412;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Day2_0.29_clinician_psil_psil_25mg_10mg;-0,24912114593171114;0,161848897621857;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;79;-15,026;12,05239162987994;79;-9,078;12,05239162987994;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Day2_0.29_clinician_psil_psil_25mg_1mg;-0,49113554613926258;0,161515313598675;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;75;-11,986;12,23693895547412;79;-9,078;12,05239162987994;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Day2_0.29_clinician_psil_psil_10mg_1mg;-0,23830404354257123;0,161795477652513;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;79;-13,043;11,12801941047912;75;-8,796;11,77794549146837;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week1_1.00_clinician_psil_psil_25mg_10mg;-0,36911477037163343;0,162598654898194;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;79;-13,043;11,12801941047912;79;-6,887;11,59020552017953;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week1_1.00_clinician_psil_psil_25mg_1mg;-0,53922249061526439;0,162004663914633;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;75;-8,796;11,77794549146837;79;-6,887;11,59020552017953;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week1_1.00_clinician_psil_psil_10mg_1mg;-0,16260640126933609;0,161487655787320;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;79;-12,000;12,01720163565628;75;-7,900;11,92994178682645;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week3_3.00_clinician_psil_psil_25mg_10mg;-0,34069351044301460;0,162395109096660;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;79;-12,000;12,01720163565628;79;-5,400;12,24394128915923;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week3_3.00_clinician_psil_psil_25mg_1mg;-0,54143627865238364;0,162028254630371;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;75;-7,900;11,92994178682645;79;-5,400;12,24394128915923;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week3_3.00_clinician_psil_psil_10mg_1mg;-0,20572488372314504;0,161648820099789;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;79;-11,530;13,44783815339848;75;-5,991;13,58793858537784;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week6_6.00_clinician_psil_psil_25mg_10mg;-0,40777834306524813;0,162901252285212;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;79;-11,530;13,44783815339848;79;-6,261;12,98565204369808;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week6_6.00_clinician_psil_psil_25mg_1mg;-0,39668059044808601;0,160683685359775;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;75;-5,991;13,58793858537784;79;-6,261;12,98565204369808;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week6_6.00_clinician_psil_psil_10mg_1mg;0,02022736455153360;0,161223146003312;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;79;-9,339;14,37221037279931;75;-6,109;14,49726525935150;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week9_9.00_clinician_psil_psil_25mg_10mg;-0,22268312464111339;0,161722489932522;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;79;-9,339;14,37221037279931;79;-5,322;14,38109856721662;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week9_9.00_clinician_psil_psil_25mg_1mg;-0,27806582665982427;0,159885943110615;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;75;-6,109;14,49726525935150;79;-5,322;14,38109856721662;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week9_9.00_clinician_psil_psil_10mg_1mg;-0,05424039656402192;0,161248901762607;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;79;-9,496;14,38109856721662;75;-5,651;14,04693204938360;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week12_12.00_clinician_psil_psil_25mg_10mg;-0,26906891465809013;0,161953575769648;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;79;-9,496;14,38109856721662;79;-6,000;14,84328467691703;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week12_12.00_clinician_psil_psil_25mg_1mg;-0,23807040049667147;0,159679538002117;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;75;-5,651;14,04693204938360;79;-6,000;14,84328467691703;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week12_12.00_clinician_psil_psil_10mg_1mg;0,02401449041642934;0,161224849872201;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;response;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;42;79;24;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Day2_0.29_clinician_psil_psil_25mg_10mg;-0,48305875461703568;0,184601397856223;0,5076560490047115;0,198707396175270;42;24;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;42;79;18;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Day2_0.29_clinician_psil_psil_25mg_1mg;-0,73920316646147111;0,193189884520747;0,8472978603872034;0,232483598709408;42;18;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24;75;18;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Day2_0.29_clinician_psil_psil_10mg_1mg;-0,25605013073695237;0,201233919986895;0,3396418113824921;0,266890728652735;24;18;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;response;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35;79;17;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week1_1.00_clinician_psil_psil_25mg_10mg;-0,54771974280242786;0,196758469095511;0,6701749785024865;0,247797087960611;35;17;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35;79;12;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week1_1.00_clinician_psil_psil_25mg_1mg;-0,81804245767283490;0,213213509731684;1,0704414117014134;0,294258910160014;35;12;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;75;12;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week1_1.00_clinician_psil_psil_10mg_1mg;-0,27021837826529371;0,230191279338547;0,4002664331989267;0,340830311978943;17;12;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;response;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;29;79;14;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week3_3.00_clinician_psil_psil_25mg_10mg;-0,50860496869956251;0,207979479793817;0,6762787614405044;0,282700846952793;29;14;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;29;79;14;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week3_3.00_clinician_psil_psil_25mg_1mg;-0,54351800232260727;0,207240964352298;0,7282385003712155;0,283892364027387;29;14;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14;75;14;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week3_3.00_clinician_psil_psil_10mg_1mg;-0,03484371103147465;0,230396909206025;0,0519597389307112;0,341856083280243;14;14;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;response;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;79;11;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week6_6.00_clinician_psil_psil_25mg_10mg;-0,57537176793779310;0,223178286826114;0,8082415262924004;0,321526154751359;26;11;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;79;16;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week6_6.00_clinician_psil_psil_25mg_1mg;-0,36121988671638899;0,203097531606742;0,4855078157817008;0,275036511694967;26;16;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;11;75;16;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week6_6.00_clinician_psil_psil_10mg_1mg;0,21419795273801784;0,237075981004254;-0,3227337105106995;0,356955921267117;11;16;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;response;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;79;12;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week9_9.00_clinician_psil_psil_25mg_10mg;-0,31622793564509760;0,224733656397081;0,4588658848352796;0,327630542153656;20;12;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;79;12;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week9_9.00_clinician_psil_psil_25mg_1mg;-0,35004349052636913;0,224091872823937;0,5108256237659907;0,328659212007104;20;12;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;75;12;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week9_9.00_clinician_psil_psil_10mg_1mg;-0,03377090884963717;0,244994243823549;0,0519597389307110;0,375066801363746;12;12;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;response;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;79;12;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week12_12.00_clinician_psil_psil_25mg_10mg;-0,51899736264531959;0,218131110395555;0,7212301493027706;0,309521098817895;26;12;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;79;13;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week12_12.00_clinician_psil_psil_25mg_1mg;-0,50067053597456312;0,213104169598532;0,6931471805599453;0,300113577980759;26;13;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;75;13;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week12_12.00_clinician_psil_psil_10mg_1mg;0,01839068431471346;0,241127423028606;-0,0280829687428252;0,366421682048123;12;13;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;response;madrs;clinician;depression;1;Post-first dose 7;Week 3-12 Sustained Response;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;79;3;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week3-12SustainedResponse_12.00_clinician_psil_psil_25mg_10mg;-0,99160609743480599;0,359674074446653;1,6220166946409604;0,608146176631818;16;3;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 7;Week 3-12 Sustained Response;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;79;6;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week3-12SustainedResponse_12.00_clinician_psil_psil_25mg_1mg;-0,61898877394486473;0,280440753604151;0,9808292530117262;0,451497741932852;16;6;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 7;Week 3-12 Sustained Response;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;3;75;6;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week3-12SustainedResponse_12.00_clinician_psil_psil_10mg_1mg;0,37269627194386418;0,400458956333702;-0,6411874416292344;0,688482707712086;3;6;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;remission;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;30;79;16;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Day2_0.29_clinician_psil_psil_25mg_10mg;-0,44674242736280145;0,201209101839793;0,5766489204916631;0,264275939411628;30;16;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;30;79;15;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Day2_0.29_clinician_psil_psil_25mg_1mg;-0,52684226306569792;0,203344838513193;0,6931471805599453;0,273282901594296;30;15;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;75;15;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Day2_0.29_clinician_psil_psil_10mg_1mg;-0,08003264000584821;0,221728017482283;0,1164982600682823;0,321208819127421;16;15;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;remission;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;25;79;8;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week1_1.00_clinician_psil_psil_25mg_10mg;-0,74343684682551936;0,245600712471635;1,0874745442576539;0,372838354811526;25;8;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;25;79;9;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week1_1.00_clinician_psil_psil_25mg_1mg;-0,70294054932581040;0,236439338957101;1,0216512475319814;0,354675422625967;25;9;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;8;75;9;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week1_1.00_clinician_psil_psil_10mg_1mg;0,04058595351917987;0,283986403909221;-0,0658232967256723;0,458387990603677;8;9;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;remission;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;23;79;7;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week3_3.00_clinician_psil_psil_25mg_10mg;-0,75912540018388175;0,257947947756852;1,1376243279431253;0,400429572515909;23;7;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;23;79;6;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week3_3.00_clinician_psil_psil_25mg_1mg;-0,88273008225015182;0,271050185749346;1,3437347467010947;0,429916819675655;23;6;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;7;75;6;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week3_3.00_clinician_psil_psil_10mg_1mg;-0,12349209492711938;0,320496322472041;0,2061104187579694;0,532477462755350;7;6;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;remission;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;79;7;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week6_6.00_clinician_psil_psil_25mg_10mg;-0,65382211876337593;0,261234604859298;0,9978623855679666;0,408491837954822;20;7;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;79;10;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week6_6.00_clinician_psil_psil_25mg_1mg;-0,46621722690354056;0,234844046305309;0,6931471805599453;0,353105571046107;20;10;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;7;75;10;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week6_6.00_clinician_psil_psil_10mg_1mg;0,18766435518260557;0,287567453972760;-0,3047152050080214;0,465688288102362;7;10;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;remission;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;79;9;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week9_9.00_clinician_psil_psil_25mg_10mg;-0,34116816345177042;0,249402839658612;0,5234044059728509;0,384212896620710;16;9;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;79;9;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week9_9.00_clinician_psil_psil_25mg_1mg;-0,37349593678986254;0,248874676341758;0,5753641449035619;0,385090450952641;16;9;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;75;9;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week9_9.00_clinician_psil_psil_10mg_1mg;-0,03228013608197812;0,276577838141005;0,0519597389307110;0,442979300916857;9;9;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;remission;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21;79;5;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week12_12.00_clinician_psil_psil_25mg_10mg;-0,89045938373218436;0,291290666364917;1,3831247863586114;0,470773285603180;21;5;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21;79;9;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week12_12.00_clinician_psil_psil_25mg_1mg;-0,56806969819056030;0,240481329850560;0,8472978603872034;0,365258405836137;21;9;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;75;9;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week12_12.00_clinician_psil_psil_10mg_1mg;0,32246213956063119;0,321327108955673;-0,5358269259714080;0,533965869629957;5;9;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;79;16,874;10,53912408759124;75;21,014;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Day2_0.29_clinician_psil_psil_25mg_10mg;-0,39654492550867360;0,162810289829870;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;79;16,874;10,53912408759124;79;23,622;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Day2_0.29_clinician_psil_psil_25mg_1mg;-0,64668668511676197;0,163256618223517;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;75;21,014;10,53912408759124;79;23,622;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Day2_0.29_clinician_psil_psil_10mg_1mg;-0,25000147259605821;0,161853348627889;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;79;18,857;10,53912408759124;75;24,204;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week1_1.00_clinician_psil_psil_25mg_10mg;-0,51215597021615411;0,163864815195660;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;79;18,857;10,53912408759124;79;25,813;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week1_1.00_clinician_psil_psil_25mg_1mg;-0,66662012176529273;0,163512602249458;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;75;24,204;10,53912408759124;79;25,813;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week1_1.00_clinician_psil_psil_10mg_1mg;-0,15423787170516007;0,161460733330932;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;79;19,900;10,53912408759124;75;25,100;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week3_3.00_clinician_psil_psil_25mg_10mg;-0,49807575184664338;0,163722432833855;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;79;19,900;10,53912408759124;79;27,300;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week3_3.00_clinician_psil_psil_25mg_1mg;-0,70917034230350318;0,164083582263683;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;75;25,100;10,53912408759124;79;27,300;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week3_3.00_clinician_psil_psil_10mg_1mg;-0,21089081277274843;0,161670647650147;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;79;20,370;10,53912408759124;75;27,009;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week6_6.00_clinician_psil_psil_25mg_10mg;-0,63590863779035878;0,165280238538101;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;79;20,370;10,53912408759124;79;26,439;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week6_6.00_clinician_psil_psil_25mg_1mg;-0,58161551451891369;0,162472569947978;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;75;27,009;10,53912408759124;79;26,439;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week6_6.00_clinician_psil_psil_10mg_1mg;0,05463989240021171;0,161249344032070;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;79;22,561;10,53912408759124;75;26,891;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week9_9.00_clinician_psil_psil_25mg_10mg;-0,41474384721076230;0,162958905257691;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;79;22,561;10,53912408759124;79;27,378;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week9_9.00_clinician_psil_psil_25mg_1mg;-0,46163155930756411;0,161237019689574;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;75;26,891;10,53912408759124;79;27,378;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week9_9.00_clinician_psil_psil_10mg_1mg;-0,04668355719105886;0,161241146956967;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;79;22,404;10,53912408759124;75;27,349;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week12_12.00_clinician_psil_psil_25mg_10mg;-0,47365088324647153;0,163484580987544;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;79;22,404;10,53912408759124;79;26,700;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week12_12.00_clinician_psil_psil_25mg_1mg;-0,41170213385619620;0,160804375658786;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;75;27,349;10,53912408759124;79;26,700;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week12_12.00_clinician_psil_psil_10mg_1mg;0,06221278976796046;0,161258341358482;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;qids-sr;self-report;depression;0;Post-first dose 3;Week 3;3,00;21,000;1;NA;79;9,800;5,20465116279070;75;11,100;5,22250000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,100;4,14000000000000;79;16,300;4,16000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_qids-sr_Week3_3.00_self-report_psil_psil_25mg_10mg;-0,24812747376470318;0,161843892248539;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;qids-sr;self-report;depression;0;Post-first dose 3;Week 3;3,00;21,000;1;NA;79;9,800;5,20465116279070;79;12,200;5,22250000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,100;4,14000000000000;79;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_qids-sr_Week3_3.00_self-report_psil_psil_25mg_1mg;-0,45811928515047246;0,161205007705512;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;qids-sr;self-report;depression;0;Post-first dose 3;Week 3;3,00;21,000;1;NA;75;11,100;5,20465116279070;79;12,200;5,22250000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,300;4,16000000000000;75;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_qids-sr_Week3_3.00_self-report_psil_psil_10mg_1mg;-0,20993510179968158;0,161666568909026;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;qids-sr;self-report;depression;0;Post-first dose 6;Week 12;12,00;84,000;0;NA;79;9,600;5,20465116279070;75;10,800;5,22250000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,100;4,14000000000000;79;16,300;4,16000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_qids-sr_Week12_12.00_self-report_psil_psil_25mg_10mg;-0,22904074501357188;0,161751602527394;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;qids-sr;self-report;depression;0;Post-first dose 6;Week 12;12,00;84,000;0;NA;79;9,600;5,20465116279070;79;10,800;5,22250000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,100;4,14000000000000;79;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_qids-sr_Week12_12.00_self-report_psil_psil_25mg_1mg;-0,22905964257523606;0,159637418544292;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;qids-sr;self-report;depression;0;Post-first dose 6;Week 12;12,00;84,000;0;NA;75;10,800;5,20465116279070;79;10,800;5,22250000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,300;4,16000000000000;75;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_qids-sr_Week12_12.00_self-report_psil_psil_10mg_1mg;0,00000000000000000;0,161218985176792;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;bdi;self-report;depression;0;Post-first dose 1;5 weeks after session 1;5,00;35,000;1;0;26;7,000;7,08763712389397;25;12,920;7,90000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17,770;8,20942141688438;26;18,400;5,45000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_bdi_5weeksaftersession1_5.00_self-report_psil_psil_22mg/kg_1mg/kg;-0,77754880367406609;0,290818652815185;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;bdi;self-report;depression;0;Post-second dose 1;5 weeks after session 2;5,00;35,000;0;1;25;5,800;7,05000000000000;24;8,170;6,07473456210228;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17,770;8,20942141688438;26;18,400;5,45000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_bdi_5weeksaftersession2_5.00_self-report_psil_psil_22mg/kg_1mg/kg;-0,35382339575641347;0,288073118615127;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;bdi;self-report;depression;0;Follow-up 1;6 months;26,09;182,625;0;1;24;6,170;6,17271415181361;22;8,000;7,03562363973514;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17,770;8,20942141688438;26;18,400;5,45000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_bdi_6months_26.09_self-report_psil_psil_22mg/kg_1mg/kg;-0,27257529146759862;0,296575805493764;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;grid-ham-d;clinician;depression;1;Post-first dose 1;5 weeks after session 1;5,00;35,000;1;0;25;6,640;5,20000000000000;25;14,800;7,25000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_grid-ham-d_5weeksaftersession1_5.00_clinician_psil_psil_22mg/kg_1mg/kg;-1,27311104197224201;0,311013705206831;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;grid-ham-d;clinician;depression;1;Post-second dose 1;5 weeks after session 2;5,00;35,000;0;1;25;6,520;7,20000000000000;24;6,500;4,21312235758707;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_grid-ham-d_5weeksaftersession2_5.00_clinician_psil_psil_22mg/kg_1mg/kg;0,00331890655475999;0,285774006447645;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;grid-ham-d;clinician;depression;1;Follow-up 1;6 months;26,09;182,625;0;1;24;6,230;6,36867333123626;22;6,950;5,81611554218105;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_grid-ham-d_6months_26.09_clinician_psil_psil_22mg/kg_1mg/kg;-0,11579698553577734;0,295418499944029;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;hads-d;self-report;depression;0;Post-first dose 1;5 weeks after session 1;5,00;35,000;1;0;26;3,920;3,77327444005866;25;6,040;3,95000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,810;3,51832346437902;26;9,480;3,55000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_hads-d_5weeksaftersession1_5.00_self-report_psil_psil_22mg/kg_1mg/kg;-0,54065489082500096;0,285337615889013;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;hads-d;self-report;depression;0;Post-second dose 1;5 weeks after session 2;5,00;35,000;0;1;25;4,280;4,45000000000000;24;4,570;3,57625502446344;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,810;3,51832346437902;26;9,480;3,55000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_hads-d_5weeksaftersession2_5.00_self-report_psil_psil_22mg/kg_1mg/kg;-0,07052468938737315;0,285865505950152;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;hads-d;self-report;depression;0;Follow-up 1;6 months;26,09;182,625;0;1;24;3,460;3,23332646047380;22;4,640;3,37709934707287;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,810;3,51832346437902;26;9,480;3,55000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_hads-d_6months_26.09_self-report_psil_psil_22mg/kg_1mg/kg;-0,35115579586740397;0,297504127606758;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;response;grid-ham-d;clinician;depression;1;Post-first dose 1;5 weeks after session 1;5,00;35,000;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;23;25;8;25;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_response_grid-ham-d_5weeksaftersession1_5.00_clinician_psil_psil_22mg/kg_1mg/kg;-1,73443550611936326;0,470184256190578;1,0560526742493137;0,297452955725044;23;8;25;25
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;response;grid-ham-d;clinician;depression;1;Post-second dose 1;5 weeks after session 2;5,00;35,000;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21;25;18;24;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_response_grid-ham-d_5weeksaftersession2_5.00_clinician_psil_psil_22mg/kg_1mg/kg;-0,30358263731036345;0,397508236769202;0,1133286853070031;0,146655843756519;21;18;25;24
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;response;grid-ham-d;clinician;depression;1;Follow-up 1;6 months;26,09;182,625;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;19;24;17;22;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_response_grid-ham-d_6months_26.09_clinician_psil_psil_22mg/kg_1mg/kg;-0,06027067386422890;0,394288867299855;0,0242142581205945;0,155993257027094;19;17;24;22
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;remission;grid-ham-d;clinician;depression;1;Post-first dose 1;5 weeks after session 1;5,00;35,000;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15;25;4;25;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_remission_grid-ham-d_5weeksaftersession1_5.00_clinician_psil_psil_22mg/kg_1mg/kg;-1,11990289316815228;0,375667318726251;1,3217558399823195;0,486483983977547;15;4;25;25
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;remission;grid-ham-d;clinician;depression;1;Post-second dose 1;5 weeks after session 2;5,00;35,000;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;25;14;24;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_remission_grid-ham-d_5weeksaftersession2_5.00_clinician_psil_psil_22mg/kg_1mg/kg;-0,22637835717215685;0,328608718760945;0,1533340199207023;0,220421038409834;17;14;25;24
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;remission;grid-ham-d;clinician;depression;1;Follow-up 1;6 months;26,09;182,625;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;24;13;22;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_remission_grid-ham-d_6months_26.09_clinician_psil_psil_22mg/kg_1mg/kg;-0,28154787481164734;0,344178896486629;0,1812526096050495;0,220511664574982;17;13;24;22
Grob 2011;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Pre-first dose 1;1 day before experimental session;-0,14;-1,000;0;1;12;16,090;12,70978882594042;12;14,369;13,64856036364275;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;Low;Some concerns;Low;Some concerns;High;High;2011;psilocybin;niacin;0.2 mg/kg;250 mg;psilocybin;niacin placebo;1;NA;NA;cancer;advanced cancer patients with mood or adjustment disorder;crossover;double-blind;10.1001/archgenpsychiatry.2010.116;NCT00302744;Grob, C., Danforth, A., Chopra, G., Hagerty, M., McKay, C., Halberstadt, A., & Greer, G. (2011). Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. ARCHIVES OF GENERAL PSYCHIATRY, 68(1), 71–78. https://doi.org/10.1001/archgenpsychiatry.2010.116;Grob2011_msd_bdi_1daybeforeexperimentalsession_-0.14_self-report_psil_ncn_NA_NA;0,12600199461443884;0,408682608848014;NA;NA;NA;NA;NA;NA
Grob 2011;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 1;1 day after experimental session;0,14;1,000;0;1;12;11,442;10,04243058228435;12;13,208;11,76755318662295;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;Low;Some concerns;Low;Some concerns;High;High;2011;psilocybin;niacin;0.2 mg/kg;250 mg;psilocybin;niacin placebo;1;NA;NA;cancer;advanced cancer patients with mood or adjustment disorder;crossover;double-blind;10.1001/archgenpsychiatry.2010.116;NCT00302744;Grob, C., Danforth, A., Chopra, G., Hagerty, M., McKay, C., Halberstadt, A., & Greer, G. (2011). Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. ARCHIVES OF GENERAL PSYCHIATRY, 68(1), 71–78. https://doi.org/10.1001/archgenpsychiatry.2010.116;Grob2011_msd_bdi_1dayafterexperimentalsession_0.14_self-report_psil_ncn_NA_NA;-0,15587305359912776;0,408912757018787;NA;NA;NA;NA;NA;NA
Grob 2011;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 2;2 weeks after experimental session;2,00;14,000;1;1;12;10,054;9,25607951564808;12;13,270;10,98120211998668;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;Low;Some concerns;Low;Some concerns;High;High;2011;psilocybin;niacin;0.2 mg/kg;250 mg;psilocybin;niacin placebo;1;NA;NA;cancer;advanced cancer patients with mood or adjustment disorder;crossover;double-blind;10.1001/archgenpsychiatry.2010.116;NCT00302744;Grob, C., Danforth, A., Chopra, G., Hagerty, M., McKay, C., Halberstadt, A., & Greer, G. (2011). Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. ARCHIVES OF GENERAL PSYCHIATRY, 68(1), 71–78. https://doi.org/10.1001/archgenpsychiatry.2010.116;Grob2011_msd_bdi_2weeksafterexperimentalsession_2.00_self-report_psil_ncn_NA_NA;-0,30576069806097955;0,410799187568030;NA;NA;NA;NA;NA;NA
Krempien 2023;psil-d;psil-d;16 mg;12 mg;msd;madrs;clinician;depression;1;Post-first dose 4;Day 21;3,00;21,000;1;NA;9;16,556;6,14600000000000;15;15,867;8,68400000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,444;4,03500000000000;9;32,611;3,66400000000000;18;NA;NA;NA;NA;NA;NA;2023;CYB003 deuterated psilocin;CYB003 deuterated psilocin;16 mg;12 mg;16 mg group;12 mg group;1;NA;NA;mdd;mdd;parallel;double-blind;10.1038/s41386-023-01755-5;NCT05385783;Krempien, S., Inamdar, A., Shenouda, M., Johnson, K., Maass-Robinsin, S., Johnson, M., Kelman, A., Nathan, P., Belser, A., Pathare, P., House-Gecewicz, A., Sorie, A., Bartlone, A., Varty, G., Morgan, M., Avery, K., Muhammad, A., Nivorozhkin, A., & Palfreyman, M. (2023). Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CYB003, a Deuterated Psilocybin Analog in Patients With Major Depressive Disorder. NEUROPSYCHOPHARMACOLOGY, 48, 195–196;Krempien2023_msd_madrs_Day21_3.00_clinician_psil-d_psil-d_16mg_12mg;0,08467365452156889;0,421826984238059;NA;NA;NA;NA;NA;NA
Krempien 2023;psil-d;pcb;16 mg;NA;msd;madrs;clinician;depression;1;Post-first dose 4;Day 21;3,00;21,000;1;NA;9;16,556;6,14600000000000;9;29,000;5,31500000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,444;4,03500000000000;9;31,556;4,92700000000000;9;NA;NA;NA;NA;NA;NA;2023;CYB003 deuterated psilocin;placebo;16 mg;NA;16 mg group;placebo;1;NA;NA;mdd;mdd;parallel;double-blind;10.1038/s41386-023-01755-5;NCT05385783;Krempien, S., Inamdar, A., Shenouda, M., Johnson, K., Maass-Robinsin, S., Johnson, M., Kelman, A., Nathan, P., Belser, A., Pathare, P., House-Gecewicz, A., Sorie, A., Bartlone, A., Varty, G., Morgan, M., Avery, K., Muhammad, A., Nivorozhkin, A., & Palfreyman, M. (2023). Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CYB003, a Deuterated Psilocybin Analog in Patients With Major Depressive Disorder. NEUROPSYCHOPHARMACOLOGY, 48, 195–196;Krempien2023_msd_madrs_Day21_3.00_clinician_psil-d_pcb_16mg_NA;-2,06271669538168512;0,593738559711083;NA;NA;NA;NA;NA;NA
Krempien 2023;psil-d;pcb;12 mg;NA;msd;madrs;clinician;depression;1;Post-first dose 4;Day 21;3,00;21,000;1;NA;15;15,867;8,68400000000000;9;29,000;5,31500000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;32,611;3,66400000000000;18;31,556;4,92700000000000;9;NA;NA;NA;NA;NA;NA;2023;CYB003 deuterated psilocin;placebo;12 mg;NA;12 mg group;placebo;1;NA;NA;mdd;mdd;parallel;double-blind;10.1038/s41386-023-01755-5;NCT05385783;Krempien, S., Inamdar, A., Shenouda, M., Johnson, K., Maass-Robinsin, S., Johnson, M., Kelman, A., Nathan, P., Belser, A., Pathare, P., House-Gecewicz, A., Sorie, A., Bartlone, A., Varty, G., Morgan, M., Avery, K., Muhammad, A., Nivorozhkin, A., & Palfreyman, M. (2023). Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CYB003, a Deuterated Psilocybin Analog in Patients With Major Depressive Disorder. NEUROPSYCHOPHARMACOLOGY, 48, 195–196;Krempien2023_msd_madrs_Day21_3.00_clinician_psil-d_pcb_12mg_NA;-1,66123853816432954;0,489338185039199;NA;NA;NA;NA;NA;NA
Lewis 2025;psil-mbsr;mbsr;NA;NA;msd;qids-sr;self-report;depression;1;Post-first dose 1;2 weeks;2,00;14,000;1;NA;12;4,800;2,50000000000000;10;9,900;3,20000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;Low;Low;Low;Some concerns;Low;Some concerns;2025;mbsr-psilocybin;mbsr;25 mg;NA;MBSR-PAP;MBSR;1;43,6400000000000;71,8400000000000;dep;covid practitioners with burnout and depression symptoms;parallel;open-label;10.1371/journal.pmed.1004519;NCT05557643;"Lewis, B.R.; Hendrick, J.; Byrne, K.; Odette, M.; Wu, C.; Garland, E.L. (2025). Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial. PLOS Medicine, 22. https://doi.org/10.1371/journal.pmed.1004519";Lewis2025_msd_qids-sr_2weeks_2.00_self-report_psil-mbsr_mbsr_NA_NA;-1,72973732736908947;0,506761772923200;NA;NA;NA;NA;NA;NA
Lewis 2025;psil-mbsr;mbsr;NA;NA;msd;qids-sr;self-report;depression;1;Post-first dose 2;6 months;26,09;183,000;0;NA;12;6,100;3,30000000000000;10;8,000;2,90000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;Low;Low;Low;Some concerns;Low;Some concerns;2025;mbsr-psilocybin;mbsr;25 mg;NA;MBSR-PAP;MBSR;1;43,6400000000000;71,8400000000000;dep;covid practitioners with burnout and depression symptoms;parallel;open-label;10.1371/journal.pmed.1004519;NCT05557643;"Lewis, B.R.; Hendrick, J.; Byrne, K.; Odette, M.; Wu, C.; Garland, E.L. (2025). Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial. PLOS Medicine, 22. https://doi.org/10.1371/journal.pmed.1004519";Lewis2025_msd_qids-sr_6months_26.09_self-report_psil-mbsr_mbsr_NA_NA;-0,58466074360579112;0,437867090525376;NA;NA;NA;NA;NA;NA
Lewis 2025;psil-mbsr;mbsr;NA;NA;remission;qids-sr;self-report;depression;1;Post-first dose 2;2 weeks;2,00;14,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;7;13;2;12;NA;NA;NA;NA;NA;NA;Low;Low;Low;Some concerns;Low;Some concerns;2025;mbsr-psilocybin;mbsr;25 mg;NA;MBSR-PAP;MBSR;1;43,6400000000000;71,8400000000000;dep;covid practitioners with burnout and depression symptoms;parallel;open-label;10.1371/journal.pmed.1004519;NCT05557643;"Lewis, B.R.; Hendrick, J.; Byrne, K.; Odette, M.; Wu, C.; Garland, E.L. (2025). Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial. PLOS Medicine, 22. https://doi.org/10.1371/journal.pmed.1004519";Lewis2025_remission_qids-sr_2weeks_2.00_self-report_psil-mbsr_mbsr_NA_NA;-0,94026293239993042;0,525796621133611;1,1727202608218317;0,694694704601045;7;2;13;12
Luquiens 2025;psil;psil;25 mg;1 mg;msd;bdi-ii;self-report;depression;1;Post-first dose 1;Week 3;0,00;0,000;0;NA;20;15,000;12,00000000000000;10;14,000;9,00000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;11,00000000000000;20;31,000;9,00000000000000;10;Low;High;Low;Some concerns;Low;High;2025;psilocybin;psilocybin;25 mg;1 mg;25 mg group;10 mg group;2;49,6666666666667;43,3333333333333;aud;aud inpatients with depression symptoms;parallel;double-blind;10.1111/add.70152;NCT06235411;"Luquiens, A.; Belahda, D.; Graux, C.; Igounenc, N.; Serrand, C.; Rochefort, P.; Mura, T.; Sergent, F. (2025). Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial. Addiction. https://doi.org/10.1111/add.70152";Luquiens2025_msd_bdi-ii_Week3_0.00_self-report_psil_psil_25mg_1mg;0,08746376594117736;0,387472166916128;NA;NA;NA;NA;NA;NA
Luquiens 2025;psil;psil;25 mg;1 mg;msd;bdi-ii;self-report;depression;1;Post-second dose 1;Week 6;3,00;21,000;1;NA;20;12,000;13,00000000000000;10;16,000;8,00000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;11,00000000000000;20;31,000;9,00000000000000;10;Low;High;Low;Some concerns;Low;High;2025;psilocybin;psilocybin;25 mg;1 mg;25 mg group;10 mg group;2;49,6666666666667;43,3333333333333;aud;aud inpatients with depression symptoms;parallel;double-blind;10.1111/add.70152;NCT06235411;"Luquiens, A.; Belahda, D.; Graux, C.; Igounenc, N.; Serrand, C.; Rochefort, P.; Mura, T.; Sergent, F. (2025). Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial. Addiction. https://doi.org/10.1111/add.70152";Luquiens2025_msd_bdi-ii_Week6_3.00_self-report_psil_psil_25mg_1mg;-0,33465100311620588;0,389835423511669;NA;NA;NA;NA;NA;NA
Luquiens 2025;psil;psil;25 mg;1 mg;msd;bdi-ii;self-report;depression;1;Follow-up 1;Week 12;9,00;63,000;0;NA;20;15,000;14,00000000000000;9;16,000;10,00000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;11,00000000000000;20;31,000;9,00000000000000;10;Low;High;Low;Some concerns;Low;High;2025;psilocybin;psilocybin;25 mg;1 mg;25 mg group;10 mg group;2;49,6666666666667;43,3333333333333;aud;aud inpatients with depression symptoms;parallel;double-blind;10.1111/add.70152;NCT06235411;"Luquiens, A.; Belahda, D.; Graux, C.; Igounenc, N.; Serrand, C.; Rochefort, P.; Mura, T.; Sergent, F. (2025). Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial. Addiction. https://doi.org/10.1111/add.70152";Luquiens2025_msd_bdi-ii_Week12_9.00_self-report_psil_psil_25mg_1mg;-0,07508793234526946;0,401514645548271;NA;NA;NA;NA;NA;NA
Luquiens 2025;psil;psil;25 mg;1 mg;response;bdi-ii;self-report;depression;1;Follow-up 1;Week 12;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;10;20;6;9;33,000;11,00000000000000;20;31,000;9,00000000000000;10;Low;High;Low;Some concerns;Low;High;2025;psilocybin;psilocybin;25 mg;1 mg;25 mg group;10 mg group;2;49,6666666666667;43,3333333333333;aud;aud inpatients with depression symptoms;parallel;double-blind;10.1111/add.70152;NCT06235411;"Luquiens, A.; Belahda, D.; Graux, C.; Igounenc, N.; Serrand, C.; Rochefort, P.; Mura, T.; Sergent, F. (2025). Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial. Addiction. https://doi.org/10.1111/add.70152";Luquiens2025_response_bdi-ii_Week12_9.00_self-report_psil_psil_25mg_1mg;0,37143752542033442;0,461274848272599;-0,2876820724517809;0,324893144826965;10;6;20;9
Raison 2023;psil;ncn;NA;NA;change;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;51;-2,700;5,10102030610204;53;-2,700;5,20007849234323;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_change_madrs_Day2_0.29_clinician_psil_ncn_NA_NA;0,00000000000000000;0,196152409277982;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;change;madrs;clinician;depression;1;Post-first dose 2;Day 8;1,14;8,000;0;NA;NA;NA;NA;NA;NA;NA;51;-17,800;11,84165428202259;53;-5,800;12,07161078579678;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_change_madrs_Day8_1.14_clinician_psil_ncn_NA_NA;-0,99599549798874898;0,208125264900041;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;change;madrs;clinician;depression;1;Post-first dose 3;Day 15;2,14;15,000;0;NA;NA;NA;NA;NA;NA;NA;51;-18,000;12,02383357866909;53;-6,900;12,62876205283355;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_change_madrs_Day15_2.14_clinician_psil_ncn_NA_NA;-0,89317763251304971;0,205835749047960;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;change;madrs;clinician;depression;1;Post-first dose 4;Day 29;4,14;29,000;0;NA;NA;NA;NA;NA;NA;NA;51;-19,200;12,38819217196209;53;-5,500;13,00019623085807;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_change_madrs_Day29_4.14_clinician_psil_ncn_NA_NA;-1,07046182341651752;0,209921339689726;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;change;madrs;clinician;depression;1;Post-first dose 5;Day 43;6,14;43,000;1;NA;NA;NA;NA;NA;NA;NA;51;-19,100;13,11690935854809;53;-6,800;13,74306458690710;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_change_madrs_Day43_6.14_clinician_psil_ncn_NA_NA;-0,90844823571866895;0,206161577613683;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;change;smdds;self-report;depression;0;Post-first dose 2;Day 8;1,14;8,000;0;NA;NA;NA;NA;NA;NA;NA;51;-21,100;14,39216443507360;48;-9,600;14,31593014419174;NA;NA;NA;NA;43,200;8,70000000000000;51;44,300;5,90000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_change_smdds_Day8_1.14_self-report_psil_ncn_NA_NA;-0,79488908013194914;0,209003320149336;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;change;smdds;self-report;depression;0;Post-first dose 5;Day 43;6,14;43,000;1;NA;NA;NA;NA;NA;NA;NA;50;-21,800;14,79151940237166;42;-10,800;14,38327655003785;NA;NA;NA;NA;43,200;8,70000000000000;51;44,300;5,90000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_change_smdds_Day43_6.14_self-report_psil_ncn_NA_NA;-0,74677278098618760;0,216544760098465;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;msd;madrs;clinician;depression;1;Post-first dose 5;Day 43;6,14;43,000;1;NA;50;16,100;13,00000000000000;44;27,300;12,50000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_msd_madrs_Day43_6.14_clinician_psil_ncn_NA_NA;-0,86997194043111481;0,216378625859585;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;response;madrs;clinician;depression;1;Post-first dose 2;Day 8;1,14;8,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;27;51;5;50;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_response_madrs_Day8_1.14_clinician_psil_ncn_NA_NA;-1,26663694011237071;0,302440924827385;1,6665963262740489;0,444330050637791;27;5;51;50
Raison 2023;psil;ncn;NA;NA;response;madrs;clinician;depression;1;Post-first dose 3;Day 15;2,14;15,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;25;50;8;45;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_response_madrs_Day15_2.14_clinician_psil_ncn_NA_NA;-0,83751957077186134;0,265570629110550;1,0340737675305385;0,350396600693811;25;8;50;45
Raison 2023;psil;ncn;NA;NA;response;madrs;clinician;depression;1;Post-first dose 4;Day 29;4,14;29,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;49;7;44;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_response_madrs_Day29_4.14_clinician_psil_ncn_NA_NA;-0,97741596097536709;0,276668227108227;1,2045557247738035;0,371730070516366;26;7;49;44
Raison 2023;psil;ncn;NA;NA;response;madrs;clinician;depression;1;Post-first dose 5;Day 43;6,14;43,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;29;50;9;44;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_response_madrs_Day43_6.14_clinician_psil_ncn_NA_NA;-0,91915159297567650;0,259642749420353;1,0422378811403696;0,320728229198067;29;9;50;44
Raison 2023;psil;ncn;NA;NA;response;madrs;clinician;depression;1;Follow-up 1;Days 8-43 Sustained Response;6,14;43,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;48;5;44;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_response_madrs_Days8-43SustainedResponse_6.14_clinician_psil_ncn_NA_NA;-0,93907732959933798;0,307637231231115;1,2992829841302609;0,454356021132541;20;5;48;44
Raison 2023;psil;ncn;NA;NA;remission;madrs;clinician;depression;1;Post-first dose 2;Day 8;1,14;8,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;18;51;4;50;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_remission_madrs_Day8_1.14_clinician_psil_ncn_NA_NA;-1,00466752808606996;0,329691782803155;1,4842747694800944;0,515701185201567;18;4;51;50
Raison 2023;psil;ncn;NA;NA;remission;madrs;clinician;depression;1;Post-first dose 3;Day 15;2,14;15,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;50;6;45;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_remission_madrs_Day15_2.14_clinician_psil_ncn_NA_NA;-0,80189679432624872;0,289456084639812;1,0986122886681098;0,417665469538056;20;6;50;45
Raison 2023;psil;ncn;NA;NA;remission;madrs;clinician;depression;1;Post-first dose 4;Day 29;4,14;29,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;18;49;5;44;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_remission_madrs_Day29_4.14_clinician_psil_ncn_NA_NA;-0,82590432937777714;0,308672621340806;1,1733031812696990;0,460890572221842;18;5;49;44
Raison 2023;psil;ncn;NA;NA;remission;madrs;clinician;depression;1;Post-first dose 5;Day 43;6,14;43,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22;50;5;44;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_remission_madrs_Day43_6.14_clinician_psil_ncn_NA_NA;-0,99136754710359765;0,305383387785473;1,3537711694143306;0,450252454437811;22;5;50;44
Raison 2023;psil;ncn;NA;NA;remission;madrs;clinician;depression;1;Follow-up 1;Days 8-43 Sustained Response;6,14;43,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;48;4;44;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_remission_madrs_Days8-43SustainedResponse_6.14_clinician_psil_ncn_NA_NA;-0,65823804649686590;0,342583864748047;1,0116009116784799;0,538305421923955;12;4;48;44
Raison 2023;psil;ncn;NA;NA;imsd;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;51;32,800;13,00000000000000;53;32,300;12,50000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_imsd_madrs_Day2_0.29_clinician_psil_ncn_NA_NA;0,03893411233210140;0,196171262205403;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;imsd;madrs;clinician;depression;1;Post-first dose 2;Day 8;1,14;8,000;0;NA;51;17,700;13,00000000000000;53;29,200;12,50000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_imsd_madrs_Day8_1.14_clinician_psil_ncn_NA_NA;-0,89548458363833217;0,205884651101164;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;imsd;madrs;clinician;depression;1;Post-first dose 3;Day 15;2,14;15,000;0;NA;51;17,500;13,00000000000000;53;28,100;12,50000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_imsd_madrs_Day15_2.14_clinician_psil_ncn_NA_NA;-0,82540318144054980;0,204450551529181;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;imsd;madrs;clinician;depression;1;Post-first dose 4;Day 29;4,14;29,000;0;NA;51;16,300;13,00000000000000;53;29,500;12,50000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_imsd_madrs_Day29_4.14_clinician_psil_ncn_NA_NA;-1,02786056556747685;0,208879863202166;NA;NA;NA;NA;NA;NA
Rieser 2025;psil;pcb;NA;NA;msd;bdi;self-report;depression;1;Flexible Timepoint 1;Day -14;-2,00;-14,000;0;NA;18;12,720;8,37000000000000;19;12,210;7,75000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,060;8,99000000000000;18;11,050;8,02000000000000;19;Low;Low;Some concerns;Some concerns;Low;Some concerns;2025;psilocybin;mannitol;25 mg;100% mannitol;psilocybin;placebo;1;37,2675000000000;37,7975000000000;aud;aud;parallel;double-blind;10.1016/j.eclinm.2025.103149;NCT04141501;Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Rotz, R. von, Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: A phase 2 randomized clinical trial. eClinicalMedicine, 82. https://doi.org/10.1016/j.eclinm.2025.103149;Rieser2025_msd_bdi_Day-14_-2.00_self-report_psil_pcb_NA_NA;0,06193203084870311;0,329000423326536;NA;NA;NA;NA;NA;NA
Rieser 2025;psil;pcb;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 1;Day 1;0,14;1,000;0;NA;18;6,110;5,61000000000000;19;8,610;10,80000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,060;8,99000000000000;18;11,050;8,02000000000000;19;Low;Low;Some concerns;Some concerns;Low;Some concerns;2025;psilocybin;mannitol;25 mg;100% mannitol;psilocybin;placebo;1;37,2675000000000;37,7975000000000;aud;aud;parallel;double-blind;10.1016/j.eclinm.2025.103149;NCT04141501;Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Rotz, R. von, Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: A phase 2 randomized clinical trial. eClinicalMedicine, 82. https://doi.org/10.1016/j.eclinm.2025.103149;Rieser2025_msd_bdi_Day1_0.14_self-report_psil_pcb_NA_NA;-0,28193258331105392;0,330619388961670;NA;NA;NA;NA;NA;NA
Rieser 2025;psil;pcb;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 2;Day 14;2,00;14,000;0;NA;18;7,170;7,13000000000000;18;10,790;10,97000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,060;8,99000000000000;18;11,050;8,02000000000000;19;Low;Low;Some concerns;Some concerns;Low;Some concerns;2025;psilocybin;mannitol;25 mg;100% mannitol;psilocybin;placebo;1;37,2675000000000;37,7975000000000;aud;aud;parallel;double-blind;10.1016/j.eclinm.2025.103149;NCT04141501;Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Rotz, R. von, Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: A phase 2 randomized clinical trial. eClinicalMedicine, 82. https://doi.org/10.1016/j.eclinm.2025.103149;Rieser2025_msd_bdi_Day14_2.00_self-report_psil_pcb_NA_NA;-0,38259563495698945;0,336507979084192;NA;NA;NA;NA;NA;NA
Rieser 2025;psil;pcb;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 3;Day 30;4,29;30,000;1;NA;18;7,170;7,13000000000000;19;10,790;10,97000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,060;8,99000000000000;18;11,050;8,02000000000000;19;Low;Low;Some concerns;Some concerns;Low;Some concerns;2025;psilocybin;mannitol;25 mg;100% mannitol;psilocybin;placebo;1;37,2675000000000;37,7975000000000;aud;aud;parallel;double-blind;10.1016/j.eclinm.2025.103149;NCT04141501;Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Rotz, R. von, Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: A phase 2 randomized clinical trial. eClinicalMedicine, 82. https://doi.org/10.1016/j.eclinm.2025.103149;Rieser2025_msd_bdi_Day30_4.29_self-report_psil_pcb_NA_NA;-0,38064430600023824;0,332012714527199;NA;NA;NA;NA;NA;NA
Rieser 2025;psil;pcb;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 4;Day 96;13,71;96,000;0;NA;17;7,760;7,97000000000000;18;14,000;12,77000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,060;8,99000000000000;18;11,050;8,02000000000000;19;Low;Low;Some concerns;Some concerns;Low;Some concerns;2025;psilocybin;mannitol;25 mg;100% mannitol;psilocybin;placebo;1;37,2675000000000;37,7975000000000;aud;aud;parallel;double-blind;10.1016/j.eclinm.2025.103149;NCT04141501;Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Rotz, R. von, Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: A phase 2 randomized clinical trial. eClinicalMedicine, 82. https://doi.org/10.1016/j.eclinm.2025.103149;Rieser2025_msd_bdi_Day96_13.71_self-report_psil_pcb_NA_NA;-0,56903943380207367;0,345288659722553;NA;NA;NA;NA;NA;NA
Rieser 2025;psil;pcb;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 5;Day 190;27,14;190,000;0;NA;17;9,470;10,26000000000000;17;11,410;9,68000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,060;8,99000000000000;18;11,050;8,02000000000000;19;Low;Low;Some concerns;Some concerns;Low;Some concerns;2025;psilocybin;mannitol;25 mg;100% mannitol;psilocybin;placebo;1;37,2675000000000;37,7975000000000;aud;aud;parallel;double-blind;10.1016/j.eclinm.2025.103149;NCT04141501;Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Rotz, R. von, Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: A phase 2 randomized clinical trial. eClinicalMedicine, 82. https://doi.org/10.1016/j.eclinm.2025.103149;Rieser2025_msd_bdi_Day190_27.14_self-report_psil_pcb_NA_NA;-0,18990696449561470;0,343807205481078;NA;NA;NA;NA;NA;NA
Rosenblat 2024;psil;wl;NA;NA;change;madrs;clinician;depression;1;Post-first dose 1;Day 1;0,14;1,000;0;0;NA;NA;NA;NA;NA;NA;16;-13,277;6,30000000000000;14;-1,064;6,20740960465797;NA;NA;NA;NA;33,000;3,86000000000000;16;27,570;6,64000000000000;15;Some concerns;Low;Low;High;Low;High;2024;psilocybin;waitlist;25 mg;NA;immediate group;delayed group;1;44,1266666666667;39,1333333333333;trd;tr-mdd or bipolar ii with current mde;crossover;open-label;10.1016/j.medj.2024.01.005;NCT05029466;Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., … McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005;Rosenblat2024_change_madrs_Day1_0.14_clinician_psil_wl_NA_NA;-1,89908475272569666;0,444323125248803;NA;NA;NA;NA;NA;NA
Rosenblat 2024;psil;wl;NA;NA;change;madrs;clinician;depression;1;Post-first dose 2;Day 7;1,00;7,000;0;0;NA;NA;NA;NA;NA;NA;16;-11,319;7,82800000000000;14;-3,021;7,48331477354788;NA;NA;NA;NA;33,000;3,86000000000000;16;27,570;6,64000000000000;15;Some concerns;Low;Low;High;Low;High;2024;psilocybin;waitlist;25 mg;NA;immediate group;delayed group;1;44,1266666666667;39,1333333333333;trd;tr-mdd or bipolar ii with current mde;crossover;open-label;10.1016/j.medj.2024.01.005;NCT05029466;Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., … McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005;Rosenblat2024_change_madrs_Day7_1.00_clinician_psil_wl_NA_NA;-1,05265203301188959;0,391710041145542;NA;NA;NA;NA;NA;NA
Rosenblat 2024;psil;wl;NA;NA;change;madrs;clinician;depression;1;Post-first dose 3;Day 14;2,00;14,000;1;0;NA;NA;NA;NA;NA;NA;16;-9,600;7,60000000000000;14;-3,000;3,36749164809655;NA;NA;NA;NA;33,000;3,86000000000000;16;27,570;6,64000000000000;15;Some concerns;Low;Low;High;Low;High;2024;psilocybin;waitlist;25 mg;NA;immediate group;delayed group;1;44,1266666666667;39,1333333333333;trd;tr-mdd or bipolar ii with current mde;crossover;open-label;10.1016/j.medj.2024.01.005;NCT05029466;Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., … McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005;Rosenblat2024_change_madrs_Day14_2.00_clinician_psil_wl_NA_NA;-1,06719381767744292;0,392402176392330;NA;NA;NA;NA;NA;NA
Rosenblat 2024;psil;wl;NA;NA;msd;madrs;clinician;depression;1;Post-first dose 3;Day 14;2,00;14,000;1;0;16;23,440;8,69000000000000;14;24,570;6,52000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;3,86000000000000;16;27,570;6,64000000000000;15;Some concerns;Low;Low;High;Low;High;2024;psilocybin;waitlist;25 mg;NA;immediate group;delayed group;1;44,1266666666667;39,1333333333333;trd;tr-mdd or bipolar ii with current mde;crossover;open-label;10.1016/j.medj.2024.01.005;NCT05029466;Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., … McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005;Rosenblat2024_msd_madrs_Day14_2.00_clinician_psil_wl_NA_NA;-0,14171301667713440;0,366445267842868;NA;NA;NA;NA;NA;NA
Rosenblat 2024;psil;wl;NA;NA;imsd;madrs;clinician;depression;1;Post-first dose 1;Day 1;0,14;1,000;0;0;16;19,723;8,69000000000000;14;26,506;6,52000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;3,86000000000000;16;27,570;6,64000000000000;15;Some concerns;Low;Low;High;Low;High;2024;psilocybin;waitlist;25 mg;NA;immediate group;delayed group;1;44,1266666666667;39,1333333333333;trd;tr-mdd or bipolar ii with current mde;crossover;open-label;10.1016/j.medj.2024.01.005;NCT05029466;Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., … McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005;Rosenblat2024_imsd_madrs_Day1_0.14_clinician_psil_wl_NA_NA;-0,85065432931062279;0,382972717203476;NA;NA;NA;NA;NA;NA
Rosenblat 2024;psil;wl;NA;NA;imsd;madrs;clinician;depression;1;Post-first dose 2;Day 7;1,00;7,000;0;0;16;21,681;8,69000000000000;14;24,549;6,52000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;3,86000000000000;16;27,570;6,64000000000000;15;Some concerns;Low;Low;High;Low;High;2024;psilocybin;waitlist;25 mg;NA;immediate group;delayed group;1;44,1266666666667;39,1333333333333;trd;tr-mdd or bipolar ii with current mde;crossover;open-label;10.1016/j.medj.2024.01.005;NCT05029466;Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., … McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005;Rosenblat2024_imsd_madrs_Day7_1.00_clinician_psil_wl_NA_NA;-0,35967516091152402;0,369061136286049;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Pre-first dose 1;1 day pre-dose 1;-0,14;-1,000;0;0;14;10,400;6,90709953598470;15;16,247;7,54457155841205;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_bdi_1daypre-dose1_-0.14_self-report_psil_ncn_NA_NA;-0,78445040415340850;0,386427045543218;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 1;1 day post-dose 1;0,14;1,000;0;0;14;4,188;6,90709953598470;15;12,034;6,95200510644231;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_bdi_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA;-1,10036887261461747;0,400241252699935;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 2;2 weeks post-dose 1;2,00;14,000;0;0;14;6,636;7,15404892351178;14;13,449;7,52073134741562;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_bdi_2weekspost-dose1_2.00_self-report_psil_ncn_NA_NA;-0,90120587945026109;0,397798255450695;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 3;6 weeks post-dose 1;6,00;42,000;0;0;14;6,438;6,71627500925922;14;14,181;6,90709953598470;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_bdi_6weekspost-dose1_6.00_self-report_psil_ncn_NA_NA;-1,10350608761990276;0,407340792292258;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 4;7 weeks post-dose 1 and 1 day pre-dose 2;7,00;49,000;1;0;12;7,097;6,39473158154429;14;12,841;7,48331477354788;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_bdi_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA;-0,79404494658719260;0,409500561347812;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-second dose 2;6 weeks post-dose 2;6,00;42,000;0;1;12;6,212;6,57486486553146;11;9,545;6,80571406980928;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_bdi_6weekspost-dose2_6.00_self-report_psil_ncn_NA_NA;-0,48050139960509808;0,423845590912223;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-second dose 3;26 weeks post-dose 2;26,00;182,000;0;1;11;6,410;6,46078509161232;12;8,974;6,92820323027551;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_bdi_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA;-0,36832208305530018;0,421208871873938;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;hads-d;self-report;depression;0;Pre-first dose 1;1 day pre-dose 1;-0,14;-1,000;0;0;14;3,859;3,47974136969977;15;5,945;3,40435236131632;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_hads-d_1daypre-dose1_-0.14_self-report_psil_ncn_NA_NA;-0,58924681792804900;0,380042102654754;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;hads-d;self-report;depression;0;Post-first dose 1;1 day post-dose 1;0,14;1,000;0;0;14;2,019;3,38245827764364;15;6,164;3,21070319400595;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_hads-d_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA;-1,22287540277370277;0,406678447909128;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;hads-d;self-report;depression;0;Post-first dose 2;2 weeks post-dose 1;2,00;14,000;0;0;14;2,109;3,43484148105848;14;5,831;3,43484148105848;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_hads-d_2weekspost-dose1_2.00_self-report_psil_ncn_NA_NA;-1,05204046618656388;0,404752847895918;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;hads-d;self-report;depression;0;Post-first dose 3;6 weeks post-dose 1;6,00;42,000;0;0;14;2,263;3,47974136969977;14;6,761;3,10183397363560;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_hads-d_6weekspost-dose1_6.00_self-report_psil_ncn_NA_NA;-1,32485277849217686;0,419653953725893;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;hads-d;self-report;depression;0;Post-first dose 4;7 weeks post-dose 1 and 1 day pre-dose 2;7,00;49,000;1;0;12;2,734;3,30821704245656;14;6,101;3,28891684297429;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_hads-d_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA;-0,98874905515037670;0,418101050737959;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;hads-d;self-report;depression;0;Post-second dose 2;6 weeks post-dose 2;6,00;42,000;0;1;12;1,791;3,30821704245656;11;4,906;3,16737667478941;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_hads-d_6weekspost-dose2_6.00_self-report_psil_ncn_NA_NA;-0,92612271955594216;0,440809253309700;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;hads-d;self-report;depression;0;Post-second dose 3;26 weeks post-dose 2;26,00;182,000;0;1;11;1,960;3,33320791430718;12;4,271;3,30821704245656;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_hads-d_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA;-0,67089618622880953;0,429854469566899;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;response;bdi;self-report;depression;1;Post-first dose 1;1 day post-dose 1;0,14;1,000;0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;14;4;15;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_response_bdi_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA;-1,50223974351905665;0,530033969845441;1,1676051601550610;0,441857550844268;12;4;14;15
Ross 2016;psil;ncn;NA;NA;response;bdi;self-report;depression;1;Post-first dose 4;7 weeks post-dose 1 and 1 day pre-dose 2;7,00;49,000;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;10;12;2;14;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_response_bdi_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA;-1,81596223568402571;0,599741779377007;1,7635885922613588;0,667261639267608;10;2;12;14
Ross 2016;psil;ncn;NA;NA;response;bdi;self-report;depression;1;Post-second dose 3;26 weeks post-dose 2;26,00;182,000;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;11;7;12;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_response_bdi_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA;-0,62046695251766215;0,538490090853892;0,3383258052705359;0,282357627355504;9;7;11;12
Ross 2016;psil;ncn;NA;NA;remission;hads-d;self-report;depression;0;Post-first dose 1;1 day post-dose 1;0,14;1,000;0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;11;14;3;15;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_remission_hads-d_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA;-1,43912322147627747;0,505574636705140;1,3682758556172123;0,534927271829719;11;3;14;15
Ross 2016;psil;ncn;NA;NA;remission;hads-d;self-report;depression;0;Post-first dose 4;7 weeks post-dose 1 and 1 day pre-dose 2;7,00;49,000;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;8;12;6;14;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_remission_hads-d_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA;-0,52368289259737844;0,450158158078553;0,4418327522790392;0,370006434950477;8;6;12;14
Ross 2016;psil;ncn;NA;NA;remission;hads-d;self-report;depression;0;Post-second dose 3;26 weeks post-dose 2;26,00;182,000;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;11;7;12;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_remission_hads-d_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA;-0,62046695251766215;0,538490090853892;0,3383258052705359;0,282357627355504;9;7;11;12
Ross 2016;psil;ncn;NA;NA;response;hads-d;self-report;depression;0;Post-first dose 1;1 day post-dose 1;0,14;1,000;0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;11;14;3;15;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_response_hads-d_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA;-1,43912322147627747;0,505574636705140;1,3682758556172123;0,534927271829719;11;3;14;15
Ross 2016;psil;ncn;NA;NA;response;hads-d;self-report;depression;0;Post-first dose 4;7 weeks post-dose 1 and 1 day pre-dose 2;7,00;49,000;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;8;12;6;14;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_response_hads-d_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA;-0,52368289259737844;0,450158158078553;0,4418327522790392;0,370006434950477;8;6;12;14
Ross 2016;psil;ncn;NA;NA;response;hads-d;self-report;depression;0;Post-second dose 3;26 weeks post-dose 2;26,00;182,000;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;11;7;12;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_response_hads-d_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA;-0,62046695251766215;0,538490090853892;0,3383258052705359;0,282357627355504;9;7;11;12
Ross 2016;psil;ncn;NA;NA;remission;bdi;self-report;depression;1;Post-first dose 1;1 day post-dose 1;0,14;1,000;0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;14;4;15;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_remission_bdi_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA;-1,50223974351905665;0,530033969845441;1,1676051601550610;0,441857550844268;12;4;14;15
Ross 2016;psil;ncn;NA;NA;remission;bdi;self-report;depression;1;Post-first dose 4;7 weeks post-dose 1 and 1 day pre-dose 2;7,00;49,000;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;10;12;2;14;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_remission_bdi_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA;-1,81596223568402571;0,599741779377007;1,7635885922613588;0,667261639267608;10;2;12;14
Ross 2016;psil;ncn;NA;NA;remission;bdi;self-report;depression;1;Post-second dose 3;26 weeks post-dose 2;26,00;182,000;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;11;7;12;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_remission_bdi_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA;-0,62046695251766215;0,538490090853892;0,3383258052705359;0,282357627355504;9;7;11;12
Ross 2025;psil;ncn;NA;NA;msd;hads-d;self-report;depression;1;Post-first dose 1;Day 1;0,14;1,000;0;0;17;6,590;4,46000000000000;18;8,500;3,57000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,880;3,48000000000000;17;11,670;3,27000000000000;18;Low;Low;Low;Some concerns;Low;Some concerns;2025;psilocybin;niacin;25 mg;100 mg;psilocybin;placebo;1;55,9628571428571;54,5428571428571;cancer;life-threatening cancer patients with precipitated psychological distress;crossover;double-blind;10.1016/j.genhosppsych.2025.08.001;ACTRN12619001225101;"Ross, M.L.; Iyer, R.; Williams, M.L.; Boughey, M.; O'Callaghan, C.; Hiscock, R.; Dwyer, J. (2025). Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial. General Hospital Psychiatry, 96. https://doi.org/10.1016/j.genhosppsych.2025.08.001";Ross2025_msd_hads-d_Day1_0.14_self-report_psil_ncn_NA_NA;-0,46353334402311136;0,342919999984711;NA;NA;NA;NA;NA;NA
Ross 2025;psil;ncn;NA;NA;msd;hads-d;self-report;depression;1;Post-first dose 2;Week 3;3,00;21,000;0;0;17;6,570;4,70000000000000;18;9,280;3,92000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,880;3,48000000000000;17;11,670;3,27000000000000;18;Low;Low;Low;Some concerns;Low;Some concerns;2025;psilocybin;niacin;25 mg;100 mg;psilocybin;placebo;1;55,9628571428571;54,5428571428571;cancer;life-threatening cancer patients with precipitated psychological distress;crossover;double-blind;10.1016/j.genhosppsych.2025.08.001;ACTRN12619001225101;"Ross, M.L.; Iyer, R.; Williams, M.L.; Boughey, M.; O'Callaghan, C.; Hiscock, R.; Dwyer, J. (2025). Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial. General Hospital Psychiatry, 96. https://doi.org/10.1016/j.genhosppsych.2025.08.001";Ross2025_msd_hads-d_Week3_3.00_self-report_psil_ncn_NA_NA;-0,61354207410417083;0,346427109292292;NA;NA;NA;NA;NA;NA
Ross 2025;psil;ncn;NA;NA;msd;hads-d;self-report;depression;1;Post-first dose 3;Week 6-7;6,00;42,000;1;0;14;4,840;4,26000000000000;18;8,380;4,10000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,880;3,48000000000000;17;11,670;3,27000000000000;18;Low;Low;Low;Some concerns;Low;Some concerns;2025;psilocybin;niacin;25 mg;100 mg;psilocybin;placebo;1;55,9628571428571;54,5428571428571;cancer;life-threatening cancer patients with precipitated psychological distress;crossover;double-blind;10.1016/j.genhosppsych.2025.08.001;ACTRN12619001225101;"Ross, M.L.; Iyer, R.; Williams, M.L.; Boughey, M.; O'Callaghan, C.; Hiscock, R.; Dwyer, J. (2025). Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial. General Hospital Psychiatry, 96. https://doi.org/10.1016/j.genhosppsych.2025.08.001";Ross2025_msd_hads-d_Week6-7_6.00_self-report_psil_ncn_NA_NA;-0,82750220689741383;0,371811877928267;NA;NA;NA;NA;NA;NA
Ross 2025;psil;ncn;NA;NA;msd;bdi-ii;self-report;depression;0;Post-first dose 1;Day 1;0,14;1,000;0;0;17;11,900;9,31000000000000;18;17,200;8,26000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21,000;7,18000000000000;17;22,700;7,61000000000000;18;Low;Low;Low;Some concerns;Low;Some concerns;2025;psilocybin;niacin;25 mg;100 mg;psilocybin;placebo;1;55,9628571428571;54,5428571428571;cancer;life-threatening cancer patients with precipitated psychological distress;crossover;double-blind;10.1016/j.genhosppsych.2025.08.001;ACTRN12619001225101;"Ross, M.L.; Iyer, R.; Williams, M.L.; Boughey, M.; O'Callaghan, C.; Hiscock, R.; Dwyer, J. (2025). Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial. General Hospital Psychiatry, 96. https://doi.org/10.1016/j.genhosppsych.2025.08.001";Ross2025_msd_bdi-ii_Day1_0.14_self-report_psil_ncn_NA_NA;-0,58949991240284649;0,345801894681828;NA;NA;NA;NA;NA;NA
Ross 2025;psil;ncn;NA;NA;msd;bdi-ii;self-report;depression;0;Post-first dose 2;Week 3;3,00;21,000;0;0;17;12,400;8,09000000000000;18;18,800;9,61000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21,000;7,18000000000000;17;22,700;7,61000000000000;18;Low;Low;Low;Some concerns;Low;Some concerns;2025;psilocybin;niacin;25 mg;100 mg;psilocybin;placebo;1;55,9628571428571;54,5428571428571;cancer;life-threatening cancer patients with precipitated psychological distress;crossover;double-blind;10.1016/j.genhosppsych.2025.08.001;ACTRN12619001225101;"Ross, M.L.; Iyer, R.; Williams, M.L.; Boughey, M.; O'Callaghan, C.; Hiscock, R.; Dwyer, J. (2025). Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial. General Hospital Psychiatry, 96. https://doi.org/10.1016/j.genhosppsych.2025.08.001";Ross2025_msd_bdi-ii_Week3_3.00_self-report_psil_ncn_NA_NA;-0,70220007394235073;0,348937266321390;NA;NA;NA;NA;NA;NA
Ross 2025;psil;ncn;NA;NA;msd;bdi-ii;self-report;depression;0;Post-first dose 3;Week 6-7;6,00;42,000;1;0;14;9,230;5,72000000000000;18;19,100;7,10000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21,000;7,18000000000000;17;22,700;7,61000000000000;18;Low;Low;Low;Some concerns;Low;Some concerns;2025;psilocybin;niacin;25 mg;100 mg;psilocybin;placebo;1;55,9628571428571;54,5428571428571;cancer;life-threatening cancer patients with precipitated psychological distress;crossover;double-blind;10.1016/j.genhosppsych.2025.08.001;ACTRN12619001225101;"Ross, M.L.; Iyer, R.; Williams, M.L.; Boughey, M.; O'Callaghan, C.; Hiscock, R.; Dwyer, J. (2025). Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial. General Hospital Psychiatry, 96. https://doi.org/10.1016/j.genhosppsych.2025.08.001";Ross2025_msd_bdi-ii_Week6-7_6.00_self-report_psil_ncn_NA_NA;-1,47160897825765136;0,403230724263689;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;bdi;self-report;depression;0;Pre-first dose 1;Day -1;-0,14;-1,000;0;NA;26;25,695;6,31768517734146;26;24,798;10,01957334420982;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,900;10,02467236372342;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_bdi_Day-1_-0.14_self-report_psil_pcb_NA_NA;0,10548091002400753;0,277548842334483;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;bdi;self-report;depression;0;DOSE 1;Day 0;0,00;0,000;0;NA;26;12,242;7,18961751416583;26;20,191;10,89150568103419;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,900;10,02467236372342;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_bdi_Day0_0.00_self-report_psil_pcb_NA_NA;-0,84840536845533920;0,289926959286354;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;bdi;self-report;depression;0;Post-first dose 1;Day 2;0,29;2,000;0;NA;26;11,823;8,93348218781456;26;22,293;11,76853703737215;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,900;10,02467236372342;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_bdi_Day2_0.29_self-report_psil_pcb_NA_NA;-0,98703435264889661;0,294244283502394;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;bdi;self-report;depression;0;Post-first dose 2;Day 8;1,14;8,000;0;NA;26;13,584;11,54927919828766;26;21,148;11,54927919828766;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,900;10,02467236372342;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_bdi_Day8_1.14_self-report_psil_pcb_NA_NA;-0,64505929083009739;0,284688371674402;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;bdi;self-report;depression;0;Post-first dose 3;Day 14;2,00;14,000;1;NA;26;13,379;10,23883118329431;26;20,729;11,33002135920317;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,900;10,02467236372342;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_bdi_Day14_2.00_self-report_psil_pcb_NA_NA;-0,67040650657638035;0,285268239079986;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;madrs;clinician;depression;1;Pre-first dose 1;Day -1;-0,14;-1,000;0;NA;26;23,534;4,18629502065968;26;24,948;7,44456848984546;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_madrs_Day-1_-0.14_clinician_psil_pcb_NA_NA;-0,23060285431836317;0,278298712350879;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;madrs;clinician;depression;1;DOSE 1;Day 0;0,00;0,000;0;NA;26;11,727;7,21511261173379;26;21,034;9,53516649041851;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_madrs_Day0_0.00_clinician_psil_pcb_NA_NA;-1,08416213909409986;0,297613339412923;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;26;9,775;7,90857926558241;26;20,632;11,16685273476820;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_madrs_Day2_0.29_clinician_psil_pcb_NA_NA;-1,10515607016573902;0,298377744492480;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;madrs;clinician;depression;1;Post-first dose 2;Day 8;1,14;8,000;0;NA;26;12,065;8,83660081705630;26;19,957;10,46828706140599;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_madrs_Day8_1.14_clinician_psil_pcb_NA_NA;-0,80242972515504940;0,288626644278412;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;madrs;clinician;depression;1;Post-first dose 3;Day 14;2,00;14,000;1;NA;26;11,162;9,76972138804378;26;20,696;10,23883118329431;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_madrs_Day14_2.00_clinician_psil_pcb_NA_NA;-0,93836788231098855;0,292661784694183;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;response;madrs;clinician;depression;1;Post-first dose 3;Day 14;2,00;14,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15;26;4;26;24,118;5,11431657213356;26;24,528;6,74600281648325;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_response_madrs_Day14_2.00_clinician_psil_pcb_NA_NA;-1,09412740860668056;0,371085838569234;1,3217558399823193;0,489636180999311;15;4;26;26
von Rotz 2023;psil;pcb;NA;NA;remission;madrs;clinician;depression;1;Post-first dose 3;Day 14;2,00;14,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14;26;3;26;24,118;5,11431657213356;26;24,528;6,74600281648325;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_remission_madrs_Day14_2.00_clinician_psil_pcb_NA_NA;-1,18976883955491308;0,401968864868958;1,5404450409471488;0,572572115841165;14;3;26;26
von Rotz 2023;psil;pcb;NA;NA;response;bdi;self-report;depression;0;Post-first dose 3;Day 14;2,00;14,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14;26;3;26;26,541;6,31768517734146;26;25,900;10,02467236372342;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_response_bdi_Day14_2.00_self-report_psil_pcb_NA_NA;-1,18976883955491308;0,401968864868958;1,5404450409471488;0,572572115841165;14;3;26;26
von Rotz 2023;psil;pcb;NA;NA;remission;bdi;self-report;depression;0;Post-first dose 3;Day 14;2,00;14,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;26;3;26;26,541;6,31768517734146;26;25,900;10,02467236372342;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_remission_bdi_Day14_2.00_self-report_psil_pcb_NA_NA;-1,02235583542038633;0,401968864868958;1,3862943611198906;0,582875278034323;12;3;26;26
>>>>>>> Stashed changes
>>>>>>> 13bab84 (update diagnosis)
